CLDF Title
Home | Contact Us | Bookmark
HEPATITIS
HBV HCV HDV
CIRRHOSIS
HEPATIC ENCEPHALOPATHY (HE) HEPATORENAL SYNDROME (HRS) THROMBOCYTOPENIA
NASH
CHOLESTATIC
PRIMARY BILIARY CHOLANGITIS (PBC)
HCC PEDIATRIC LIVER DISEASE
About CLDF
Board of Trustees Board of Advisors/Faculty 2020 GI Fellow Board of Advisors CLDF Committees
Centers of Educational Expertise  
Live Events Slide Library Webcasts Abstract Library Committee Members Conference Highlights
 
NASH | Abstract Library
Abstract Library
 
The summaries are free for public use. The Chronic Liver Disease Foundation will continue to add and archive summaries of articles deemed relevant to CLDF by the Board of Trustees and its Advisors.
1.MAFLD in Obese Children: A Challenging Definition
 

Children (Basel). 2021 Mar 23;8(3):247. doi: 10.3390/children8030247.

Anna Di Sessa 1, Stefano Guarino 1, Giuseppina Rosaria Umano 1, Mattia Arenella 1, Salvatore Alfiero 1, Gaetano Quaranta 1, Emanuele Miraglia Del Giudice 1, Pierluigi Marzuillo 1
 
2.Role of Angiogenesis in the Pathogenesis of NAFLD
 

J Clin Med. 2021 Mar 24;10(7):1338. doi: 10.3390/jcm10071338.

Lin Lei 1, Haquima Ei Mourabit 1, Chantal Housset 1 2, Axelle Cadoret 1, Sara Lemoinne 1 2
 
3.PNPLA3 Single Nucleotide Polymorphism Prevalence and Association with Liver Disease in a Diverse Cohort of Persons Living with HIV
 

Biology (Basel). 2021 Mar 21;10(3):242. doi: 10.3390/biology10030242.

Kenneth E Sherman 1, Susan D Rouster 1, Heidi Meeds 1, Javier Tamargo 2, Jun Chen 3, Richard Ehman 3, Marianna Baum 2
 
4.Comparison of Ketogenic Diets with and without Ketone Salts versus a Low-Fat Diet: Liver Fat Responses in Overweight Adults
 

Nutrients. 2021 Mar 17;13(3):966. doi: 10.3390/nu13030966.

Christopher D Crabtree 1, Madison L Kackley 1, Alexandru Buga 1, Brandon Fell 1, Richard A LaFountain 1, Parker N Hyde 1, Teryn N Sapper 1, William J Kraemer 1, Debbie Scandling 2, Orlando P Simonetti 2 3, Jeff S Volek 1
 
5.PNPLA3 and SERPINA1 Variants Are Associated with Severity of Fatty Liver Disease at First Referral to a Tertiary Center
 

J Pers Med. 2021 Mar 1;11(3):165. doi: 10.3390/jpm11030165.

Georg Semmler 1 2 3, Lorenz Balcar 1 2, Hannes Oberkofler 4, Stephan Zandanell 1, Michael Strasser 1, David Niederseer 5, Alexandra Feldman 1, Felix Stickel 6, Pavel Strnad 7, Christian Datz 3, Bernhard Paulweber 1, Elmar Aigner 1
 
6.Association of obstructive sleep apnea with non-alcoholic fatty liver disease in patients with obesity: an observational study
 

Eat Weight Disord. 2021 Apr 3;1-9. doi: 10.1007/s40519-021-01182-9. Online ahead of print.

Silvia Bettini 1, Roberto Serra 2, Roberto Fabris 2, Chiara Dal Prà 2, Francesca Favaretto 3 2, Francesca Dassie 3, Claudio Duso 3, Roberto Vettor 3 2, Luca Busetto 3 2
 
7.Comparison between magnetic resonance and ultrasound-derived indicators of hepatic steatosis in a pooled NAFLD cohort
 

PLoS One. 2021 Apr 1;16(4):e0249491. doi: 10.1371/journal.pone.0249491. eCollection 2021.

Cayden Beyer 1, Chloe Hutton 1, Anneli Andersson 1, Kento Imajo 2, Atsushi Nakajima 2, Dustin Kiker 3, Rajarshi Banerjee 1, Andrea Dennis 1
 
8.The Diabetes Syndrome - A Collection of Conditions with Common, Interrelated Pathophysiologic Mechanisms
 

Int J Gen Med. 2021 Mar 18;14:923-936. doi: 10.2147/IJGM.S305156. eCollection 2021.

Amy W Rachfal 1, Struan F A Grant 2 3 4, Stanley S Schwartz 5 6
 
9.Experimental and Investigational Targeted Therapies for the Management of Fibrosis in NASH: An Update
 

J Exp Pharmacol. 2021 Mar 18;13:329-338. doi: 10.2147/JEP.S265286.eCollection 2021.

Tsipora M Huisman 1, Douglas T Dieterich 1, Scott L Friedman 1
 
10.Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes
 

Front Endocrinol (Lausanne). 2021 Mar 4;12:642432. doi: 10.3389/fendo.2021.642432.eCollection 2021.

Jacqueline Bayliss 1, Geraldine J Ooi 2, William De Nardo 1, Yazmin Johari Halim Shah 2, Magdalene K Montgomery 1, Catriona McLean 3, William Kemp 4, Stuart K Roberts 4, Wendy A Brown 2, Paul R Burton 2, Matthew J Watt 1
 
11.The prevalence of metabolic associated fatty liver detected by FibroScan® in women with gestational diabetes in a multiethnic population
 

Diabetes Res Clin Pract. 2021 Mar 17;174:108757. doi: 10.1016/j.diabres.2021.108757.Online ahead of print.

Difei Deng 1, Jacob George 2, Dharmintra Pasupathy 3, N Wah Cheung 4
 
12.Endoplasmic Reticulum Stress and Autophagy in the Pathogenesis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Evidence and Perspectives
 

Curr Obes Rep. 2021 Mar 22. doi: 10.1007/s13679-021-00431-3.Online ahead of print.

Christina-Maria Flessa 1 2, Ioannis Kyrou 2 3 4, Narjes Nasiri-Ansari 1, Gregory Kaltsas 5, Athanasios G Papavassiliou 1, Eva Kassi 6 7, Harpal S Randeva 8 9
 
13.Alternative Etiologies of Liver Disease in Children With Suspected NAFLD
 

Pediatrics. 2021 Mar 30;147(4):e2020009829. doi: 10.1542/peds.2020-009829.Online ahead of print.

Toshifumi Yodoshi 1, Sarah Orkin 1, Ana Catalina Arce-Clachar 1 2, Kristin Bramlage 1, Stavra A Xanthakos 1 2, Pamela L Valentino 3, Marialena Mouzaki 4 2
 
14.LI-RADS v2018 major criteria: Do hepatocellular carcinomas in non-alcoholic steatohepatitis differ from those in virus-induced chronic liver disease on MRI?
 

Eur J Radiol. 2021 Mar 11;138:109651. doi: 10.1016/j.ejrad.2021.109651. Online ahead of print.

Maxime Barat 1, Thi Thuy Linh Nguyen 2, Clémence Hollande 3, Jean-Baptiste Coty 4, Christine Hoeffel 5, Benoit Terris 6, Anthony Dohan 4, Vincent Mallet 3, Stanislas Pol 3, Philippe Soyer 4
 
15.NASH limits anti-tumour surveillance in immunotherapy-treated HCC
 

Nature. 2021 Mar 24. doi: 10.1038/s41586-021-03362-0. Online ahead of print.

Dominik Pfister 1 2, Nicolás Gonzalo Núñez 3, Roser Pinyol 4, Olivier Govaere 5, Matthias Pinter 6 7, Marta Szydlowska 1, Revant Gupta 8 9, Mengjie Qiu 10, Aleksandra Deczkowska 11, Assaf Weiner 11, Florian Müller 1, Ankit Sinha 12 13, Ekaterina Friebel 3, Thomas Engleitner 14 15 16, Daniela Lenggenhager 17, Anja Moncsek 18, Danijela Heide 1, Kristin Stirm 1, Jan Kosla 1, Eleni Kotsiliti 1, Valentina Leone 1 19, Michael Dudek 20, Suhail Yousuf 10, Donato Inverso 21 22, Indrabahadur Singh 1 23, Ana Teijeiro 24, Florian Castet 4, Carla Montironi 4, Philipp K Haber 25, Dina Tiniakos 5 26, Pierre Bedossa 5, Simon Cockell 27, Ramy Younes 5 28, Michele Vacca 29, Fabio Marra 30, Jörn M Schattenberg 31, Michael Allison 32, Elisabetta Bugianesi 28, Vlad Ratziu 33, Tiziana Pressiani 34, Antonio D'Alessio 34, Nicola Personeni 34 35, Lorenza Rimassa 34 35, Ann K Daly 5, Bernhard Scheiner 6 7, Katharina Pomej 6 7, Martha M Kirstein 36 37, Arndt Vogel 36, Markus Peck-Radosavljevic 38, Florian Hucke 38, Fabian Finkelmeier 39, Oliver Waidmann 39, Jörg Trojan 39, Kornelius Schulze 40, Henning Wege 40, Sandra Koch 41, Arndt Weinmann 41, Marco Bueter 42, Fabian Rössler 42, Alexander Siebenhüner 43, Sara De Dosso 44, Jan-Philipp Mallm 45, Viktor Umansky 46 47, Manfred Jugold 48, Tom Luedde 49, Andrea Schietinger 50 51, Peter Schirmacher 52, Brinda Emu 1, Hellmut G Augustin 21 22, Adrian Billeter 53, Beat Müller-Stich 53, Hiroto Kikuchi 54, Dan G Duda 54, Fabian Kütting 55, Dirk-Thomas Waldschmidt 55, Matthias Philip Ebert 56, Nuh Rahbari 57, Henrik E Mei 58, Axel Ronald Schulz 58, Marc Ringelhan 59 60 61, Nisar Malek 62, Stephan Spahn 62, Michael Bitzer 62, Marina Ruiz de Galarreta 25 63, Amaia Lujambio 25 63 64, Jean-Francois Dufour 65 66, Thomas U Marron 25 67, Ahmed Kaseb 68, Masatoshi Kudo 69, Yi-Hsiang Huang 70 71, Nabil Djouder 24, Katharina Wolter 72 73, Lars Zender 72 73 74, Parice N Marche 75 76, Thomas Decaens 75 76 77, David J Pinato 78 79, Roland Rad 14 15 16, Joachim C Mertens 18, Achim Weber 17 80, Kristian Unger 19, Felix Meissner 12, Susanne Roth 10, Zuzana Macek Jilkova 75 76 78, Manfred Claassen 8 9, Quentin M Anstee 5 81, Ido Amit 11, Percy Knolle 20, Burkhard Becher 3, Josep M Llovet 82 83 84, Mathias Heikenwalder 85

Affiliations collapse
 
16.Bariatric Surgery Reduces Cancer Risk in Adults with Nonalcoholic Fatty Liver Disease and Severe Obesity
 

Gastroenterology. 2021 Mar 17;S0016-5085(21)00529-1. doi: 10.1053/j.gastro.2021.03.021.Online ahead of print.

Vinod K Rustgi 1, You Li 2, Kapil Gupta 2, Carlos D Minacapelli 2, Abhishek Bhurwal 2, Carolyn Catalano 2, Mohamed I Elsaid 2
 
17.The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk
 

Curr Diab Rep. 2021 Mar 19;21(5):15. doi: 10.1007/s11892-021-01383-7.

Cyrielle Caussy 1, Adrien Aubin 2, Rohit Loomba 3 4 5
 
18.Sex differences in NAFLD: estrogen influence on the liver-adipose tissue crosstalk
 

Antioxid Redox Signal. 2021 Mar 19. doi: 10.1089/ars.2021.0044. Online ahead of print.

Andrea Morán-Costoya 1 2, Ana María Proenza 1 3 4, Magdalena Gianotti 5 3 6, Isabel Lladó 1 3 7, Adamo Valle 1 3 8
 
19.Ten Thousand Points of Light - Heterogeneity Among the Stars of NASH Fibrosis
 

Hepatology. 2021 Mar 16.doi: 10.1002/hep.31807. Online ahead of print.

James Carter 1, Shuang Wang 1, Scott L Friedman 1
 
20.The clinical impact of cirrhosis on the postoperative outcomes of patients undergoing bariatric surgery: propensity score-matched analysis of 2011-2017 US hospitals
 

Expert Rev Gastroenterol Hepatol. 2021 Mar 12. doi: 10.1080/17474124.2021.1902803.Online ahead of print.

David Uihwan Lee 1, Gregory Hongyuan Fan 1, David Jeffrey Hastie 1, Elyse Ann Addonizio 1, Vibhav Narayan Prakasam 1, Ryan Richard Ahern 1, Kristen Jin Seog 1, Raffi Karagozian 1
 
21.Awareness of non-alcoholic steatohepatitis and treatment guidelines: What are physicians telling us?
 

World J Hepatol. 2021 Feb 27;13(2):233-241. doi: 10.4254/wjh.v13.i2.233.

David Hermanus Wessels 1, Zeil Rosenberg 2
 
22.Coronary artery disease and non-alcoholic fatty liver disease: Clinical correlation using computed tomography coronary calcium scans
 

JGH Open. 2021 Feb 19;5(3):390-395. doi: 10.1002/jgh3.12509. eCollection 2021 Mar.

Richard S Kirby 1, Dina Halegoua-DeMarzio 2
 
23.Increased adipose tissue fibrogenesis, not impaired expandability, is associated with nonalcoholic fatty liver disease
 

Hepatology. 2021 Mar 20. doi: 10.1002/hep.31822. Online ahead of print.

Joseph W Beals 1, Gordon I Smith 1, Mahalakshmi Shankaran 2, Anja Fuchs 3, George G Schweitzer 1, Jun Yoshino 1, Tyler Field 2, Marcy Matthews 2, Edna Nyangau 2, Darya Morozov 4, Bettina Mittendorfer 1, Marc K Hellerstein 2, Samuel Klein 1
 
24.European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease?
 

JHEP Rep. 2021 Jan 21;3(2):100234. doi: 10.1016/j.jhepr.2021.100234. eCollection 2021 Apr.

Jeffrey V Lazarus 1, Adam Palayew 2, Patrizia Carrieri 3, Mattias Ekstedt 4, Giulio Marchesini 5, Katja Novak 6, Vlad Ratziu 7, Manuel Romero-Gómez 8, Frank Tacke 9, Shira Zelber-Sagi 10, Helena Cortez-Pinto 11, Quentin M Anstee 12 13
 
25.Treatment candidacy for pharmacologic therapies for NASH
 

Clin Gastroenterol Hepatol. 2021 Mar 9;S1542-3565(21)00228-7.doi: 10.1016/j.cgh.2021.03.005. Online ahead of print.

Ian A Rowe 1, Vincent Wai-Sun Wong 2, Rohit Loomba 3
 
26.The Impact of Macronutrient Intake on Non-alcoholic Fatty Liver Disease (NAFLD): Too Much Fat, Too Much Carbohydrate, or Just Too Many Calories?
 

Front Nutr. 2021 Feb 16;8:640557. doi: 10.3389/fnut.2021.640557. eCollection 2021.

Theresa Hydes 1 2, Uazman Alam 1 2, Daniel J Cuthbertson 1 2
 
27.Treatments for NAFLD: State of Art
 

Int J Mol Sci. 2021 Feb 26;22(5):2350. doi: 10.3390/ijms22052350.

Alessandro Mantovani 1, Andrea Dalbeni 2
 
28.The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis
 

Contemp Clin Trials. 2021 Feb 28;106335. doi: 10.1016/j.cct.2021.106335. Online ahead of print.

Manal F Abdelmalek 1, Edgar D Charles 2, Arun J Sanyal 3, Stephen A Harrison 4, Brent A Neuschwander-Tetri 5, Zachary Goodman 6, Richard A Ehman 7, Morten Karsdal 8, Atsushi Nakajima 9, Shuyan Du 10, Giridhar S Tirucherai 10, George H Klinger 10, Johanna Mora 10, Masayuki Yamaguchi 10, Diane E Shevell 10, Rohit Loomba 11
 
29.Artificial Intelligence in NASH Histology: Human Teaches a Machine for the Machine to help Humans
 

Hepatology. 2021 Feb 26. doi: 10.1002/hep.31777. Online ahead of print.

Mazen Noureddin 1 2 3 4
 
30.Case-finding strategies in non-alcoholic fatty liver disease
 

JHEP Rep. 2020 Dec 5;3(2):100219. doi: 10.1016/j.jhepr.2020.100219.eCollection 2021 Apr.

Jerome Boursier 1 2, Emmanuel A Tsochatzis 3 4
 
31.Evaluation of a primary to secondary care referral pathway and novel nurse-led one-stop clinic for patients with suspected non-alcoholic fatty liver disease
 

Frontline Gastroenterol. 2020 Apr 7;12(2):102-107. doi: 10.1136/flgastro-2019-101304.eCollection 2021.

Andrew J Fowell 1, Kirsty Fancey 1, Karen Gamble 1, Kelly Bicknell 2, Joanna K Dowman 1, Paul Howden 3, Richard J Aspinall 1
 
32.Non-alcoholic fatty liver disease and cognitive function in middle-aged adults: the CARDIA study
 

BMC Gastroenterol. 2021 Mar 2;21(1):96. doi: 10.1186/s12876-021-01681-0.

Yariv Gerber 1 2 3, Lisa B VanWagner 4, Kristine Yaffe 5, James G Terry 6, Jamal S Rana 7 5, Jared P Reis 8, Stephen Sidney 7
 
33.Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease
 

Obes Surg. 2021 Feb 22. doi: 10.1007/s11695-020-04996-1. Online ahead of print.

Saleh A Alqahtani 1 2 3, Pegah Golabi 4 5, James M Paik 4 5, Brian Lam 4, Amir H Moazez 5, Hazem A Elariny 5, Zachary Goodman 4, Zobair M Younossi 6 7
 
34.TLR9 in MAFLD and NASH: At the Intersection of Inflammation and Metabolism
 

Front Endocrinol (Lausanne). 2021 Jan 29;11:613639.doi: 10.3389/fendo.2020.613639. eCollection 2020.

Christopher R Shepard 1
 
35.Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis
 

Front Endocrinol (Lausanne). 2021 Jan 27;11:575843. doi: 10.3389/fendo.2020.575843.eCollection 2020.

Andrea Dennis 1, Matt D Kelly 1, Carolina Fernandes 1, Sofia Mouchti 1, Jonathan A Fallowfield 2, Gideon Hirschfield 3, Michael Pavlides 4 5 6, Stephen Harrison 4 7, Manu V Chakravarthy 8, Rajarshi Banerjee 1, Arun Sanyal 9
 
36.Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions
 

Clin Ther. 2021 Feb 11;S0149-2918(21)00048-5. doi: 10.1016/j.clinthera.2021.01.021.Online ahead of print.

Patrick Campbell 1, Allison Symonds 2, A Sidney Barritt 4th 3
 
37.Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT
 

ESC Heart Fail. 2021 Feb 14. doi: 10.1002/ehf2.13250. Online ahead of print.

Anthony E Peters 1, Ambarish Pandey 2, Colby Ayers 2, Kara Wegermann 3, Robert W McGarrah 1, Justin L Grodin 2, Manal F Abdelmalek 3, Tarek Bekfani 4, Vanessa L Blumer 1, Anna Mae Diehl 3, Cynthia A Moylan 3, Marat Fudim 1
 
38.Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
 

Clin Ther. 2021 Feb 10;S0149-2918(21)00016-3. doi: 10.1016/j.clinthera.2021.01.012.Online ahead of print.

Shannon Kogachi 1, Mazen Noureddin 2
 
39.A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis
 

J Hepatol. 2021 Feb 10;S0168-8278(21)00099-4. doi: 10.1016/j.jhep.2021.01.047.Online ahead of print.

Stephen A Harrison 1, Mustafa R Bashir 2, Kyoung-Jin Lee 3, Jennifer Shim-Lopez 3, Jonathan Lee 3, Brandee Wagner 3, Nicholas D Smith 3, Hubert C Chen 4, Eric J Lawitz 5
 
40.Insulin resistance dysregulates CYP7B1 leading to oxysterol accumulation: a pathway for NAFL to NASH transition
 

J Lipid Res. 2020 Dec;61(12):1629-1644. doi: 10.1194/jlr.RA120000924. Epub 2021 Jan 12.

Genta Kakiyama 1, Dalila Marques 2, Rebecca Martin 3, Hajime Takei 4, Daniel Rodriguez-Agudo 2, Sandra A LaSalle 5, Taishi Hashiguchi 6, Xiaoying Liu 7, Richard Green 7, Sandra Erickson 8, Gregorio Gil 9, Michael Fuchs 2, Mitsuyoshi Suzuki 10, Tsuyoshi Murai 11, Hiroshi Nittono 4, Phillip B Hylemon 12, Huiping Zhou 12, William M Pandak 13
 
41.Editorial: Emerging metabolic and transcriptomic signature of PNPLA3 associated NASH
 

Hepatology. 2021 Feb 5. doi: 10.1002/hep.31735. Online ahead of print.

Debanjan Dhar 1, Rohit Loomba 1 2 3
 
42.Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition?
 

J Clin Med. 2021 Jan 31;10(3):492. doi: 10.3390/jcm10030492.

Amedeo Lonardo 1
 
43.Tumor Incidence in Patients with Non-Alcoholic Fatty Liver Disease
 

Dtsch Arztebl Int. 2020 Oct 23;117(43):719-724. doi: 10.3238/arztebl.2020.0719.

Yvonne Huber 1, Christian Labenz, Maurice Michel, Marcus-A Wörns, Peter R Galle, Karel Kostev, Jörn M Schattenberg
 
44.Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AM
 

BMJ Open Gastroenterol. 2021 Feb;8(1):e000572. doi: 10.1136/bmjgast-2020-000572.

Kelly Lee Hayward 1 2, Amy L Johnson 1 2, Leigh U Horsfall 1 2, Chris Moser 3, Patricia C Valery # 1 4, Elizabeth E Powell # 5 2
 
45.NAFLD-related HCC
 

Adv Cancer Res. 2021;149:143-169. doi: 10.1016/bs.acr.2020.11.001. Epub 2021 Jan 21.

Bubu A Banini 1, Arun J Sanyal 2
 
46.A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH
 

Hepatology. 2021 Feb 11. doi: 10.1002/hep.31750. Online ahead of print.

Amaro Taylor-Weiner 1, Harsha Pokkalla 1, Ling Han 2, Catherine Jia 2, Ryan Huss 2, Chuhan Chung 2, Hunter Elliott 1, Benjamin Glass 1, Kishalve Pethia 1, Oscar Carrasco-Zevallos 1, Chinmay Shukla 1, Urmila Khettry 3, Robert Najarian 4, Ross Taliano 5, G Mani Subramanian 2, Robert P Myers 2, Ilan Wapinski 1, Aditya Khosla 1, Murray Resnick 1 5, Michael C Montalto 1, Quentin M Anstee 6, Vincent Wai-Sun Wong 7, Michael Trauner 8, Eric J Lawitz 9, Stephen A Harrison 10, Takeshi Okanoue 11, Manuel Romero-Gomez 12, Zachary Goodman 13 14, Rohit Loomba 15, Andrew H Beck 1, Zobair M Younossi 13 14
 
47.Human Nonalcoholic Steatohepatitis on a Chip
 

Hepatol Commun. 2020 Nov 29;5(2):217-233. doi: 10.1002/hep4.1647. eCollection 2021 Feb.

May S Freag 1 2, Bumseok Namgung 1 2, Maria E Reyna Fernandez 1 2, Ermanno Gherardi 3, Shiladitya Sengupta 1 2 4, Hae Lin Jang 1
 
48.Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting
 

Hepatol Commun. 2020 Oct 31;5(2):158-167. doi: 10.1002/hep4.1618.eCollection 2021 Feb.

Joana Vieira Barbosa 1 2, Michelle Lai 1
 
49.Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications
 

Curr Diab Rep. 2021 Feb 5;21(3):8. doi: 10.1007/s11892-021-01377-5.

Katherine Martin 1 2 3, Anas Hatab 4 5, Varinder S Athwal 4 5 6, Elliot Jokl 4 5, Karen Piper Hanley 7 8
 
50.Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?
 

Gut. 2021 Feb 4;gutjnl-2020-322564. doi: 10.1136/gutjnl-2020-322564. Online ahead of print.

Ramy Younes 1 2 3, Olivier Govaere 1, Salvatore Petta 4, Luca Miele 5 6, Dina Tiniakos 1 7, Alastair Burt 1, Ezio David 3, Fabio Maria Vecchio 5 8, Marco Maggioni 9, Daniela Cabibi 10, Duncan McLeod 11, Maria Jesus Pareja 12, Anna Ludovica Fracanzani 13, Rocio Aller 14, Chiara Rosso 3, Javier Ampuero 15, Rocío Gallego-Durán 15, Angelo Armandi 3, Gian Paolo Caviglia 3, Marco Y W Zaki 1 16, Antonio Liguori 5, Paolo Francione 13, Grazia Pennisi 4, Antonio Grieco 5 6, Giovanni Birolo 3, Piero Fariselli 3, Mohammed Eslam 17, Luca Valenti 18, Jacob George 17, Manuel Romero-Gómez 15, Quentin Mark Anstee 19 20, Elisabetta Bugianesi 21
 
51.Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease
 

Sci Rep. 2021 Feb 3;11(1):2858. doi: 10.1038/s41598-021-82315-z.

Katharine M Irvine # 1 2, Satomi Okano # 3, Preya J Patel 4 5, Leigh U Horsfall 4 6, Suzanne Williams 7, Anthony Russell 8 9, Elizabeth E Powell 10 11
 
52.Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement
 

Hepatology. 2021 Jan 23. doi: 10.1002/hep.31726. Online ahead of print.

Hannes Hagström 1 2 3, Leon A Adams 4, Alina M Allen 5, Christopher D Byrne 6 7, Yoosoo Chang 8, Henning Grønbaek 9, Mona Ismail 10 11, Peter Jepsen 9, Fasiha Kanwal 12, Jennifer Kramer 12, Jeffrey V Lazarus 13, Michelle T Long 14, Rohit Loomba 15, Philip N Newsome 16 17, Ian A Rowe 18, Seungho Ryu 8 19, Jörn M Schattenberg 20, Marina Serper 21, Nick Sheron 22, Tracey G Simon 23 24, Elliot B Tapper 25, Sarah Wild 26, Vincent Wai-Sun Wong 27, Yusuf Yilmaz 28 29, Shira Zelber-Sagi 30, Fredrik Åberg 31 32
 
53.NAFLD as a metabolic disease in humans: A literature review
 

Diabetes Obes Metab. 2021 Jan 19. doi: 10.1111/dom.14322. Online ahead of print.

Bertrand Cariou 1, Christopher D Byrne 2, Rohit Loomba 3, Arun J Sanyal 4
 
54.Pathophysiology of NASH in endocrine diseases
 

Endocr Connect. 2021 Jan 1;EC-20-0490.R1. doi: 10.1530/EC-20-0490.Online ahead of print.

Karim Gariani 1, François R Jornayvaz 2
 
55.Adherence to Ideal Cardiovascular Health Metrics Is Associated With Reduced Odds of Hepatic Steatosis
 

Hepatol Commun. 2020 Oct 10;5(1):74-82. doi: 10.1002/hep4.1614. eCollection 2021 Jan.

Leah R DeCoste 1, Na Wang 2, Joseph N Palmisano 2, Jean Mendez 3, Udo Hoffmann 4, Emelia J Benjamin 5 6 7, Michelle T Long 3
 
56.Association of liver enzymes with incident diabetes in US Hispanic/Latino adults
 

Diabet Med. 2021 Jan 12;e14522. doi: 10.1111/dme.14522. Online ahead of print.

Simin Hua 1, Qibin Qi 1, Jorge R Kizer 2, Jessica Williams-Nguyen 3, Howard D Strickler 1, Bharat Thyagarajan 4, Martha Daviglus 5, Gregory A Talavera 6, Neil Schneiderman 7, Scott J Cotler 8, Jianwen Cai 9, Robert Kaplan 1 3, Carmen R Isasi 1
 
57.Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease
 

Diagnostics (Basel). 2021 Jan 9;11(1):E98. doi: 10.3390/diagnostics11010098.

Stefano Ballestri 1, Alessandro Mantovani 2, Enrica Baldelli 3, Simonetta Lugari 4, Mauro Maurantonio 4, Fabio Nascimbeni 4, Alessandra Marrazzo 1, Dante Romagnoli 5, Giovanni Targher 2, Amedeo Lonardo 6
 
58.Liver Fat Quantification by Ultrasound in Children: A Prospective Study
 

AJR Am J Roentgenol. 2021 Jan 13. doi: 10.2214/AJR.20.24874. Online ahead of print.

Aurélie D'Hondt 1, Erika Rubesova 1, Hua Xie 2, Vijay Shamdasani 3, Richard A Barth 1
 
59.Metabolic associated fatty liver disease: Addressing a new era in liver transplantation
 

World J Hepatol. 2020 Dec 27;12(12):1168-1181. doi: 10.4254/wjh.v12.i12.1168

Madeleine G Gill 1, Avik Majumdar 1
 
60.Digital Intervention With Lifestyle Coach Support to Target Dietary and Physical Activity Behaviors of Adults With Nonalcoholic Fatty Liver Disease: Systematic Development Process of VITALISE Using Intervention Mapping
 

J Med Internet Res. 2021 Jan 15;23(1):e20491. doi: 10.2196/20491.

Kate Hallsworth 1 2 3, Stuart McPherson 1 2 3, Quentin M Anstee 1 2 3, Darren Flynn 4, Laura Haigh 1 2 3, Leah Avery 3 4
 
61.Ceramide Salvage, Gut Mucosal IgA Signaling, and Diet-Induced NASH
 

Hepatology. 2021 Jan 15. doi: 10.1002/hep.31707. Online ahead of print.

Scott A McHenry 1, Nicholas O Davidson 1
 
62.Gut microbiome changes in Nonalcoholic fatty liver disease & alcoholic liver disease
 

Transl Gastroenterol Hepatol. 2021 Jan 5;6:3. doi: 10.21037/tgh.2020.02.18.eCollection 2021.

Eric K Kwong 1, Puneet Puri 2 3
 
63.Basic science to clinical trials in non-alcoholic fatty liver disease and alcohol-related liver disease: collaboration with industry
 

Transl Gastroenterol Hepatol. 2021 Jan 5;6:5. doi: 10.21037/tgh.2020.01.04.eCollection 2021.

Amon Asgharpour 1, Amreen Dinani 1, Scott L Friedman 1
 
64.Maternal Diet Alters Trained Immunity in the Pathogenesis of Pediatric NAFLD
 

J Cell Immunol. 2020;2(6):315-325. doi: 10.33696/immunology.2.061.

Karen R Jonscher 1 2, Jesse Abrams 2, Jacob E Friedman 2 3
 
65.Non-alcoholic Fatty Liver and Liver Fibrosis Predictive Analytics: Risk Prediction and Machine Learning Techniques for Improved Preventive Medicine
 

J Med Syst. 2021 Jan 11;45(2):22. doi: 10.1007/s10916-020-01693-5.

Orit Goldman 1, Ofir Ben-Assuli 2, Ori Rogowski 3, David Zeltser 3, Itzhak Shapira 3, Shlomo Berliner 3, Shira Zelber-Sagi 4 5, Shani Shenhar-Tsarfaty 3
 
66.Efficacy and Safety of Intragastric Balloon (IGB) in Non-alcoholic Fatty Liver Disease (NAFLD): a Comprehensive Review and Meta-analysis
 

Obes Surg. 2021 Jan 6. doi: 10.1007/s11695-020-05084-0. Online ahead of print.

Saurabh Chandan 1, Babu P Mohan 2, Shahab R Khan 3, Antonio Facciorusso 4, Daryl Ramai 5, Lena L Kassab 6, Neil Bhogal 7, Ravishankar Asokkumar 8, Gortrand Lopez-Nava 8, Stephanie McDonough 2, Douglas G Adler 9
 
67.Dietary approaches to managing nonalcoholic fatty liver disease
 

Nurse Pract. 2020 Dec 31;Publish Ahead of Print. doi: 10.1097/01.NPR.0000731560.23509.ff.Online ahead of print.

Dalia El Khoury 1, Rosemary J Pauley, Carol Lynn Berseth
 
68.Lean NAFLD: an underrecognized and challenging disorder in medicine
 

Rev Endocr Metab Disord. 2021 Jan 3. doi: 10.1007/s11154-020-09621-1.Online ahead of print.

Sheila Maier 1, Amanda Wieland 2, Melanie Cree-Green 3, Kristen Nadeau 3, Shelby Sullivan 4, Miguel A Lanaspa 5, Richard J Johnson 5, Thomas Jensen 6 7
 
69.Cannabis use history is associated with increased prevalence of ascites among patients with nonalcoholic fatty liver disease: A nationwide analysis
 

World J Hepatol. 2020 Nov 27;12(11):993-1003. doi: 10.4254/wjh.v12.i11.993.

Catherine J Choi 1, Stanley H Weiss 2, Umair M Nasir 1, Nikolaos T Pyrsopoulos 3
 
70.Insulin Resistance is Mechanistically Linked to Hepatic Mitochondrial Remodeling in Nonalcoholic Fatty Liver Disease
 

Mol Metab. 2020 Dec 22;101154. doi: 10.1016/j.molmet.2020.101154. Online ahead of print.

Chris E Shannon 1, Mukundan Ragavan 2, Juan Pablo Palavicini 3, Marcel Fourcaudot 1, Terry Bakewell 1, Ivan A Valdez 1, Iriscilla Ayala 1, Eunsook S Jin 4, Muniswamy Madesh 5, Xianlin Han 6, Matthew E Merritt 2, Luke Norton 7
 
71.Glycogenosis is Common in Nonalcoholic Fatty Liver Disease and is Independently Associated with Ballooning, but Lower Steatosis and Lower Fibrosis
 

Liver Int. 2020 Dec 22. doi: 10.1111/liv.14773. Online ahead of print.

Daniela S Allende 1, Samer Gawrieh 2, Oscar W Cummings 3, Patricia Belt 4, Laura Wilson 4, Mark Van Natta 4, Cynthia A Behling 5, Danielle Carpenter 6, Ryan M Gill 7, David E Kleiner 8, Mathew M Yeh 9, Naga Chalasani 2, Cynthia D Guy 10, NASH Clinical Research Network
 
72.Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steato-hepatitis: a hierarchical network meta-analysis
 

Diabetes Obes Metab. 2020 Dec 23. doi: 10.1111/dom.14304. Online ahead of print.

Simona Panunzi 1, Sabina Maltese 2, Ornella Verrastro 3 4, Luca Labbate 2, Andrea De Gaetano 1, Maurizio Pompili 3 4, Esmeralda Capristo 3 4, Stefan R Bornstein 5 6, Geltrude Mingrone 3 4 6
 
73.FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
 

Front Endocrinol (Lausanne). 2020 Dec 14;11:601290.doi: 10.3389/fendo.2020.601290. eCollection 2020.

Erik J Tillman 1, Tim Rolph 1
 
74.Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study
 

Patient. 2020 Dec 18. doi: 10.1007/s40271-020-00485-w. Online ahead of print.

Lynda C Doward 1, Maria-Magdalena Balp 2, James Twiss 3, Christina Slota 4, Donna Cryer 5, Clifford A Brass 6, Quentin M Anstee 7 8, Arun J Sanyal 9
 
75.Metabolic drivers of non-alcoholic fatty liver disease
 

Mol Metab. 2020 Dec 17;101143. doi: 10.1016/j.molmet.2020.101143. Online ahead of print.

Kendra K Bence 1, Morris J Birnbaum 2
 
76.Incidence of Depression and Anxiety in a Cohort of Adolescents with Nonalcoholic Fatty Liver Disease
 

J Pediatr Gastroenterol Nutr. 2020 Dec 16;Publish Ahead of Print.doi: 10.1097/MPG.0000000000003024. Online ahead of print.

Sheila Noon 1, Danielle D'Annibale, Melanie Schwimmer, Jacqueline Shiels, Jennifer Arin, Janis Durelle, Kimberly Newton, Nidhi Goyal, Jeffrey Schwimmer
 
77.Evaluation of Non-Alcoholic Fatty Liver Disease in Pediatric Patients with Inflammatory Bowel Disease
 

J Pediatr Gastroenterol Nutr. 2020 Dec 16;Publish Ahead of Print.doi: 10.1097/MPG.0000000000003023. Online ahead of print.

Mallory E Cohen 1, Parakkal Deepak, Geetika Khanna, Charles M Samson
 
78.Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: A cross-sectional and longitudinal analysis
 

World J Gastroenterol. 2020 Dec 14;26(46):7367-7381. doi: 10.3748/wjg.v26.i46.7367.

Peter Hoffmann 1, Victoria Jung 2, Rouven Behnisch 3, Annika Gauss 2
 
79.Non-alcoholic fatty liver disease - a special consideration in TIPS?
 

Liver Transpl. 2020 Dec 21. doi: 10.1002/lt.25976. Online ahead of print.

Sarah Wang 1, Juan G Abraldes 1
 
80.A large-scale internal validation study of unsupervised virtual trichrome staining technologies on nonalcoholic steatohepatitis liver biopsies
 

Mod Pathol. 2020 Dec 9. doi: 10.1038/s41379-020-00718-1. Online ahead of print.

Joshua J Levy 1 2 3, Nasim Azizgolshani 4, Michael J Andersen Jr 5, Arief Suriawinata 5, Xiaoying Liu 5, Mikhail Lisovsky 5, Bing Ren 5, Carly A Bobak 6 7 8 9, Brock C Christensen 4 10 11, Louis J Vaickus 5
 
81.Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease
 

Cell Metab. 2020 Dec 3;S1550-4131(20)30605-7. doi: 10.1016/j.cmet.2020.11.010.Online ahead of print.

S R Sharpton 1, B Schnabl 2, R Knight 3, R Loomba 4
 
82.NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment
 

Diabetes Metab. 2020 Dec 6;101215. doi: 10.1016/j.diabet.2020.101215.Online ahead of print.

Giovanni Targher 1, Kathleen E Corey 2, Christopher D Byrne 3a
 
83. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease
 

Clin Mol Hepatol. 2020 Dec 10. doi: 10.3350/cmh.2020.0129. Online ahead of print.

Erica Jennison 1, Christopher D Byrne 2 3
 
84.Emerging Therapies for the Treatment of Non-Alcoholic Steatohepatitis: A Systematic Review
 

Pharmacotherapy. 2020 Dec 5. doi: 10.1002/phar.2489. Online ahead of print.

Erenie Guirguis 1, Yasmin Grace 1, Anthony Bolson 1, Matthew J DellaVecchia 1, Melissa Ruble 2
 
85.Fibrosis progression rate in a systematic review of placebo-treated nonalcoholic steatohepatitis
 

Liver Int. 2020 Dec 7. doi: 10.1111/liv.14749. Online ahead of print.

Anna Roskilly 1, Amy Hicks 1, Eleanor J Taylor 1, Rebecca Jones 1, Richard Parker 1, Ian A Rowe 1 2
 
86.Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations
 

Am J Gastroenterol. 2020 Dec 7. doi: 10.14309/ajg.0000000000001054. Online ahead of print.

Zobair M Younossi 1, Mazen Noureddin 2, David Bernstein 3, Paul Kwo 4, Mark Russo 5, Mitchell L Shiffman 6, Ziad Younes 7, Manal Abdelmalek 8
 
87.Regulation of gene transcription by thyroid hormone receptor ß agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH)
 

PLoS One. 2020 Dec 11;15(12):e0240338. doi: 10.1371/journal.pone.0240338. eCollection 2020.

Xuan G Luong 1, Sarah K Stevens 1, Andreas Jekle 1, Tse-I Lin 2, Kusum Gupta 1, Dinah Misner 1, Sushmita Chanda 1, Sucheta Mukherjee 1, Caroline Williams 1, Antitsa Stoycheva 1, Lawrence M Blatt 1, Leonid N Beigelman 1, Julian A Symons 1, Pierre Raboisson 2, David McGowan 2, Koen Vandyck 2, Jerome Deval 1
 
88.The Association of Histologic and Non-invasive Tests with Adverse Clinical and Patient-Reported Outcomes in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH)
 

Gastroenterology. 2020 Dec 8;S0016-5085(20)35529-3. doi: 10.1053/j.gastro.2020.12.003.Online ahead of print.

Zobair M Younossi 1, Quentin M Anstee 2, Vincent Wai-Sun Wong 3, Michael Trauner 4, Eric J Lawitz 5, Stephen A Harrison 6, Marianne Camargo 7, Kathryn Kersey 7, G Mani Subramanian 7, Robert P Myers 7, Maria Stepanova 8
 
89.Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression
 

Metabolism. 2020 Dec 1;154457. doi: 10.1016/j.metabol.2020.154457. Online ahead of print.

Nisreen Nimer 1, Ibrahim Choucair 2, Zeneng Wang 2, Ina Nemet 2, Lin Li 2, Janet Gukasyan 3, Taylor L Weeks 2, Naim Alkhouri 4, Nizar Zein 5, W H Wilson Tang 6, Michael A Fischbach 5, J Mark Brown 2, Hooman Allayee 3, Srinivasan Dasarathy 7, Valentin Gogonea 8, Stanley L Hazen 9
 
90.Microbiome Biomarkers: One Step Closer in NAFLD-Cirrhosis
 

Hepatology. 2020 Nov 29. doi: 10.1002/hep.31660. Online ahead of print.

Tracey G Simon 1 2 3, Andrew T Chan 1 2 3 4 5 6, Curtis Huttenhower 5 6 7
 
91.Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver
 

Curr Hypertens Rev. 2020 Dec 9. doi: 10.2174/1573402116999201209203534.Online ahead of print.

Eddison Godinez-Leiva 1, Fernando Bril 2
 
92.The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007-2017
 

Hepatol Commun. 2020 Sep 14;4(12):1769-1780. doi: 10.1002/hep4.1599. eCollection 2020 Dec.

James M Paik 1, Pegah Golabi 1, Youssef Younossi 2, Manirath Srishord 1, Alita Mishra 3, Zobair M Younossi 1 3
 
93.AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease (NAFLD): Expert Review
 

Gastroenterology. 2020 Dec 8;S0016-5085(20)35538-4.doi: 10.1053/j.gastro.2020.11.051. Online ahead of print.

Zobair M Younossi 1, Kathleen E Corey 2, Joseph K Lim 3
 
94.Epidemiology and natural history of non-alcoholic fatty liver disease
 

Metabolism. 2016 Aug;65(8):1017-25. doi: 10.1016/j.metabol.2016.01.012.Epub 2016 Jan 29.

Yousef Fazel 1, Aaron B Koenig 1, Mehmet Sayiner 1, Zachary D Goodman 2, Zobair M Younossi 3
 
95.Liver Transplantation for NASH-Related Hepatocellular Carcinoma Versus Non-NASH Etiologies of Hepatocellular Carcinoma
 

Transplantation. 2018 Apr;102(4):640-647.doi: 10.1097/TP.0000000000002043.

Erin M Sadler 1 2, Neil Mehta 3, Mamatha Bhat 1 4, Anand Ghanekar 1 2, Paul D Greig 1 2, David R Grant 1 2, Francis Yao 3, Gonzalo Sapisochin 1 2
 
96.A diabetologist
 

Liver Int. 2020 Feb;40 Suppl 1:82-88. doi: 10.1111/liv.14350.

Kenneth Cusi 1 2
 
97.Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?
 

Gut. 2002 May;50(5):585-8.doi: 10.1136/gut.50.5.585.

C P Day 1
 
98.Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016
 

Medicine (Baltimore). 2018 Aug;97(31):e11518.doi: 10.1097/MD.0000000000011518.

Pegah Golabi 1, Haley Bush 1, Maria Stepanova 2, Cameron T Locklear 3, Ira M Jacobson 4, Alita Mishra 3, Gregory Trimble 3, Madeline Erario 3, Chapy Venkatesan 3, Issah Younossi 2, Zachary Goodman 1 3, Zobair M Younossi 1 3
 
99.Practice patterns in NAFLD and NASH: real life differs from published guidelines
 

Therap Adv Gastroenterol. 2016 Jan;9(1):4-12. doi: 10.1177/1756283X15611581.

Mary E Rinella 1, Zurabi Lominadze 2, Rohit Loomba 3, Michael Charlton 4, Brent A Neuschwander-Tetri 5, Stephen H Caldwell 6, Kris Kowdley 7, Stephen A Harrison 8
 
100.Transient Versus 2-Dimensional Shear-Wave Elastography in a Multistep Strategy to Detect Advanced Fibrosis in NAFLD
 

Hepatology. 2020 Nov 24. doi: 10.1002/hep.31655. Online ahead of print.

Christophe Cassinotto 1 2, Jérome Boursier 3 4, Anita Paisant 5, Boris Guiu 1, Marie Irles-Depe 6, Clémence Canivet 3 4, Christophe Aube 4 5, Victor de Ledinghen 6
 
101.Can You Trust Your Gut? Implicating a Disrupted Intestinal Microbiome in the Progression of NAFLD/NASH
 

Front Endocrinol (Lausanne). 2020 Oct 21;11:592157.doi: 10.3389/fendo.2020.592157. eCollection 2020.

Kavita Jadhav 1, Taylor S Cohen 1
 
102.Nonalcoholic Fatty Liver Disease: Common Questions and Answers on Diagnosis and Management
 

Am Fam Physician. 2020 Nov 15;102(10):603-612.

Erin Westfall 1, Robert Jeske 1, Andrew R Bader 2
 
103.GPCRs get Fatty: The Role of G Protein-Coupled Receptor Signaling in the Development and Progression of Nonalcoholic Fatty Liver Disease
 

Am J Physiol Gastrointest Liver Physiol. 2020 Nov 18. doi: 10.1152/ajpgi.00275.2020.Online ahead of print.

Ryan Kurtz 1, Meghan F Anderman 1, Blythe D Shepard 1
 
104.NAFLD and COVID-19: a Pooled Analysis
 

SN Compr Clin Med. 2020 Nov 6;1-4. doi: 10.1007/s42399-020-00631-3. Online ahead of print.

Sonali Sachdeva 1, Harshwardhan Khandait 2, Jonathan Kopel 3, Mark M Aloysius 4, Rupak Desai 5, Hemant Goyal 4
 
105.Genetic and epigenetic factors determining NAFLD risk
 

Mol Metab. 2020 Nov 4;101111. doi: 10.1016/j.molmet.2020.101111. Online ahead of print.

Wenke Jonas 1, Annette Schürmann 2
 
106.Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes
 

Hepatol Commun. 2020 Aug 28;4(11):1637-1650. doi: 10.1002/hep4.1581. eCollection 2020 Nov.

Zobair M Younossi 1 2, Vincent Wai-Sun Wong 3, Quentin M Anstee 4 5, Manuel Romero-Gomez 6, Michael H Trauner 7, Stephen A Harrison 8, Eric J Lawitz 9, Takeshi Okanoue 10, Marianne Camargo 11, Kathryn Kersey 11, Robert P Myers 11, Zachary Goodman 1 2, Maria Stepanova 12
 
107.Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis due to NASH
 

Hepatology. 2020 Nov 10. doi: 10.1002/hep.31622. Online ahead of print.

Rohit Loomba 1, Mazen Noureddin 2, Kris V Kowdley 3, Anita Kohli 4, Aasim Sheikh 5, Guy Neff 6, Bal Raj Bhandari 7, Nadege Gunn 8, Stephen H Caldwell 9, Zachary Goodman 10, Ilan Wapinski 11, Murray Resnick 11, Andrew H Beck 11, Dora Ding 12, Catherine Jia 12, Jen-Chieh Chuang 12, Ryan S Huss 12, Chuhan Chung 12, G Mani Subramanian 12, Robert P Myers 12, Keyur Patel 13, Brian B Borg 14, Reem Ghalib 15, Heidi Kabler 16, John Poulos 17, Ziad Younes 18, Magdy Elkhashab 19, Tarek Hassanein 20, Rajalakshmi Iyer 21, Peter Ruane 22, Mitchell L Shiffman 23, Simone Strasser 24, Vincent Wai-Sun Wong 25, Naim Alkhouri 26, ATLAS Investigators
 
108.MRI-PDFF treatment response criteria in nonalcoholic steatohepatitis
 

Hepatology. 2020 Nov 11. doi: 10.1002/hep.31624. Online ahead of print.

Rohit Loomba 1 2
 
109.A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
 

N Engl J Med. 2020 Nov 13. doi: 10.1056/NEJMoa2028395. Online ahead of print.

Philip N Newsome 1, Kristine Buchholtz 1, Kenneth Cusi 1, Martin Linder 1, Takeshi Okanoue 1, Vlad Ratziu 1, Arun J Sanyal 1, Anne-Sophie Sejling 1, Stephen A Harrison 1, NN9931-4296 Investigators
 
110.Retrospective analysis of a dedicated care pathway for nonalcoholic fatty liver disease in an integrated US healthcare system demonstrates support of weight management and improved ALT
 

BMC Gastroenterol. 2020 Oct 31;20(1):362. doi: 10.1186/s12876-020-01492-9.

Heather Patton 1 2, Raoul Burchette 3, Stephanie Tovar 3, Jose Pio 3, Jiaxiao Shi 3, Lisa M Nyberg 4 3
 
111.Relationship of IGF-1 and IGF Binding Proteins to Disease Severity and Glycemia in Non-Alcoholic Fatty Liver Disease
 

J Clin Endocrinol Metab. 2020 Oct 30;dgaa792. doi: 10.1210/clinem/dgaa792.Online ahead of print.

Takara L Stanley 1, Lindsay T Fourman 1, Isabel Zheng 1, Colin M McClure 1, Meghan N Feldpausch 1, Martin Torriani 2, Kathleen E Corey 3, Raymond T Chung 3, Hang Lee 4, David E Kleiner 5, Colleen M Hadigan 6, Steven K Grinspoon 1
 
112.NASH: Connecting the dots with patients in mind
 

Endocrinol Diabetes Metab. 2020 Oct 21;3(4):e00109. doi: 10.1002/edm2.109.eCollection 2020 Oct.

Donna R Cryer 1
 
113.Drug discovery and treatment paradigms in nonalcoholic steatohepatitis
 

Endocrinol Diabetes Metab. 2019 Dec 10;3(4):e00105. doi: 10.1002/edm2.105.eCollection 2020 Oct.

Mazen Noureddin 1, Mark D Muthiah 2 3, Arun J Sanyal 4
 
114.Determinants of Physical Activity Engagement in Patients With Nonalcoholic Fatty Liver Disease: The Need for an Individualized Approach to Lifestyle Interventions
 

Phys Ther. 2020 Oct 26;pzaa195. doi: 10.1093/ptj/pzaa195. Online ahead of print.

Philip O'Gorman 1, Ann Monaghan 1, Marie McGrath 2, Sara Naimimohasses 2 3, John Gormley 1, Suzanne Norris 2 3
 
115.Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors
 

PLoS One. 2020 Oct 27;15(10):e0241357. doi: 10.1371/journal.pone.0241357. eCollection 2020.

Jake P Mann 1 2 3, Paul Carter 3 4, Matthew J Armstrong 5, Hesham K Abdelaziz 6 7, Hardeep Uppal 3, Billal Patel 6, Suresh Chandran 8, Ranjit More 6, Philip N Newsome 9 10, Rahul Potluri 3
 
116.Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination
 

Sci Rep. 2020 Oct 27;10(1):18345. doi: 10.1038/s41598-020-75227-x.

Valentin Blank 1 2, David Petroff 2 3, Sebastian Beer 1, Albrecht Böhlig 4, Maria Heni 1, Thomas Berg 4, Yvonne Bausback 5, Arne Dietrich 2 6, Anke Tönjes 7, Marcus Hollenbach 1, Matthias Blüher 2 7, Volker Keim 1, Johannes Wiegand 4, Thomas Karlas 8
 
117.Nonalcoholic fatty liver disease: Reporting histologic findings in clinical practice
 

Hepatology. 2020 Oct 27. doi: 10.1002/hep.31599. Online ahead of print.

Elizabeth M Brunt 1, David E Kleiner 2, Danielle H Carpenter 3, Mary Rinella 4, Stephen A Harrison 5, Rohit Loomba 6, Zobair Younossi 7, Brent A Neuschwander-Tetri 8, Arun J Sanyal 9, American Association for the Study of Liver Diseases NASH Task Force
 
118.Non-alcoholic fatty liver disease (NAFLD) in non-obese individuals
 

Frontline Gastroenterol. 2019 Dec 13;11(6):478-483.doi: 10.1136/flgastro-2018-101119. eCollection 2020 Oct.

Meaghan Phipps 1, Julia Wattacheril 2
 
119.Performance of morphologic criteria for the diagnosis of cirrhosis in patients with non-alcoholic steatohepatitis compared to other etiologies of chronic liver disease: effect of level of training and experience
 

Abdom Radiol (NY). 2020 Sep 9. doi: 10.1007/s00261-020-02719-9. Online ahead of print.

Roberto Cannella 1 2, Navya Dasyam 3, Su-Hun Seo 4, Alessandro Furlan 3, Amir A Borhani 3 5
 
120.Lipoprotein and Metabolic Profiles Indicate Similar Cardiovascular Risk of Liver Steatosis and NASH
 

Digestion. 2020 Oct 20;1-11. doi: 10.1159/000510600. Online ahead of print.

Aline Gottlieb 1 2, Anna-Sophia Leven 3, Jan-Peter Sowa 2 4, Katrin Borucki 5, Alexander Link 2, Elvan Yilmaz 6, Sitke Aygen 6, Ali Canbay 7, Mustafa Porsch-Özcürümez 4
 
121.Pathogenesis and pathways: nonalcoholic fatty liver disease & alcoholic liver disease
 

Transl Gastroenterol Hepatol. 2020 Oct 5;5:49. doi: 10.21037/tgh.2019.12.05.eCollection 2020.

Kyle E Robinson 1, Vijay H Shah 1
 
122.Non-alcoholic Fatty Liver Disease as a Canonical Example of Metabolic Inflammatory-Based Liver Disease Showing a Sex-Specific Prevalence: Relevance of Estrogen Signaling
 

Front Endocrinol (Lausanne). 2020 Sep 18;11:572490.doi: 10.3389/fendo.2020.572490. eCollection 2020.

Sara Della Torre 1
 
123.What's Past Is Prologue: History of Nonalcoholic Fatty Liver Disease
 

Metabolites. 2020 Oct 8;10(10):E397. doi: 10.3390/metabo10100397.

Giovanni Targher 1
 
124.Pediatric Non-Alcoholic Fatty Liver Disease: Nutritional Origins and Potential Molecular Mechanisms
 

Nutrients. 2020 Oct 16;12(10):E3166. doi: 10.3390/nu12103166.

Ashok Mandala 1, Rachel C Janssen 1, Sirish Palle 2, Kevin R Short 1 3 4, Jacob E Friedman 1 3 4
 
125.Expert Panel Review on Non-Alcoholic Fatty Liver Disease in Persons with HIV
 

Clin Gastroenterol Hepatol. 2020 Oct 15;S1542-3565(20)31431-2.doi: 10.1016/j.cgh.2020.10.018. Online ahead of print.

Jordan E Lake 1, Turner Overton 2, Susanna Naggie 3, Mark Sulkowski 4, Rohit Loomba 5, David E Kleiner 6, Jennifer C Price 7, Kara W Chew 8, Raymond T Chung 9, Kathleen E Corey 10
 
126.Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers
 

Contemp Clin Trials. 2020 Oct 8;106174. doi: 10.1016/j.cct.2020.106174. Online ahead of print.

Stephen A Harrison 1, Salvatore Calanna 2, Kenneth Cusi 3, Martin Linder 4, Takeshi Okanoue 5, Vlad Ratziu 6, Arun Sanyal 7, Anne-Sophie Sejling 8, Philip N Newsome 9
 
127.Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis
 

J Hepatol. 2020 Oct 7;S0168-8278(20)33673-4. doi: 10.1016/j.jhep.2020.09.029.Online ahead of print.

Catherine Frenette 1, Zeid Kayali 2, Edward Mena 3, Parvez S Mantry 4, Kathryn J Lucas 5, Guy Neff 6, Miguel Rodriguez 7, Paul J Thuluvath 8, Ethan Weinberg 9, Bal R Bhandari 10, James Robinson 11, Nicole Wedick 12, Jean L Chan 11, David T Hagerty 11, Kris V Kowdley 13, IDN-6556-17 Study Investigators
 
128.One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial
 

J Clin Med. 2020 Oct 6;9(10):E3213. doi: 10.3390/jcm9103213.

Louise Vedtofte 1 2, Emilie Bahne 1 2, Signe Foghsgaard 1 2 3, Jonatan I Bagger 1 2, Camilla Andreasen 1 2, Charlotte Strandberg 4, Peter M Gørtz 5, Jens J Holst 6 7, Henning Grønbæk 8, Jens A Svare 9, Tine D Clausen 10, Elisabeth R Mathiesen 11 12, Peter Damm 12 13, Lise L Gluud 12 14, Filip K Knop 1 2 7 12, Tina Vilsbøll 1 2 12
 
129.The European NAFLD registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease
 

Contemp Clin Trials. 2020 Oct 9;106175. doi: 10.1016/j.cct.2020.106175. Online ahead of print.

Timothy Hardy 1, Kristy Wonders 2, Ramy Younes 3, Guruprasad P Aithal 4, Rocio Aller 5, Michael Allison 6, Pierre Bedossa 2, Fay Betsou 7, Jerome Boursier 8, M Julia Brosnan 9, Alastair Burt 1, Jeremy Cobbold 10, Helena Cortez-Pinto 11, Chris P Day 1, Jean-Francois Dufour 12, Mattias Ekstedt 13, Sven Francque 14, Stephen Harrison 15, Luca Miele 16, Patrik Nasr 13, George Papatheodoridis 17, Salvatore Petta 18, Dina Tiniakos 19, Richard Torstenson 20, Luca Valenti 21, Adriaan G Holleboom 22, Hannele Yki-Jarvinen 23, Andreas Geier 24, Manuel Romero-Gomez 25, Vlad Ratziu 26, Elisabetta Bugianesi 27, Jörn M Schattenberg 28, Quentin M Anstee 29, LITMUS Consortium
 
130.Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort
 

Gut. 2020 Oct 9;gutjnl-2020-322786. doi: 10.1136/gutjnl-2020-322786. Online ahead of print.

Tracey G Simon 1 2 3, Bjorn Roelstraete 4, Hamed Khalili 1 2 3, Hannes Hagström 5, Jonas F Ludvigsson 6 7 8 9 10
 
131.Testosterone is Associated With Nonalcoholic Steatohepatitis (NASH) and Fibrosis in Pre-Menopausal Women With NAFLD
 

Clin Gastroenterol Hepatol. 2020 Sep 30;S1542-3565(20)31375-6.doi: 10.1016/j.cgh.2020.09.045. Online ahead of print.

Monika Sarkar 1, Ayako Suzuki 2, Manal Abdelmalek 2, Katherine Yates 3, Laura Wilson 3, Nathan M Bass 4, Ryan Gill 2, Marcelle Cedars 5, Norah Terrault 6, NASH Clinical Research Network (NASH CRN)
 
132.Non-Alcoholic Fatty Liver Disease in a sample of individuals with Bipolar Disorders: Results From the FACE-BD Cohort
 

Acta Psychiatr Scand. 2020 Oct 4. doi: 10.1111/acps.13239. Online ahead of print.

Ophelia Godin 1 2, Marion Leboyer 1 2, Raoul Belzeaux 1 3, Frank Bellivier 1 4, Joséphine Loftus 1 5, Philippe Courtet 1 6, Caroline Dubertret 1 7, Sebastien Gard 1 8, Chantal Henry 9, Pierre-Michel Llorca 1 10, Raymund Schwan 1 11, Christine Passerieux 1 12, Mircea Polosan 1 13, Ludovic Samalin 1 10, Emilie Olié 1 6, Bruno Etain 1 4, FondaMental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) Collaborators

 

Collaborators

  • FondaMental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) Collaborators: 

B Etain, C Henry, E Olié, M Leboyer, E Haffen, P M Llorca, V Barteau, S Bensalem, O Godin, H Laouamri, K Souryis, H Mondor, S Hotier, A Pelletier, N Drancourt, J P Sanchez, E Saliou, C Hebbache, J Petrucci, L Willaume, E Bourdin, F Bellivier, M Carminati, B Etain, J Maruani, E Marlinge, M Meyrel, B Antoniol, A Desage, S Gard, A Jutant, K Mbailara, I Minois, L Zanouy, L Bardin, A Cazals, P Courtet, B Deffinis, D Ducasse, M Gachet, A Henrion, F Molière, B Noisette, E Olié, G Tarquini, R Belzeaux, N Correard, F Groppi, A Lefrere, L Lescalier, E Moreau, J Pastol, M Rebattu, B Roux, N Viglianese, R Cohen, Raymund Schwan, J P Kahn, M Milazzo, O Wajsbrot-Elgrabli, T Bougerol, B Fredembach, A Suisse, B Halili, A Pouchon, M Polosan, A M Galliot, I Grévin, A S Cannavo, N Kayser, C Passerieux, P Roux, V Aubin, I Cussac, M A Dupont, J Loftus, I Medecin, C Dubertret, N Mazer, C Portalier, C Scognamiglio, A Bing
 
133.Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease
 

Curr Diab Rep. 2020 Oct 5;20(11):59. doi: 10.1007/s11892-020-01349-1.

Jeffrey Budd 1, Kenneth Cusi 2 3
 
134.Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease
 

Aliment Pharmacol Ther. 2020 Oct;52(7):1185-1194. doi: 10.1111/apt.16016. Epub 2020 Aug 17.

Ali Canbay 1, Nandita Kachru 2, Jennifer Scarlet Haas 3, Jan-Peter Sowa 1, Dominic Meise 3, Ahmet Burak Ozbay 2
 
135.Identifying High-Risk NASH Patients: What We Know so Far
 

Hepat Med. 2020 Aug 21;12:125-138. doi: 10.2147/HMER.S265473.eCollection 2020.

Marten Schulz 1, Frank Tacke 1
 
136.Systematic review of the impact of non-alcoholic fatty liver disease on mortality and adverse clinical outcomes for individuals with chronic kidney disease
 

BMJ Open. 2020 Sep 28;10(9):e040970. doi: 10.1136/bmjopen-2020-040970.

Theresa Hydes 1, Ryan Buchanan 2, Oliver J Kennedy 2, Simon Fraser 2, Julie Parkes 2, Paul Roderick 2
 
137.Late diagnosis of chronic liver disease in a community cohort (UK biobank): determinants and impact on subsequent survival
 

Public Health. 2020 Sep 26;187:165-171. doi: 10.1016/j.puhe.2020.07.017. Online ahead of print.

H Innes 1, J R Morling 2, E A Aspinall 3, D J Goldberg 3, S J Hutchinson 3, I N Guha 4
 
138.Clinical Characteristics of a Non-Alcoholic Fatty Liver Disease Population Across the Fibrosis Spectrum Measured by Magnetic Resonance Elastography: Analysis of Screening Data
 

Adv Ther. 2020 Oct 1.doi: 10.1007/s12325-020-01503-x. Online ahead of print.

Grit Andersen 1, Leona Plum-Mörschel 2, Paul D Hockings 3 4, Anni Morsing 5, Mads S Palle 6, Olivia Svolgaard 5, Anne Flint 7
 
139.The pharmacological treatment of non-alcoholic fatty liver disease in children
 

Expert Rev Clin Pharmacol. 2020 Sep 26. doi: 10.1080/17512433.2020.1829468.Online ahead of print.

Annalisa Crudele 1, Nadia Panera 1, Maria Rita Braghini 1, Clara Balsano 2, Anna Alisi 1
 
140.Liver Stiffness by Magnetic Resonance Elastography Predicts Future Cirrhosis, Decompensation and Death in NAFLD
 

Clin Gastroenterol Hepatol. 2020 Sep 30;S1542-3565(20)31374-4.doi:10.1016/j.cgh.2020.09.044. Online ahead of print.

Tolga Gidener 1, Omar T Ahmed 1, Joseph J Larson 2, Kristin C Mara 2, Terry M Therneau 2, Sudhakar K Venkatesh 3, Richard L Ehman 3, Meng Yin 3, Alina M Allen 4
 
141.The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care
 

JHEP Rep. 2020 Aug 4;2(6):100168. doi: 10.1016/j.jhepr.2020.100168. eCollection 2020 Dec.

Wolf Peter Hofmann 1 2, Peter Buggisch 2 3, Lisa Schubert 1 4, Nektarios Dikopoulos 5, Jeannette Schwenzer 6, Marion Muche 4, Gisela Felten 7, Renate Heyne 8, Patrick Ingiliz 9, Anna Schmidt 10, Kerstin Stein 11, Heiner Wedemeyer 12, Thomas Berg 13, Johannes Wiegand 13, Frank Lammert 14, Stefan Zeuzem 15, Jörn M Schattenberg 16 17
 
142.A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis
 

Sci Rep. 2020 Sep 17;10(1):15308. doi: 10.1038/s41598-020-71995-8.

Andrea Dennis 1, Sofia Mouchti 2, Matt Kelly 2, Jonathan A Fallowfield 3, Gideon Hirschfield 4, Michael Pavlides 5, Rajarshi Banerjee 2
 
143.Abnormal cardiac and metabolic measures correlate significantly with lower performance and activity in overweight chronic liver disease
 

J Clin Hypertens (Greenwich). 2020 Sep 17. doi: 10.1111/jch.13938. Online ahead of print.

Jillian Price 1, Carey Escheik 1 2, Ali Weinstein 3, Patrice Winter 1 2, Lynn Gerber 1, Zobair Younossi 1 2
 
144.A look to the future in non-alcoholic fatty liver disease: Are GLP-1 analogues or SGLT-2 inhibitors the answer?
 

Diabetes Obes Metab. 2020 Sep 18. doi: 10.1111/dom.14196. Online ahead of print.

Rebecca K Vincent # 1, David M Williams # 2, Marc Evans 2
 
145.Histological Endpoints for Nonalcoholic Steatohepatitis Trials: Lights and Shadows
 

Semin Liver Dis. 2020 Sep 9. doi: 10.1055/s-0040-1709491. Online ahead of print.

Ian A Rowe 1 2 3
 
146.Nonalcoholic Fatty Liver Disease Is Common in IBD Patients However Progression to Hepatic Fibrosis by Noninvasive Markers Is Rare
 

Dig Dis Sci. 2020 Sep 7. doi: 10.1007/s10620-020-06588-6. Online ahead of print.

Gabrielle Ritaccio 1, Gianna Stoleru 1, Ameer Abutaleb 2, Raymond K Cross 2, Kirti Shetty 2, Sasan Sakiani 2, Uni Wong 3
 
147.A Fad too Far? Dietary Strategies for the Prevention and Treatment of NAFLD
 

Obesity (Silver Spring). 2020 Sep 6. doi: 10.1002/oby.22964. Online ahead of print.

Mary P Moore # 1 2, Rory P Cunningham # 1 2, Ryan J Dashek 1 3, Justine M Mucinski 2, R Scott Rector 1 2 4
 
148.Change in MRI-PDFF and Histologic Response in Patients with Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
 

Clin Gastroenterol Hepatol. 2020 Aug 31;S1542-3565(20)31220-9.doi: 10.1016/j.cgh.2020.08.061. Online ahead of print.

Jonathan G Stine, Nagambika Munaganuru, Abbey Barnard, Jennifer L Wang, Kellee Kaulback, Curtis K Argo, Siddarth Singh, Kathryn J Fowler, Claude B Sirlin, Rohit Loomba
 
149.Non-Alcoholic Fatty Liver Disease Modifies Serum Gamma-Glutamyl Transferase in Cigarette Smokers
 

J Clin Med Res. 2020 Aug;12(8):472-482. doi: 10.14740/jocmr3932. Epub 2020 Jul 22.

Ebenezer T Oni 1, Vincent Figueredo 2, Ehimen Aneni 3, Emir Veladar 4, John W McEvoy 5, Michael J Blaha 5 6, Roger S Blumenthal 5, Raquel D Conceicao 7, Jose A M Carvalho 7, Raul D Santos 7 8, Khurram Nasir 9
 
150.Improvement in Insulin Resistance and Estimated Hepatic Steatosis and Fibrosis after Endoscopic Sleeve Gastroplasty
 

Gastrointest Endosc. 2020 Aug 27;S0016-5107(20)34733-7. doi:10.1016/j.gie.2020.08.023.Online ahead of print.

Kaveh Hajifathalian 1, Amit Mehta 1, Bryan Ang 2, Daniel Skaf 2, Shawn Shah 1, Monica Saumoy 3, Qais Dawod 1, Enad Dawod 2, Alpana Shukla 4, Louis Aronne 4, Robert Brown 1, David Cohen 1, Andrew J Dannenberg 5, Brett Fortune 1, Sonal Kumar 1, Reem Z Sharaiha 6
 
151.Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging
 

Alzheimers Dement (N Y). 2020 Aug 24;6(1):e12065.doi: 10.1002/trc2.12065. eCollection 2020.

Vincenzo Solfrizzi 1, Emanuele Scafato 2 3, Carlo Custodero 1, Francesca Loparco 1, Alessandro Ciavarella 1, Francesco Panza 4 5, Davide Seripa 4 6, Bruno Pietro Imbimbo 7, Madia Lozupone 8, Nicola Napoli 1, Giuseppina Piazzolla 1, Lucia Galluzzo 3, Claudia Gandin 2, Marzia Baldereschi 9, Antonio Di Carlo 9, Domenico Inzitari 9 10, Alberto Pilotto 1 11, Carlo Sabbà 1, Italian Longitudinal Study on Aging Working Group
 
152.Tackling NAFLD: Three Targeted Populations
 

Hepatology. 2020 Aug 31. doi: 10.1002/hep.31533. Online ahead of print.

Kara Wegermann 1, Ayako Suzuki 1 2, Alisha M Mavis 3, Manal F Abdelmalek 1, Anna Mae Diehl 1, Cynthia A Moylan 1 2
 
153.Too Much of a Good Thing? An Evolutionary Theory to Explain the Role of Ceramides in NAFLD
 

Front Endocrinol (Lausanne). 2020 Jul 31;11:505. doi: 10.3389/fendo.2020.00505.eCollection 2020.

Annelise M Poss 1, Scott A Summers 1
 
154.NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes
 

J Diabetes Complications. 2020 Jul 17;107684. doi: 10.1016/j.jdiacomp.2020.107684.Online ahead of print.

Rosa Lombardi 1, Lorena Airaghi 2, Giovanni Targher 3, Gaetano Serviddio 4, Gabriele Maffi 2, Alessandro Mantovani 3, Claudio Maffeis 5, Antonio Colecchia 6, Rosanna Villani 4, Luca Rinaldi 7, Emanuela Orsi 8, Giuseppina Pisano 2, Luigi Elio Adinolfi 7, Silvia Fargion 2, Anna Ludovica Fracanzani 2
 
155.Mechanisms of nonalcoholic fatty liver disease and implications for surgery
 

Langenbecks Arch Surg. 2020 Aug 24. doi: 10.1007/s00423-020-01965-1.Online ahead of print.

Benedikt Kaufmann 1 2, Agustina Reca 1, Baocai Wang 2, Helmut Friess 2, Ariel E Feldstein 1, Daniel Hartmann 3
 
156.Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic
 

JHEP Rep. 2020 Oct;2(5):100169. doi: 10.1016/j.jhepr.2020.100169.Epub 2020 Aug 4.

Tobias Boettler 1, Thomas Marjot 2, Philip N Newsome 3 4, Mario U Mondelli 5, Mojca Maticic 6 7, Elisa Cordero 8, Rajiv Jalan 9, Richard Moreau 10 11, Markus Cornberg 12 13, Thomas Berg 14
 
157.Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program
 

PLoS One. 2020 Aug 25;15(8):e0237430.doi: 10.1371/journal.pone.0237430. eCollection 2020.

Marina Serper 1 2 3, Marijana Vujkovic 1, David E Kaplan 1 2, Rotonya M Carr 1 2, Kyung Min Lee 4 5 6, Qing Shao 4, Donald R Miller 4, Peter D Reaven 7, Lawrence S Phillips 8 9, Christopher J O'Donnell 10 11, James B Meigs 12, Peter W F Wilson 8 9, Rachel Vickers-Smith 13, Henry R Kranzler 13 14, Amy C Justice 15 16 17, John M Gaziano 10 18, Sumitra Muralidhar 19, Saiju Pyarajan 10 11, Scott L DuVall 6 20, Themistocles L Assimes 21 22, Jennifer S Lee 21 22, Philip S Tsao 21 22, Daniel J Rader 2 23 24 25, Scott M Damrauer 1 26, Julie A Lynch 6 27, Danish Saleheen 1 28, Benjamin F Voight 1 23 29, Kyong-Mi Chang 1 2, VA Million Veteran Program
 
158.History of Nonalcoholic Fatty Liver Disease
 

Int J Mol Sci. 2020 Aug 16;21(16):E5888. doi: 10.3390/ijms21165888.

Amedeo Lonardo 1, Simona Leoni 2, Khalid A Alswat 3, Yasser Fouad 4
 
159.Maintaining Patient Safety and Data Integrity of NASH Clinical Trials During the SARS-CoV-2 Pandemic
 

Hepatology. 2020 Aug 14;10.1002/hep.31522. doi: 10.1002/hep.31522. Online ahead of print.

Naim Alkhouri 1, Anita Kohli 1, Rohit Loomba 2, Stephen A Harrison 3
 
160.The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in Nonalcoholic Steatohepatitis
 

Hepatology. 2020 Aug 13. doi: 10.1002/hep.31523. Online ahead of print.

Rohit Loomba 1, Lei Ling 2, Duy M Dinh 3, Alex M DePaoli 2, Hsiao D Lieu 2, Stephen A Harrison 4 5, Arun J Sanyal 6
 
161.Anti-inflammatory Activities of Green Tea Catechins along the Gut-liver Axis in Nonalcoholic Fatty Liver Disease: Lessons Learned from Preclinical and Human Studies
 

J Nutr Biochem. 2020 Aug 12;108478. doi: 10.1016/j.jnutbio.2020.108478.Online ahead of print.

Joanna K Hodges 1, Geoffrey Y Sasaki 1, Richard S Bruno 2
 
162.Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes
 

J Hepatocell Carcinoma. 2020 Jul 30;7:107-116. doi: 10.2147/JHC.S252506.eCollection 2020.

Claudia Campani # 1, Carolina Bensi # 1, Stefano Milani 1, Andrea Galli 1, Mirko Tarocchi 1
 
163.Racial and Socioeconomic Disparities in Hospitalization of Pediatrics with Liver Disease from 2005 to 2015
 

Dig Dis Sci. 2020 Aug 14. doi: 10.1007/s10620-020-06530-w. Online ahead of print.

Melissa Martin 1, Biyao Zou 2, Joseph Hoang 2, Donghak Jeong 2, Rachel Bensen 1, Mindie H Nguyen 3
 
164.Trimethylamine N-Oxide levels are associated with NASH in obese subjects with type 2 diabetes
 

Diabetes Metab. 2020 Aug 10;S1262-3636(20)30102-6. doi: 10.1016/j.diabet.2020.07.010.Online ahead of print.

Paola León-Mimila 1, Hugo Villamil-Ramírez 2, Xinmin S Li 3, Diana M Shih 1, Simon T Hui 1, Elvira Ocampo-Medina 2, Blanca López-Contreras 2, Sofía Morán-Ramos 4, Marisol Olivares-Arevalo 2, Paula Grandini-Rosales 2, Luis Macías-Kauffer 2, Israel González-González 5, Rogelio Hernández-Pando 6, Francisco Gómez-Pérez 7, Francisco Campos-Pérez 5, Carlos Aguilar-Salinas 8, Elena Larrieta-Carrasco 9, Teresa Villarreal-Molina 10, Zeneng Wang 3, Aldons J Lusis 1, Stanley L Hazen 11, Adriana Huertas-Vazquez 12, Samuel Canizales-Quinteros 13
 
165.Prevalence of NASH/NAFLD in people with obesity who are currently classified as metabolically healthy
 

Surg Obes Relat Dis. 2020 Jul 14;S1550-7289(20)30411-1. doi: 10.1016/j.soard.2020.07.009.Online ahead of print.

Sébastien Frey 1, Stéphanie Patouraux 2, Tarek Debs 3, Jean Gugenheim 4, Rodolphe Anty 5, Antonio Iannelli 6
 
166.Vitamin E as an Adjuvant Treatment for Non-alcoholic Fatty Liver Disease in Adults: A Systematic Review of Randomized Controlled Trials
 

Cureus. 2020 Jul 6;12(7):e9018. doi: 10.7759/cureus.9018.

Muhammad Usman 1 2, Nabiyah Bakhtawar 3
 
167.NAFLD and NASH in postmenopausal women: implications for diagnosis and treatment
 

Endocrinology. 2020 Aug 10;bqaa134.doi: 10.1210/endocr/bqaa134. Online ahead of print.

Johanna K DiStefano 1
 
168.Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
 

Gastroenterology. 2020 Aug 8;S0016-5085(20)35018-6. doi: 10.1053/j.gastro.2020.08.004.Online ahead of print.

Stephen A Harrison 1, Guy Neff 2, Cynthia D Guy 3, Mustafa R Bashir 4, Angelo H Paredes 5, Juan P Frias 6, Ziad Younes 7, James F Trotter 8, Nadege T Gunn 9, Sam E Moussa 10, Anita Kohli 11, Kristin Nelson 12, Mildred Gottwald 12, William C G Chang 12, Andrew Z Yan 12, Alex M DePaoli 12, Lei Ling 13, Hsiao D Lieu 12
 
169.Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future
 

Cell Host Microbe. 2020 Aug 12;28(2):233-244. doi: 10.1016/j.chom.2020.07.007.

Sonja Lang 1, Bernd Schnabl 2
 
170.A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study
 

Lancet Gastroenterol Hepatol. 2020 Aug 4;S2468-1253(20)30252-1.doi: 10.1016/S2468-1253(20)30252-1. Online ahead of print.

Stephen A Harrison 1, Vlad Ratziu 2, Jérôme Boursier 3, Sven Francque 4, Pierre Bedossa 5, Zouher Majd 6, Geneviève Cordonnier 6, Fouad Ben Sudrik 6, Raphael Darteil 7, Roman Liebe 8, Jérémy Magnanensi 6, Yacine Hajji 6, John Brozek 6, Alice Roudot 6, Bart Staels 9, Dean W Hum 6, Sophie Jeannin Megnien 10, Suneil Hosmane 6, Noémie Dam 6, Pierre Chaumat 6, Rémy Hanf 11, Quentin M Anstee 12, Arun J Sanyal 13
 
171.Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities
 

Hepatol Commun. 2020 May 19;4(8):1136-1148. doi: 10.1002/hep4.1534. eCollection 2020 Aug.

Pegah Golabi 1, James M Paik 1, Tamoore Arshad 2, Youssef Younossi 3, Alita Mishra 2, Zobair M Younossi 1 2
 
172.The Emerging Role of Hepatocellular eNOS in Non-alcoholic Fatty Liver Disease Development
 

Physiol. 2020 Jul 3;11:767. doi: 10.3389/fphys.2020.00767. eCollection 2020.

Rory P Cunningham 1 2, Ryan D Sheldon 3, R Scott Rector 1 2 4
 
173.Non-invasive diagnostic tools for pediatric NAFLD: where are we now?
 

Expert Rev Gastroenterol Hepatol. 2020 Jul 25.doi: 10.1080/17474124.2020.1801413.Online ahead of print.

Antonella Mosca 1, Nadia Panera 2, Annalisa Crudele 2, Anna Alisi 2
 
174.Protocol for a phase IV, open-label feasibility study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised background therapy (OBT) plus maraviroc or OBT alone
 

BMJ Open. 2020 Jul 6;10(7):e035596. doi: 10.1136/bmjopen-2019-035596.

Daniel Bradshaw 1, Yvonne Gilleece 2, Sumita Verma 3, Iga Abramowicz 3, Stephen Bremner 3, Nicky Perry 3
 
175.A Description of Risk Factors for Non-alcoholic Fatty Liver Disease in the Southern Community Cohort Study: A Nested Case-Control Study
 

Front Nutr. 2020 May 21;7:71. doi: 10.3389/fnut.2020.00071. eCollection 2020.

Sudipa Sarkar 1, Loren Lipworth 2 3, Edmond K Kabagambe 2 3, Aihua Bian 3 4, Thomas G Stewart 4, William J Blot 2 5, T Alp Ikizler 3 6, Adriana M Hung 3 6
 
176.Baseline HOMA IR and Circulating FGF21 Levels Predict NAFLD Improvement in Patients Undergoing a Low Carbohydrate Dietary Intervention for Weight Loss: A Prospective Observational Pilot Study
 

Nutrients. 2020 Jul 18;12(7):E2141. doi: 10.3390/nu12072141.

Mikiko Watanabe 1, Renata Risi 1, Elisabetta Camajani 1, Savina Contini 1, Agnese Persichetti 1, Dario Tuccinardi 2, Ilaria Ernesti 3, Stefania Mariani 1, Carla Lubrano 1, Alfredo Genco 3, Giovanni Spera 1, Lucio Gnessi 1, Sabrina Basciani 1
 
177.Brain MR Spectroscopy Markers of Encephalopathy Due to Nonalcoholic Steatohepatitis
 

J Neuroimaging. 2020 Jul 23. doi: 10.1111/jon.12728. Online ahead of print.

Thao T Tran 1, Ke Wei 1, Soren Cole 1, Edward Mena 2, Marie Csete 1, Kevin S King 1
 
178.Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
 

J Hepatol. 2020 Jun 28;S0168-8278(20)30399-8. doi: 10.1016/j.jhep.2020.06.025.Online ahead of print.

Beth A Davison 1, Stephen A Harrison 2, Gad Cotter 3, Naim Alkhouri 4, Arun Sanyal 5, Christopher Edwards 3, Jerry R Colca 6, Julie Iwashita 6, Gary G Koch 7, Howard C Dittrich 6
 
179.Review article: The impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis
 

Aliment Pharmacol Ther. 2020 Jul 8. doi: 10.1111/apt.15935. Online ahead of print.

Margery A Connelly 1, Jonathan Velez Rivera 2, John R Guyton 2, Mohammad Shadab Siddiqui 3, Arun J Sanyal 3
 
180.Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH
 

Clin Mol Hepatol. 2020 Jul 17. doi: 10.3350/cmh.2020.0067. Online ahead of print.

Theresa J Hydes 1, Sujan Ravi 1, Rohit Loomba 2, Meagan E Gray 1
 
181.Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Co-morbid Diseases
 

Ethan M Weinberg 1, Huy N Trinh 2, Roberto J Firpi 3, Kalyan Ram Bhamidimarri 4, Samuel Klein 5, Jonathan Durlam 6, Stephanie Watkins 6, K Rajender Reddy 1, Michael Weiss 7, Richard C Zink 6, Anna S Lok 8

Clin Gastroenterol Hepatol. 2020 Jul 3;S1542-3565(20)30930-7. doi:10.1016/j.cgh.2020.06.066.Online ahead of print.

 
 
182.Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices
 

Aliment Pharmacol Ther. 2020 Aug;52(3):513-526. doi: 10.1111/apt.15830. Epub 2020 Jun 29.

Zobair M Younossi 1, Kathleen E Corey 2, Naim Alkhouri 3, Mazen Noureddin 4, Ira Jacobson 5, Brian Lam 1, Stephen Clement 1, Rita Basu 6, Stuart Gordon 7, Natarajan Ravendhra 8, Puneet Puri 9, Mary Rinella 10, Peter Scudera 1, Ashwani K Singal 11, Linda Henry 12, US Members of the Global Nash Council
 
183.Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial
 

Am J Gastroenterol. 2020 Jul;115(7):1055-1065. doi: 10.14309/ajg.0000000000000661.

Laura Craven 1, Adam Rahman 2 3, Seema Nair Parvathy 4, Melanie Beaton 2 3, Justin Silverman 5, Karim Qumosani 2 3, Irene Hramiak 2 6, Rob Hegele 2 6 7, Tisha Joy 2 6, Jon Meddings 8, Brad Urquhart 2, Ruth Harvie 9, Charles McKenzie 2 7, Kelly Summers 1 2, Gregor Reid 1 2 9, Jeremy P Burton 1 2 9, Michael Silverman 1 2 4
 
184.Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes
 

Diabet Med. 2020 Jul 3. doi: 10.1111/dme.14356. Online ahead of print.

T J Hydes 1, N Summers 2, E Brown 3 4, U Alam 3 4 5, H Thomaides-Brears 6, J P H Wilding 3 4, D J Cuthbertson 3 4
 
185.Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)
 

Hepatol Int. 2020 Jul 4;1-11.doi: 10.1007/s12072-020-10072-8. Online ahead of print.

Shiv Kumar Sarin 1, Ashok Choudhury 2, George K Lau 3, Ming-Hua Zheng 3 4, Dong Ji 3 5, Sherief Abd-Elsalam 6, Jaeseok Hwang 7, Xiaolong Qi 8, Ian Homer Cua 9, Jeong Ill Suh 10, Jun Gi Park 10, Opass Putcharoen 11, Apichat Kaewdech 12, Teerha Piratvisuth 12, Sombat Treeprasertsuk 11, Sooyoung Park 13, Salisa Wejnaruemarn 11, Diana A Payawal 14, Oidov Baatarkhuu 15, Sang Hoon Ahn 16, Chang Dong Yeo 16, Uzziel Romar Alonzo 14, Tserendorj Chinbayar 17, Imelda M Loho 18, Osamu Yokosuka 19, Wasim Jafri 20, Soeksiam Tan 21, Lau Ing Soo 21, Tawesak Tanwandee 22, Rino Gani 23, Lovkesh Anand 24, Eslam Saber Esmail 6, Mai Khalaf 6, Shahinul Alam 25, Chun-Yu Lin 26, Wan-Long Chuang 26, A S Soin 27, Hitendra K Garg 28, Kemal Kalista 29, Badamnachin Batsukh 15, Hery Djagat Purnomo 30, Vijay Pal Dara 31, Pravin Rathi 32, Mamun Al Mahtab 25, Akash Shukla 33, Manoj K Sharma 2, Masao Omata 34 35, APASL COVID Task Force, APASL COVID Liver Injury Spectrum Study (APCOLIS Study-NCT 04345640)
 
186.Role of Extracellular Vesicles in the Pathophysiology, Diagnosis and Tracking of Non-Alcoholic Fatty Liver Disease
 

J Clin Med. 2020 Jun 29;9(7):E2032. doi: 10.3390/jcm9072032.

Lauren A Newman 1, Michael J Sorich 1, Andrew Rowland 1

 
 
187.Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis-4 Score
 

Hepatol Commun.. 2020 May 26;4(7):998-1011. doi: 10.1002/hep4.1524. eCollection 2020 Jul.

Stuart C Gordon 1, Nandita Kachru 2, Emily Parker 3, Stephanie Korrer 3, A Burak Ozbay 2, Robert J Wong 4
 
188.Evolving Role for Pharmacotherapy in NAFLD/NASH
 

Clin Transl Sci. 2020 Jun 25. doi: 10.1111/cts.12839. Online ahead of print.

Suzanna L Attia 1, Samir Softic 1 2 3, Marialena Mouzaki 4
 
189.Nonalcoholic Fatty Liver Disease (NAFLD) Is an Independent Risk Factor for Nephrolithiasis in Women: Findings From NHANES III
 

J Endourol. 2020 Jun 22.doi: 10.1089/end.2020.0486. Online ahead of print.

Rourke Douglas Decker 1, Eric M Ghiraldi 2, Alexandra H Weiss 3, John P Gaughan 4, Justin I Friedlander 5 6
 
190.Dysregulated Neurovascular Control Underlies Declining Microvascular Functionality in People With Non-alcoholic Fatty Liver Disease (NAFLD) at Risk of Liver Fibrosis
 

Front Physiol. 2020 Jun 3;11:551. doi: 10.3389/fphys.2020.00551. eCollection 2020.

Geraldine F Clough 1, Andrew J Chipperfield 2, Marjola Thanaj 2, Eleonora Scorletti 1 3 4, Philip C Calder 1 3, Christopher D Byrne 1 3
 
191.Cirrhosis in a Young Child Due to Fatty Liver; Importance of Early Screening: A Case Report and Review of the Literature
 

Am J Case Rep. 2020 Jun 25;21:e923250. doi: 10.12659/AJCR.923250.

Hamza Hassan Khan 1, Christine E Klingert 1 2, Sanjay Kumar 2 3, Hernando Lyons 2 3
 
192.COVID-19 and Nonalcoholic Fatty Liver Disease: Two Intersecting Pandemics
 

Eur J Clin Invest. 2020 Jun 26;e13338. doi: 10.1111/eci.13338. Online ahead of print.

Piero Portincasa 1, Marcin Krawczyk 2 3, Wiktor Smyk 4, Frank Lammert 2, Agostino Di Ciaula 1
 
193.A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease
 

Ann Pharmacother. 2020 Jun 22;1060028020935105. doi: 10.1177/1060028020935105.Online ahead of print.

John A Dougherty 1, Erenie Guirguis 1, Krisy-Ann Thornby 1
 
194.Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States
 

Gastroenterol Hepatol. 2020 Jun 9;S1542-3565(20)30775-8.doi: 10.1016/j.cgh.2020.05.064. Online ahead of print.

Zobair M Younossi 1, Maria Stepanova 2, Janus Ong 3, Greg Trimble 4, Saleh AlQahtani 5, Issah Younossi 2, Aijaz Ahmed 6, Andrei Racila 7, Linda Henry 2
 
195.Selonsertib for Patients With Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results From Randomized Phase III STELLAR Trials
 

Hepatol. 2020 Jul;73(1):26-39. doi: 10.1016/j.jhep.2020.02.027. Epub 2020 Mar 6.

Stephen A Harrison 1, Vincent Wai-Sun Wong 2, Takeshi Okanoue 3, Natalie Bzowej 4, Raj Vuppalanchi 5, Ziad Younes 6, Anita Kohli 7, Shiv Sarin 8, Stephen H Caldwell 9, Naim Alkhouri 10, Mitchell L Shiffman 11, Marianne Camargo 12, Georgia Li 12, Kathryn Kersey 12, Catherine Jia 12, Yanni Zhu 12, C Stephen Djedjos 12, G Mani Subramanian 12, Robert P Myers 12, Nadege Gunn 13, Aasim Sheikh 14, Quentin M Anstee 15, Manuel Romero-Gomez 16, Michael Trauner 17, Zachary Goodman 18, Eric J Lawitz 10, Zobair Younossi 18, STELLAR-3 and STELLAR-4 Investigators
 
196.Development of an Algorithm to Identify Cases of Nonalcoholic Steatohepatitis Cirrhosis in the Electronic Health Record
 

Dig Dis Sci. 2020 Jun 13. doi: 10.1007/s10620-020-06388-y. Online ahead of print.

Christopher J Danford 1, Jennifer Y Lee 2, Ian A Strohbehn 3, Kathleen E Corey 3, Michelle Lai 4
 
197.From NAFLD to MAFLD: Implications of a Premature Change in Terminology
 

Hepatology. 2020 Jun 16. doi: 10.1002/hep.31420. Online ahead of print.

Zobair M Younossi 1 2, Mary E Rinella 3, Arun Sanyal 4, Stephen A Harrison 5, Elizabeth Brunt 6, Zachary Goodman 1 2, David E Cohen 7, Rohit Loomba 8
 
198.Novel Antisense Inhibition of Diacylglycerol O-acyltransferase 2 for Treatment of Non-Alcoholic Fatty Liver Disease: A Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Trial
 

Lancet Gastroenterol Hepatol. 2020 Jun 15;S2468-1253(20)30186-2.doi: 10.1016/S2468-1253(20)30186-2. Online ahead of print.

Rohit Loomba 1, Erin Morgan 2, Lynnetta Watts 2, Shuting Xia 2, Lisa A Hannan 2, Richard S Geary 2, Brenda F Baker 2, Sanjay Bhanot 2
 
199.Effect of Gut Microbiota and PNPLA3 rs738409 Variant on Non-Alcoholic Fatty Liver Disease (NAFLD) in Obese Youth
 

J Clin Endocrinol Metab. 2020 Jun 19;dgaa382. doi: 10.1210/clinem/dgaa382.Online ahead of print.

Ayesha Monga Kravetz 1 2, Todd Testerman 3, Brittany Galuppo 2, Joerg Graf 3, Bridget Pierpont 2, Stephan Siebel 2, Richard Feinn 1, Nicola Santoro 2 4
 
200.Effect of TSH on Non-Alcoholic Fatty Liver Disease (NAFLD) Independent of Obesity in Children of Predominantly Hispanic/Latino Ancestry by Causal Mediation Analysis
 

PLoS One. 2020 Jun 22;15(6):e0234985. doi: 10.1371/journal.pone.0234985. eCollection 2020.

Presley H Nichols 1, Yue Pan 2, Benjamin May 3, Martina Pavlicova 2, John C Rausch 1 4, Ali A Mencin 4, Vidhu V Thaker 4
 
201.Non-alcoholic Fatty Liver Disease in Pregnancy Is Associated With Adverse Maternal and Perinatal Outcomes
 

J Hepatol. 2020 Apr 15;S0168-8278(20)30215-4. doi: 10.1016/j.jhep.2020.03.049.Online ahead of print.

Monika Sarkar 1, Joshua Grab 2, Jennifer L Dodge 3, Erica P Gunderson 4, Jessica Rubin 5, Roxanna A Irani 6, Marcelle Cedars 7, Norah Terrault 8
 
202.Use of Metabolic Syndrome Severity to Assess Treatment With Vitamin-E and Pioglitazone for Non-alcoholic Steatohepatitis
 

Gastroenterol Hepatol. 2020 Jun 7. doi: 10.1111/jgh.15131. Online ahead of print.

Matthew J Gurka 1, Jasmine A Mack 1, Xiaofei Chi 1, Mark D DeBoer 2
 
203.Biopsy Rate and Nonalcoholic Steatohepatitis (NASH) in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
 

Scand J Gastroenterol. 2020 Jun 1;1-6. doi: 10.1080/00365521.2020.1766554.Online ahead of print.

Florian Gerhardt 1, David Petroff 2, Valentin Blank 1 3, Albrecht Böhlig 1, Florian van Bömmel 1, Christian Wittekind 4, Thomas Berg 1, Thomas Karlas 1, Johannes Wiegand 1
 
204.Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Where Do Diabetologists Stand?
 

Clin Diabetes Endocrinol. 2020 Jun 5;6:9. doi: 10.1186/s40842-020-00097-1.eCollection 2020.

Shaheen Tomah 1 2, Naim Alkhouri 3, Osama Hamdy 1 2
 
205.Prediction of Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease Using Gut Microbiota-Based Approaches Compared With Simple Non-Invasive Tools
 

Sci Rep. 2020 Jun 10;10(1):9385. doi: 10.1038/s41598-020-66241-0.

Sonja Lang 1 2, Fedja Farowski 3 4 5, Anna Martin 1, Hilmar Wisplinghoff 6 7 8, Maria J G T Vehreschild 3 4 5, Marcin Krawczyk 9 10, Angela Nowag 6 8, Anne Kretzschmar 6, Claus Scholz 6, Philipp Kasper 1, Christoph Roderburg 11, Frank Lammert 9, Tobias Goeser 1, Hans-Michael Steffen 1, Münevver Demir 12 13
 
206.Nonalcoholic Fatty Liver Disease: An Important Consideration for Primary Care Providers in Hawai
 

Hawaii J Health Soc Welf. 2020 Jun 1;79(6):180-186.

Robert J Pattison 1, James Phillip Esteban 2, Tomoki Sempokuya 3, Jakrin Kewcharoen 1, Sumodh Kalathil 4, Scott K Kuwada 5
 
207.Noninvasive Tests in the Assessment of NASH and NAFLD Fibrosis: Now and Into the Future
 

Semin Liver Dis. 2020 Jun 11. doi: 10.1055/s-0040-1713006. Online ahead of print.

Leon A Adams 1 2, Wah-Kheong Chan 3
 
208.Burden of Nonalcoholic Fatty Liver Disease in Canada, 2019-2030: A Modelling Study
 

 

CMAJ Open. 2020 Jun 9;8(2):E429-E436. doi: 10.9778/cmajo.20190212. Print Apr-Jun 2020.

Mark G Swain 1, Alnoor Ramji 1, Keyur Patel 1, Giada Sebastiani 1, Abdel Aziz Shaheen 1, Edward Tam 1, Paul Marotta 1, Magdy Elkhashab 1, Harpreet S Bajaj 1, Chris Estes 2, Homie Razavi 1

 

 
 
209.Utilization of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-Analysis
 

Hepatology. 2020 May 8.doi: 10.1002/hep.31309. Online ahead of print.

Erin Wolf 1, Nicole E Rich 1, Jorge A Marrero 1, Neehar Parikh 2, Amit G Singal 1
 
210.Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies
 

Clin Exp Hepatol. May-Jun 2020;10(3):245-254. doi: 10.1016/j.jceh.2019.07.002.Epub 2019 Jul 15.

Yala K Reddy 1, Hemnishil K Marella 1, Yu Jiang 2, Surosree Ganguli 3, Peter Snell 1, Pradeep S B Podila 4, Benedict Maliakkal 1, Sanjaya K Satapathy 5
 
211.Advances in Non-Invasive Biomarkers for the Diagnosis and Monitoring of Non-Alcoholic Fatty Liver Disease
 

Metabolism. 2020 May 5;154259. doi: 10.1016/j.metabol.2020.154259.Online ahead of print.

Michelle T Long 1, Sanil Gandhi 2, Rohit Loomba 3
 
212.Genetic Determinants of Cirrhosis and Hepatocellular Carcinoma Due to Fatty Liver Disease: What's the Score?
 

Hepatology. 2020 Jun 7. doi: 10.1002/hep.31413. Online ahead of print.

Ruth M Pfeiffer 1, Yaron Rotman 2, Thomas R O'Brien 1
 
213.Comparison of MAFLD and NAFLD Diagnostic Criteria in Real World
 

Liver Int .2020 Jun 1. doi: 10.1111/liv.14548. Online ahead of print.

Su Lin 1, Jiaofeng Huang 1, Mingfang Wang 1, Rahul Kumar 2, Yuxiu Liu 1, Shiying Liu 1, Yinlian Wu 1, Xiaozhong Wang 3, Yueyong Zhu 1
 
214.Combination Therapy for Non-Alcoholic Steatohepatitis: Rationale, Opportunities and Challenges
 

Gut. 2020 May 7;gutjnl-2019-319104. doi: 10.1136/gutjnl-2019-319104.Online ahead of print.

Jean-François Dufour 1 2, Cyrielle Caussy 3 4, Rohit Loomba 5
 
215.Review Article: The Emerging Role of Genetics in Precision Medicine for Patients With Non-Alcoholic Steatohepatitis
 

Aliment Pharmacol Ther. 2020 Jun;51(12):1305-1320. doi: 10.1111/apt.15738.Epub 2020 May 7.

Björn Carlsson 1, Daniel Lindén 1 2, Gabriella Brolén 3, Mathias Liljeblad 1, Mikael Bjursell 1, Stefano Romeo 4 5 6, Rohit Loomba 7
 
216.Increased Atherogenic Lipoprotein Profile in Children With Non-Alcoholic Steatohepatitis
 

Pediatr Obes. 2020 May 4;e12648 doi: 10.1111/ijpo.12648. Online ahead of print.

Eduardo Castillo-Leon 1, Margery A Connelly 2, Juna V Konomi 1, Shelley Caltharp 3 4, Rebecca Cleeton 1, Miriam B Vos 1 4 5
 
217.Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease Are Major Drivers of Liver Mortality in the United States
 

Hepatol Commun. 2020 Apr 4;4(6):890-903. doi: 10.1002/hep4.1510. eCollection 2020 Jun.

James M Paik 1, Pegah Golabi 1, Rakesh Biswas 1, Saleh Alqahtani 2, Chapy Venkatesan 1, Zobair M Younossi 1 3
 
218.Low Thyroid Function in Nonalcoholic Fatty Liver Disease Is an Independent Predictor of All-Cause and Cardiovascular Mortality
 

Am J Gastroenterol. 2020 Jun 3. doi: 10.14309/ajg.0000000000000654. Online ahead of print.

Donghee Kim 1, Luis Miguel Vazquez-Montesino 2, Jessica A Escober 1, Christopher T Fernandes 1, George Cholankeril 1, Rohit Loomba 3 4, Stephen A Harrison 5 6, Zobair M Younossi 7, Aijaz Ahmed 1
 
219.Biopsy Rate and Nonalcoholic Steatohepatitis (NASH) in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
 

Scand J Gastroenterol. 2020 Jun 1;1-6. doi: 10.1080/00365521.2020.1766554.Online ahead of print.

Florian Gerhardt 1, David Petroff 2, Valentin Blank 1 3, Albrecht Böhlig 1, Florian van Bömmel 1, Christian Wittekind 4, Thomas Berg 1, Thomas Karlas 1, Johannes Wiegand 1
 
220.Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations From the Liver Forum
 

J Hepatol. 2020 Apr 27;S0168-8278(20)30274-9.doi: 10.1016/j.jhep.2020.04.030.Online ahead of print.

Oliver Glass 1, Claudia Filozof 2, Mazen Noureddin 3, Mark Berner-Hansen 4, Elmer Schabel 5, Stephanie O Omokaro 6, Jörn M Schattenberg 7, Katherine Barradas 8, Veronica Miller 8, Sven Francque 9, Manal F Abdelmalek 10, Liver Forum Standard of Care Working Group
 
221.Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial
 

Gastroenterol. 2020 May 15. doi: 10.14309/ajg.0000000000000661. Online ahead of print.

Laura Craven 1, Adam Rahman 2 3, Seema Nair Parvathy 4, Melanie Beaton 2 3, Justin Silverman 5, Karim Qumosani 2 3, Irene Hramiak 2 6, Rob Hegele 2 6 7, Tisha Joy 2 6, Jon Meddings 8, Brad Urquhart 2, Ruth Harvie 9, Charles McKenzie 2 7, Kelly Summers 1 2, Gregor Reid 1 2 9, Jeremy P Burton 1 2 9, Michael Silverman 1 2 4
 
222.Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease
 

Gastroenterol. 2020 May 25. doi: 10.14309/ajg.0000000000000676. Online ahead of print.

Ramy Younes 1 2, Olivier Govaere 2, Salvatore Petta 3, Luca Miele 4 5, Dina Tiniakos 2, Alastair Burt 2, Ezio David 6, Fabio M Vecchio 4 7, Marco Maggioni 8, Daniela Cabibi 9, Anna L Fracanzani 10, Chiara Rosso 1, Maria J Garcia Blanco 11, Angelo Armandi 1, Gian Paolo Caviglia 1, Marco Y W Zaki 2 12, Antonio Liguori 4, Paolo Francione 10, Grazia Pennisi 3, Antonio Grieco 4 5, Luca Valenti 13, Quentin M Anstee 2 14, Elisabetta Bugianesi 1
 
223.Nonalcoholic Fatty Liver Disease Progression Rates to Cirrhosis and Progression of Cirrhosis to Decompensation and Mortality: A Real World Analysis of Medicare Data
 

Aliment Pharmacol Ther. 2020 Jun;51(11):1149-1159. doi: 10.1111/apt.15679. Epub 2020 May 5.

Rohit Loomba 1 2, Robert Wong 3, Jeremy Fraysse 4, Sanatan Shreay 4, Suying Li 5, Stephen Harrison 6, Stuart C Gordon 7
 
224.Alanine Aminotransferase and Gamma Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis
 

Hepatology. 2020 May 16.doi: 10.1002/hep.31317. Online ahead of print.

Kimberly P Newton 1 2, Joel E Lavine 3, Laura Wilson 4 5, Cynthia Behling 6 7, Miriam B Vos 8, Jean P Molleston 9, Philip Rosenthal 10, Tamir Miloh 11, Mark H Fishbein 12, Ajay K Jain 13, Karen F Murray 14, Jeffrey B Schwimmer 1 2, Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)

Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN): 

Donna Garner, Paula Hertel, Ryan Himes, Alicia Lawson, Tamir Miloh, Nicole Triggs, Kristin Bramlage, April Carr, Kim Cecil, Meghan McNeill, Marialena Mouzaki, Andrew Trout, Stavra Xanthakos, Kimberlee Bernstein, Stephanie DeVore, Rohit Kohli, Kathleen Lake, Daniel Podberesky, Alex Towbin, Joel E Lavine, Ali Mencin, Elena Reynoso, Adina Alazraki, Rebecca Cleeton, Maria Cordero, Albert Hernandez, Saul Karpen, Jessica Cruz Munos, Nicholas Raviele, Miriam Vos, Molly Bozic, Laura Carr, Oscar W Cummings, Kathryn Harlow, Ann Klipsch, Jean P Molleston, Emily Ragozzino, Girish Rao, Kimberly Kafka, Ann Scheimann, Mark H Fishbein, Saeed Mohammad, Peter F Whitington, Sarah Barlow, Elizabeth M Brunt, Danielle Carpenter, Theresa Cattoor, Jose Derdoy, Janet Freebersyser, Ajay Jain Debra King, Jinping Lai, Joan Siegner, Susan Stewart, Susan Torretta, Kristina Wriston, Jennifer Arin, Cynthia Behling, Craig Bross, Carissa Carrier, Diana De La Pena, Janis Durelle, Mary Catherine Huckaby, Michael S Middleton, Kimberly Newton, Jeffrey B Schwimmer, Claude Sirlin, Patricia Ugalde-Nicalo, Jesse Courtier, Ryan Gill, Camille Langlois, Emily Rothbaum Perito, Philip Rosenthal, Patrika Tsai, Niviann Blondet, Kara Cooper, Karen Murray, Randolph Otto, Matthew Yeh, Melissa Young, Elizabeth M Brunt, Kathryn Fowler, David E Kleiner, Edward C Doo, Sherry Hall, Jay H Hoofnagle, Patricia R Robuck, Averell H Sherker, Rebecca Torrance, Patricia Belt, Jeanne M Clark, John Dodge, Michele Donithan, Milana Isaacson, Mariana Lazo, Jill Meinert, Laura Miriel, Emily P Sharkey, Jacqueline Smith, Michael Smith, Alice Sternberg, James Tonascia, Mark L Van Natta, Annette Wagoner, Laura A Wilson, Goro Yamada, Katherine P Yates
 
225.Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research
 

Clin Med. 2020 Apr 28;9(5):E1278. doi: 10.3390/jcm9051278.

Amedeo Lonardo 1, Ayako Suzuki 2
 
226.Evolving Aspects of Liver Transplantation for Nonalcoholic Steatohepatitis
 

Curr Opin Organ Transplant. 2013 Jun;18(3):251-8.doi: 10.1097/MOT.0b013e3283615d30.

Michael Charlton 1
 
227.Non-alcoholic Liver Disease and Childhood Obesity
 

Arch Dis Child. 2020 May 14;archdischild-2019-318063.doi: 10.1136/archdischild-2019-318063. Online ahead of print.

Meera Shaunak 1, Christopher D Byrne 2 3, Nikki Davis 1 2, Paul Afolabi 2 3, Saul N Faust 2 3 4, Justin Huw Davies 5 2
 
228.Decompensated Cirrhosis Is the Commonest Presentation for NAFLD Patients Undergoing Liver Transplant Assessment
 

Clin Med (Lond). 2020 May;20(3):313-318. doi: 10.7861/clinmed.2019-0250.

Ahmed Hussain 1, Preya J Patel 1, Freya Rhodes 1, Ankur Srivastava 1, David Patch 1, William Rosenberg 2
 
229.Risk Stratification of Patients With Nonalcoholic Fatty Liver Disease Using a Case Identification Pathway in Primary Care: A Cross-Sectional Study
 

MAJ Open. 2020 May 15;8(2):E370-E376.doi: 10.9778/cmajo.20200009. Print Apr-Jun 2020.

Abdel Aziz Shaheen 1, Kiarash Riazi 2, Alexandra Medellin 2, Deepak Bhayana 2, Gilaad G Kaplan 2, Jason Jiang 2, Roy Park 2, Wendy Schaufert 2, Kelly W Burak 2, Monica Sargious 2, Mark G Swain 2
 
230.The Effect of Sleep on Gastrointestinal Functioning in Common Digestive Diseases
 

Lancet Gastroenterol Hepatol. 2020 Jun;5(6):616-624.doi: 10.1016/S2468-1253(19)30412-1.

William C Orr 1, Ronnie Fass 2, Shikha S Sundaram 3, Ann O Scheimann 4
 
231.Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis
 

Clin Gastroenterol Hepatol. 2020 Apr 30;S1542-3565(20)30613-3.doi: 10.1016/j.cgh.2020.04.068. Online ahead of print.

Fateh Bazerbachi 1, Eric J Vargas 2, Monika Rizk 2, Daniel B Maselli 2, Taofic Mounajjed 3, Sudhakar K Venkatesh 4, Kymberly D Watt 2, John D Port 4, Rita Basu 5, Andres Acosta 2, Ibrahim Hanouneh 2, Naveen Gara 6, Meera Shah 7, Manpreet Mundi 7, Matthew Clark 7, Karen Grothe 7, Andrew C Storm 2, Michael J Levy 2, Barham K Abu Dayyeh 8
 
232.Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis
 

Immunity. 2020 May 1;S1074-7613(20)30159-X. doi: 10.1016/j.immuni.2020.04.001.Online ahead of print.

Jason S Seidman 1, Ty D Troutman 2, Mashito Sakai 1, Anita Gola 3, Nathanael J Spann 1, Hunter Bennett 1, Cassi M Bruni 1, Zhengyu Ouyang 1, Rick Z Li 1, Xiaoli Sun 4, BaoChau T Vu 1, Martina P Pasillas 1, Kaori M Ego 1, David Gosselin 5, Verena M Link 6, Ling-Wa Chong 7, Ronald M Evans 8, Bonne M Thompson 9, Jeffrey G McDonald 9, Mojgan Hosseini 10, Joseph L Witztum 4, Ronald N Germain 3, Christopher K Glass 11
 
233.Combination Therapy for Non-Alcoholic Steatohepatitis: Rationale, Opportunities and Challenges
 

Gut. 2020 May 7;gutjnl-2019-319104. doi: 10.1136/gutjnl-2019-319104.Online ahead of print.

Jean-François Dufour 1 2, Cyrielle Caussy 3 4, Rohit Loomba 5
 
234.Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations From the Liver Forum
 

J Hepatol. 2020 Apr 27;S0168-8278(20)30274-9 doi: 10.1016/j.jhep.2020.04.030.Online ahead of print.

Oliver Glass 1, Claudia Filozof 2, Mazen Noureddin 3, Mark Berner-Hansen 4, Elmer Schabel 5, Stephanie O Omokaro 6, Jörn M Schattenberg 7, Katherine Barradas 8, Veronica Miller 8, Sven Francque 9, Manal F Abdelmalek 10, Liver Forum Standard of Care Working Group
 
235.Antitumour Necrosis Factor-a Agents and Development of New-Onset Cirrhosis or Non-Alcoholic Fatty Liver Disease: A Retrospective Cohort
 

BMJ Open Gastroenterol. 2020 Apr 15;7(1):e000349.doi: 10.1136/bmjgast-2019-000349.eCollection 2020.

Kuo-Tung Tang 1 2 3, Jean-François Dufour 4 5, Po-Hung Chen 6, Ruben Hernaez 7 8, Susan Hutfless 6
 
236.Biomarkers of NAFLD and NASH
 

Metabolism. 2020 May 5;154259. doi: 10.1016/j.metabol.2020.154259.Online ahead of print.

Michelle T Long 1, Sanil Gandhi 2, Rohit Loomba 3
 
237.Macrophages in Metabolic Associated Fatty Liver Disease
 

World J Gastroenterol. 2020 Apr 28;26(16):1861-1878.doi: 10.3748/wjg.v26.i16.1861.

Jawaher Alharthi 1, Olivier Latchoumanin 1, Jacob George 1, Mohammed Eslam 2
 
238.Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies
 

J Clin Exp Hepatol. May-Jun 2020;10(3):245-254.doi: 10.1016/j.jceh.2019.07.002.Epub 2019 Jul 15.

Yala K Reddy 1, Hemnishil K Marella 1, Yu Jiang 2, Surosree Ganguli 3, Peter Snell 1, Pradeep S B Podila 4, Benedict Maliakkal 1, Sanjaya K Satapathy 5
 
239.Blood Lead Level Is Associated With Advanced Liver Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease: A Nationwide Survey (NHANES 2011-2016)
 

Ann Hepatol. 2020 Apr 4;S1665-2681(20)30028-4. doi: 10.1016/j.aohep.2020.03.006.Online ahead of print.

Debashis Reja 1, Aayush Visaria 2, Briette Karanfilian 3, Vinod Rustgi 4
 
240.Review Article: The Emerging Role of Genetics in Precision Medicine for Patients With Non-Alcoholic Steatohepatitis
 

Aliment Pharmacol Ther. 2020 May 7. doi: 10.1111/apt.15738. Online ahead of print.

Björn Carlsson 1, Daniel Lindén 1 2, Gabriella Brolén 3, Mathias Liljeblad 1, Mikael Bjursell 1, Stefano Romeo 4 5 6, Rohit Loomba 7
 
241.Epidemiology and Pathophysiology of the Association Between NAFLD and Metabolically Healthy or Metabolically Unhealthy Obesity
 

Ann Hepatol. 2020 Mar 21;S1665-2681(20)30023-5.doi: 10.1016/j.aohep.2020.03.001. Online ahead of print.

Amedeo Lonardo 1, Alessandro Mantovani 2, Simonetta Lugari 3, Giovanni Targher 2
 
242.The Association Between Cholecystectomy, Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease: A Population-Based Study
 

Clin Transl Gastroenterol. 2020 Apr;11(4):e00170. doi: 10.14309/ctg.0000000000000170.

Carmen S S Latenstein 1, Louise J M Alferink 2, Sarwa Darwish Murad 2, Joost P H Drenth 3, Cornelis J H M van Laarhoven 1, Philip R de Reuver 1
 
243.Nonalcoholic Fatty Liver Disease Progression Rates to Cirrhosis and Progression of Cirrhosis to Decompensation and Mortality: A Real World Analysis of Medicare Data
 

Aliment Pharmacol Ther. 2020 May 5. doi: 10.1111/apt.15679. Online ahead of print.

Rohit Loomba 1 2, Robert Wong 3, Jeremy Fraysse 4, Sanatan Shreay 4, Suying Li 5, Stephen Harrison 6, Stuart C Gordon 7
 
244.Nutrition and Genetics in NAFLD: The Perfect Binomium
 

Int J Mol Sci. 2020 Apr 23;21(8):E2986. doi: 10.3390/ijms21082986.

Marica Meroni 1 2, Miriam Longo 1 3, Alice Rustichelli 1, Paola Dongiovanni 1
 
245.Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease
 

Curr Pharm Des. 2020 Apr 28.doi: 10.2174/1381612826666200429093648.Online ahead of print.

Francesco Tovoli 1, Silvia Ferri 2, Fabio Piscaglia 1
 
246.Thyroid Hormone Signaling and the Liver
 

Hepatology. 2020 Apr 28.doi: 10.1002/hep.31296. Online ahead of print.

Megan J Ritter 1, Izuki Amano 1 2, Anthony N Hollenberg 1
 
247.Extrahepatic Manifestations and Healthcare Expenditures of Non-Alcoholic Fatty Liver Disease in the Medicare Population
 

Hepatol Int. 2020 Apr 16. doi: 10.1007/s12072-020-10038-w. Online ahead of print.

Mehmet Sayiner 1 2, Tamoore Arshad 1, Pegah Golabi 2, James Paik 2, Freba Farhat 1, Zobair M Younossi 3 4
 
248.How Good Are Controlled Attenuation Parameter Scores From Fibroscan to Assess Steatosis, NASH, and Fibrosis?
 

Dig Dis Sci. 2020 Apr 27.doi: 10.1007/s10620-020-06269-4. Online ahead of print.

Joshua Trowell 1, Joseph Alukal 1, Talan Zhang 1, Li Liu 2, Anurag Maheshwari 1 3, Hwan Y Yoo 1, Paul J Thuluvath 4 5
 
249.Distinguishing NASH Histological Severity Using a Multiplatform Metabolomics Approach
 

Metabolites. 2020 Apr 24;10(4):E168. doi: 10.3390/metabo10040168.

George N Ioannou 1 2 3, G A Nagana Gowda 4, Danijel Djukovic 4, Daniel Raftery 4 5 6
 
250.Extrahepatic Manifestations and Healthcare Expenditures of Non-Alcoholic Fatty Liver Disease in the Medicare Population
 

Hepatol Int. 2020 Apr 16. doi: 10.1007/s12072-020-10038-w. Online ahead of print.

Mehmet Sayiner 1 2, Tamoore Arshad 1, Pegah Golabi 2, James Paik 2, Freba Farhat 1, Zobair M Younossi 3 4
 
251.Is Bariatric Surgery Resolving NAFLD via Microbiota-Mediated Bile Acid Ratio Reversal? A Comprehensive Review
 

Surg Obes Relat Dis. 2020 Mar 20;S1550-7289(20)30131-3. doi: 10.1016/j.soard.2020.03.013.Online ahead of print.

Eider Talavera-Urquijo 1, Marc Beisani 2, José M Balibrea 3, John C Alverdy 4
 
252.Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations From the Liver Forum
 

J Hepatol. 2020 Apr 27;S0168-8278(20)30274-9. doi: 10.1016/j.jhep.2020.04.030.Online ahead of print.

Oliver Glass 1, Claudia Filozof 2, Mazen Noureddin 3, Mark Berner-Hansen 4, Elmer Schabel 5, Stephanie O Omokaro 6, Jörn M Schattenberg 7, Katherine Barradas 8, Veronica Miller 8, Sven Francque 9, Manal F Abdelmalek 10, Liver Forum Standard of Care Working Group
 
253.Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research
 

J Clin Med. 2020 Apr 28;9(5):E1278. doi: 10.3390/jcm9051278.

Amedeo Lonardo 1, Ayako Suzuki 2
 
254. Metabolic Risk Factors and Incident Advanced Liver Disease in Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review and Meta-Analysis of Population-Based Observational Studies
 

Med. 2020 Apr 30;17(4):e1003100. doi: 10.1371/journal.pmed.1003100.eCollection 2020 Apr.

Helen Jarvis 1, Dawn Craig 1, Robert Barker 1, Gemma Spiers 1, Daniel Stow 1, Quentin M Anstee 2 3, Barbara Hanratty 1
 
255.African Americans Have a Distinct Clinical and Histologic Profile With Lower Prevalence of NASH and Advanced Fibrosis Relative to Caucasians
 

Eur J Gastroenterol Hepatol. 2020 Apr 20. doi: 10.1097/MEG.0000000000001735.Online ahead of print.

Sanjaya K Satapathy 1 2, Hemnishil K Marella 3, Rajiv P Heda 3, Surosree Ganguli 4, Yala Kirthi Reddy 5, Pradeep S B Podila 1, Ian Clark 6, Benedict Maliakkal 1
 
256.Potential Implications of COVID-19 in Non-Alcoholic Fatty Liver Disease
 

Liver Int. 2020 Apr 19. doi: 10.1111/liv.14484. Online ahead of print.

Grietje H Prins 1, Peter Olinga 1
 
257.Obesity as a Risk Factor for Greater Severity of COVID-19 in Patients With Metabolic Associated Fatty Liver Disease
 

Metabolism. 2020 Apr 19;154244. doi: 10.1016/j.metabol.2020.154244. Online ahead of print.

Kenneth I Zheng 1, Feng Gao 2, Xiao-Bo Wang 3, Qing-Feng Sun 4, Ke-Hua Pan 5, Ting-Yao Wang 6, Hong-Lei Ma 1, Wen-Yue Liu 7, Jacob George 8, Ming-Hua Zheng 9
 
258.FXR Agonists as Therapy for Liver Disease
 

Hoofnagle JH1. Hepatology. 2020 Apr 10. doi: 10.1002/hep.31265. [Epub ahead of print]
 
259.Obeticholic acid for the treatment of nonalcoholic steatohepatitis
 

Shah RA1, Kowdley KV1. Expert Rev Gastroenterol Hepatol. 2020 Apr 3. doi: 10.1080/17474124.2020.1748498. [Epub ahead of print]
 
260.Bile acids associate with specific gut microbiota, low level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease
 

Adams LA1,2, Wang Z1,2, Liddle C3, Melton PE4,5, Ariff A4, Chandraratna H6, Tan J7, Ching H1, Coulter S3, de Boer B8, Christophersen CT9,10, O'Sullivan TA9, Morrison M11, Jeffrey GP1,2. Liver Int. 2020 Apr 3. doi: 10.1111/liv.14453. [Epub ahead of print]
 
261.Dietary Factors in Relation to Liver Fat Content: A Cross-sectional Study
 

Watzinger C1, Nonnenmacher T2, Grafetstätter M1, Sowah SA1,3, Ulrich CM4, Kauczor HU2, Kaaks R1, Schübel R1,2, Nattenmüller J2, Kühn T1. Nutrients. 2020 Mar 20;12(3). pii: E825. doi: 10.3390/nu12030825.
 
262.Relationship between Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease in Persons with HIV
 

Kaplan A1,2, Simon TG2, Henson JB2, Wang T2, Zheng H3, Osganian SA2, Rosenblatt R1, Lake J4, Corey KE2. J Acquir Immune Defic Syndr. 2020 Mar 31. doi: 10.1097/QAI.0000000000002359. [Epub ahead of print]
 
263.Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study
 

Newsome PN1, Palmer M2, Freilich B3, Sheikh MY4, Sheikh A5, Sarles H6, Herring R7, Mantry P8, Kayali Z9, Hassanein T10, Lee HM2, Aithal GP11; Volixibat in Adults study group. J Hepatol. 2020 Mar 28. pii: S0168-8278(20)30186-0. doi: 10.1016/j.jhep.2020.03.024. [Epub ahead of print]
 
264.Familial non-alcoholic steatohepatitis leading to hepatocellular carcinoma
 

Neuman MG Prof1, Cohen LB Dr2, Malnick S Dr3. Chem Biol Interact. 2020 Mar 23;323:109054. doi: 10.1016/j.cbi.2020.109054. [Epub ahead of print]
 
265.Management of nonalcoholic fatty liver disease and the role of bariatric surgery: a brief review for surgeons
 

Jorge JM1, Golas A1, Patel N1, Gonzalvo JP1, Murr MM2. Surg Obes Relat Dis. 2020 Feb 5. pii: S1550-7289(20)30049-6. doi: 10.1016/j.soard.2020.01.028. [Epub ahead of print]
 
266.Influence of adiposity, insulin resistance and intrahepatic triglyceride content on insulin kinetics
 

Smith GI1, Polidori DC2, Yoshino M1, Kearney ML1, Patterson BW1, Mittendorfer B1, Klein S1. J Clin Invest. 2020 Mar 19. pii: 136756. doi: 10.1172/JCI136756. [Epub ahead of print]
 
267.Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges
 

Goldner D1, Lavine JE2. Gastroenterology. 2020 Mar 20. pii: S0016-5085(20)30168-2. doi: 10.1053/j.gastro.2020.01.048. [Epub ahead of print]
 
268.Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It
 

Traish AM1. World J Mens Health. 2020 Mar 20. doi: 10.5534/wjmh.200012. [Epub ahead of print]
 
269.Assessing physician preferences on future therapeutic options and diagnostic practices in non-alcoholic steatohepatitis
 

Cook N1, Geier A2, Schmid A3, Hirschfield G4, Kautz A5, Schattenberg JM6, Balp MM1. JHEP Rep. 2020 Feb 1;2(2):100081. doi: 10.1016/j.jhepr.2020.100081. eCollection 2020 Apr.
 
270.Nonalcoholic Steatohepatitis: A Review
 

Sheka AC1, Adeyi O2, Thompson J3, Hameed B4, Crawford PA5, Ikramuddin S1. JAMA. 2020 Mar 24;323(12):1175-1183. doi: 10.1001/jama.2020.2298.
 
271.Sarcopenia is a new risk factor of non-alcoholic fatty liver disease in patients with inflammatory bowel disease
 

Kang MK, Kim KO, Kim MC, Park JG, Jang BI. Dig Dis. 2020 Mar 5. doi: 10.1159/000506938. [Epub ahead of print]
 
272.Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk
 

Han E1, Lee YH2,3, Kim YD4, Kim BK2,5,6, Park JY2,5,6, Kim DY2,5,6, Ahn SH2,5,6, Lee BW2,3, Kang ES2,3, Cha BS2,3, Han KH2,5,6, Nam HS4, Heo JH4, Kim SU2,5,6. Am J Gastroenterol. 2020 Mar 3. doi: 10.14309/ajg.0000000000000572. [Epub ahead of print]
 
273. Managing NAFLD in Type 2 Diabetes: The Effect of Lifestyle Interventions, a Narrative Review
 

Parry SA1, Hodson L2,3. Adv Ther. 2020 Mar 7. doi: 10.1007/s12325-020-01281-6. [Epub ahead of print]
 
274.Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review
 

Pan CS1, Stanley TL1,2. Front Endocrinol (Lausanne). 2020 Feb 21;11:70. doi: 10.3389/fendo.2020.00070. eCollection 2020.
 
275.Predictive Factors and Time to Development of Hepatic Decompensation in Patients with Non-alcoholic Fatty Liver Disease
 

Ahmed HS1,2, Pedersen N3, Jayanna MB3,4, Ten Eyck P5, Sanchez A3, Murali AR3,6. J Gen Intern Med. 2020 Mar 10. doi: 10.1007/s11606-020-05725-1. [Epub ahead of print]
 
276.Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials
 

Harrison SA1, Wai-Sun Wong V2, Okanoue T3, Bzowej N4, Vuppalanchi R5, Younes Z6, Kohli A7, Sarin S8, Caldwell SH9, Alkhouri N10, Shiffman ML11, Camargo M12, Li G12, Kersey K12, Jia C12, Zhu Y12, Djedjos CS12, Subramanian GM12, Myers RP12, Gunn N13, Sheikh A14, Anstee QM15, Romero-Gomez M16, Trauner M17, Goodman Z18, Lawitz EJ10, Younossi Z18; STELLAR-3 and STELLAR-4 Investigators. J Hepatol. 2020 Mar 5. pii: S0168-8278(20)30126-4. doi: 10.1016/j.jhep.2020.02.027. [Epub ahead of print]
 
277.Cilofexor, a Nonsteroidal FXR Agonist, in Non-Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial
 

Patel K1, Harrison SA2, Elkashab M3, Trotter JF4, Herring R5, Rojter S6, Kayali Z7, Wong VW8, Greenbloom S9, Jayakumar S10, Shiffman ML11, Freilich B12, Lawitz EJ, Gane E13,14, Harting E15, Xu J15, Billin AN15, Chung C15, Djedjos CS15, Subramanian GM15, Myers RP15, Middleton MS10, Rinella M16, Noureddin M17. Hepatology. 2020 Mar 1. doi: 10.1002/hep.31205. [Epub ahead of print]
 
278.Thyroid hormones and thyromimetics: A new approach to NASH?
 

Sinha RA1, Bruinstroop E2, Singh BK3, Yen PM3. Hepatology. 2020 Feb 27. doi: 10.1002/hep.31204. [Epub ahead of print]
 
279.Epidemiology of Non-alcoholic Fatty Liver Disease in North America
 

Arshad T1, Golabi P2, Henry L3, Younossi ZM1. Curr Pharm Des. 2020 Mar 2. doi: 10.2174/1381612826666200303114934. [Epub ahead of print]
 
280.Sarcopenia in nonalcoholic fatty liver disease: new challenges for clinical practice
 

El Sherif O1, Dhaliwal A1,2, Newsome PN1,2,3, Armstrong MJ1,2,3. Expert Rev Gastroenterol Hepatol. 2020 Feb 23:1-9. doi: 10.1080/17474124.2020.1731303. [Epub ahead of print]
 
281.Advances in non-invasive assessment of hepatic fibrosis
 

Loomba R1, Adams LA2. Gut. 2020 Feb 17. pii: gutjnl-2018-317593. doi: 10.1136/gutjnl-2018-317593. [Epub ahead of print]
 
282.A Microbial Signature Identifies Advanced Fibrosis in Patients with Chronic LiverDisease Mainly Due to NAFLD
 

Dong TS1, Katzka W1,2, Lagishetty V1,2, Luu K1,2, Hauer M1,2, Pisegna J3, Jacobs JP4,5,6. Sci Rep. 2020 Feb 17;10(1):2771. doi: 10.1038/s41598-020-59535-w.
 
283.Longitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study
 

VanWagner LB1,2, Wilcox JE2,3, Ning H2, Lewis CE4, Carr JJ5, Rinella ME1, Shah SJ3, Lima JAC6, Lloyd-Jones DM2,3. J Am Heart Assoc. 2020 Feb 18;9(4):e014279. doi: 10.1161/JAHA.119.014279. Epub 2020 Feb 6.
 
284.Adipose tissue-liver cross talk in the control of whole-body metabolism: implications in non-alcoholic fatty liver disease
 

Azzu V1, Vacca M2, Virtue S2, Allison M3, Vidal-Puig A4. Gastroenterology. 2020 Feb 12. pii: S0016-5085(20)30224-9. doi: 10.1053/j.gastro.2019.12.054.

 
285.Circadian Rhythms in the Pathogenesis and Treatment of Fatty Liver Disease
 

Saran AR1, Dave S1, Zarrinpar A2. Gastroenterology. 2020 Feb 12. pii: S0016-5085(20)30221-3. doi: 10.1053/j.gastro.2020.01.050.
 
286.A diabetologist's perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions
 

Cusi K1,2. Liver Int. 2020 Feb;40 Suppl 1:82-88. doi: 10.1111/liv.14350.

 
 
287.New drugs for non-alcoholic steatohepatitis
 

Cardoso AC1,2, de Figueiredo-Mendes C3, A Villela-Nogueira C1,2, Sanyal AJ4. Liver Int. 2020 Feb;40 Suppl 1:96-101. doi: 10.1111/liv.14354.
 
288.New drugs for non-alcoholic steatohepatitis and HIV infection: great expectations with a great absent?
 

Guaraldi G1, Maurice JB2, Marzolini C3, Monteith K4, Milic J1, Tsochatzis E5, Bhagani S6, Morse CG7, Price JC8, Ingiliz P9,10, Lemoine M11, Sebastiani G12; SHIVER Network. Hepatology. 2020 Feb 13. doi: 10.1002/hep.31177. [Epub ahead of print]
 
289.The association of nonalcoholic steatohepatitis and hepatocellular carcinoma
 

Asfari MM1,2, Talal Sarmini M2, Alomari M2, Lopez R3, Dasarathy S4,5,6, McCullough AJ4,5,6. Eur J Gastroenterol Hepatol. 2020 Feb 18. doi: 10.1097/MEG.0000000000001681. [Epub ahead of print]
 
290.MAFLD: A consensus-driven proposed nomenclature for metabolic associated fattyliver disease
 

Eslam M1, Sanyal AJ2, George J3; an international consensus panel. Gastroenterology. 2020 Feb 7. pii: S0016-5085(20)30171-2. doi: 10.1053/j.gastro.2019.11.312. [Epub ahead of print]
 
291.Nonalcoholic fatty liver disease burden: Australia, 2019-2030
 

Adams LA1, Roberts SK2, Strasser SI3, Mahady SE4,5, Powell E6, Estes C7, Razavi H7, George J8. J Gastroenterol Hepatol. 2020 Feb 11. doi: 10.1111/jgh.15009. [Epub ahead of print]
 
292.NAFLD as a driver of chronic kidney disease
 

Byrne CD1, Targher G2. J Hepatol. 2020 Feb 11. pii: S0168-8278(20)30030-1. doi: 10.1016/j.jhep.2020.01.013. [Epub ahead of print]
 
293.NAFLD 2020: The State of the Disease
 

Cotter TG1, Rinella M2. Gastroenterology. 2020 Feb 12. pii: S0016-5085(20)30223-7. doi: 10.1053/j.gastro.2020.01.052. [Epub ahead of print]
 
294.Therapeutic landscape for NAFLD in 2020
 

Neuschwander-Tetri BA1. Gastroenterology. 2020 Feb 12. pii: S0016-5085(20)30222-5. doi: 10.1053/j.gastro.2020.01.051. [Epub ahead of print]
 
295.Natural history of NASH and HCC
 

Negro F1. Liver Int. 2020 Feb;40 Suppl 1:72-76. doi: 10.1111/liv.14362.
 
296.Mechanisms of Fibrosis Development in NASH
 

Schwabe RF1, Tabas I2, Pajvani UB3. Gastroenterology. 2020 Feb 7. pii: S0016-5085(20)30169-4. doi: 10.1053/j.gastro.2019.11.311. [Epub ahead of print]
 
297.Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant
 

Chandrakumaran A1, Siddiqui MS2. Gastroenterol Clin North Am. 2020 Mar;49(1):165-178. doi: 10.1016/j.gtc.2019.09.005.
 
298.Burden of Disease due to Nonalcoholic Fatty Liver Disease
 

Muthiah MD1, Sanyal AJ2. Gastroenterol Clin North Am. 2020 Mar;49(1):1-23. doi: 10.1016/j.gtc.2019.09.007.
 
299.Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease
 

Wattacheril J1. Gastroenterol Clin North Am. 2020 Mar;49(1):141-149. doi: 10.1016/j.gtc.2019.10.002. Epub 2019 Dec 24.
 
300.Exercise Training Rapidly Increases Hepatic Insulin Extraction in NAFLD
 

Hari A1, Fealy CE2, Axelrod CL3, Haus JM4, Flask CA1, McCullough AJ5, Kirwan JP1,3. Med Sci Sports Exerc. 2020 Feb 5. doi: 10.1249/MSS.0000000000002273. [Epub ahead of print]
 
301.Genetic Risk Factors and Disease Modifiers of Nonalcoholic Steatohepatitis
 

Kozlitina J1. Gastroenterol Clin North Am. 2020 Mar;49(1):25-44. doi: 10.1016/j.gtc.2019.09.001
 
302.Is NAFLD Not a Risk Factor for Cardiovascular Disease: Not Yet Time for a Change of Heart
 

Henson JB1, Roden M2,3,4, Targher G5, Corey KE6. Hepatology. 2020 Feb 3. doi: 10.1002/hep.31156. [Epub ahead of print]
 
303.Non-Alcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?
 

Budd J1, Cusi K2. Am J Med. 2020 Feb 1. pii: S0002-9343(20)30100-5. doi: 10.1016/j.amjmed.2020.01.007. [Epub ahead of print]
 
304.Extra-Hepatic Manifestations of Nonalcoholic Fatty Liver Disease: A Review
 

Tariq R1, Axley P2, Singal AK3. J Clin Exp Hepatol. 2020 Jan-Feb;10(1):81-87. doi: 10.1016/j.jceh.2019.07.008. Epub 2019 Jul 25.
 
305.Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis
 

Taylor RS1, Taylor RJ2, Bayliss S3, Hagstrom H4, Nasr P5, Schattenberg JM6, Ishigami M7, Toyoda H8, Wai-Sun Wong V9, Peleg N10, Shlomai A11, Sebastiani G12, Seko Y13, Bhala N14, Younossi ZM15, Anstee QM16, McPherson S17, Newsome PN18; Collaborators. Gastroenterology. 2020 Feb 3. pii: S0016-5085(20)30137-2. doi: 10.1053/j.gastro.2020.01.043. [Epub ahead of print]
 
306.Herbal drug discovery for the treatment of nonalcoholic fatty liver disease
 

Yan T1, Yan N2, Wang P1,3, Xia Y1,4, Hao H2, Wang G2, Gonzalez FJ1. Acta Pharm Sin B. 2020 Jan;10(1):3-18. doi: 10.1016/j.apsb.2019.11.017. Epub 2019 Dec 10.
 
307.How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis
 

Henry ZH1, Argo CK2. Gastroenterol Clin North Am. 2020 Mar;49(1):45-62. doi: 10.1016/j.gtc.2019.09.002. Epub 2019 Dec 24.
 
308.Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study
 

Ratziu V1, Sanyal A2, Harrison SA3, Wong VW4, Francque S5, Goodman Z6, Aithal GP7, Kowdley KV8, Seyedkazemi S9, Fischer L9, Loomba R10,11, Abdelmalek MF12, Tacke F13,14. Hepatology. 2020 Jan 13. doi: 10.1002/hep.31108. [Epub ahead of print]
 
309.Multicenter validation of association between decline in MRI-PDFF and histologic response in nonalcoholic steatohepatitis
 

Loomba R1, Neuschwander-Tetri BA2, Sanyal A3, Chalasani N4, Diehl AM5, Terrault N6, Kowdley K7, Dasarathy S8, Kleiner D9, Behling C1, Lavine J10, Van Natta M11, Middleton M1, Tonascia J11, Sirlin C1; NASH Clinical Research Network. Hepatology. 2020 Jan 21. doi: 10.1002/hep.31121. [Epub ahead of print]
 
310.Nonalcoholic Steatohepatitis Becomes the Leading Indication for Liver Transplant Registrants Among US Adults Born Between 1945 and 1965
 

Shirazi F1, Wang J1, Wong RJ2. J Clin Exp Hepatol. 2020 Jan-Feb;10(1):30-36. doi: 10.1016/j.jceh.2019.06.007. Epub 2019 Jul 10.
 
311.Multiparametric Magnetic Resonance Elastography Improves the Detection of NASHRegression Following Bariatric Surgery
 

Allen AM1, Shah VH1, Therneau TM2, Venkatesh SK3, Mounajjed T4, Larson JJ2, Mara KC2, Kellogg TA5, Kendrick ML5, McKenzie TJ5, Greiner SM1, Li J3, Glaser KJ3, Wells ML3, Gunneson TJ6, Ehman RL3, Yin M3. Hepatol Commun. 2019 Nov 5;4(2):185-192. doi: 10.1002/hep4.1446. eCollection 2020 Feb.
 
312.FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study
 

Newsome PN1, Sasso M2, Deeks JJ3, Paredes A4, Boursier J5, Chan WK6, Yilmaz Y7, Czernichow S8, Zheng MH9, Wong VW10, Allison M11, Tsochatzis E12, Anstee QM13, Sheridan DA14, Eddowes PJ15, Guha IN15, Cobbold JF16, Paradis V17, Bedossa P18, Miette V2, Fournier-Poizat C19, Sandrin L2, Harrison SA20. Lancet Gastroenterol Hepatol. 2020 Feb 3. pii: S2468-1253(19)30383-8. doi: 10.1016/S2468-1253(19)30383-8. [Epub ahead of print]
 
313.Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis
 

Esteban JPG1, Asgharpour A2. Gastroenterol Clin North Am. 2020 Mar;49(1):105-121. doi: 10.1016/j.gtc.2019.10.003.
 
314.Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C
 

Tanwar S1, Rhodes F1, Srivastava A1, Trembling PM1, Rosenberg WM1. World J Gastroenterol. 2020 Jan 14;26(2):109-133. doi: 10.3748/wjg.v26.i2.109.
 
315.Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis
 

Ma X1, Liu S2,3, Zhang J1, Dong M1, Wang Y1, Wang M1, Xin Y4,5. BMC Gastroenterol. 2020 Jan 14;20(1):10. doi: 10.1186/s12876-020-1165-z.
 
316.Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)?
 

Ritchie M1, Hanouneh IA1,2, Noureddin M3, Rolph T4, Alkhouri N5. Expert Opin Investig Drugs. 2020 Feb;29(2):197-204. doi: 10.1080/13543784.2020.1718104. Epub 2020 Jan 22.
 
317.Synbiotic Alters Fecal Microbiomes, but not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Non-alcoholic Fatty Liver Disease
 

Scorletti E1, Afolabi PR2, Miles EA3, Smith DE2, Almehmadi A3, Alshathry A3, Childs CE3, Del Fabbro S3, Beavis J3, Moyses HE4, Clough GF3, Sethi JK5, Patel J6, Wright M6, Breen DJ7, Peebles C7, Darekar A8, Aspinall R9, Fowell AJ9, Dowman JK9, Nobili V10, Targher G11, Delzenne NM12, Bindels LB12, Calder PC13, Byrne CD2. Gastroenterology. 2020 Jan 24. pii: S0016-5085(20)30124-4. doi: 10.1053/j.gastro.2020.01.031. [Epub ahead of print]
 
318.Work up of fatty liver by primary care physicians, review
 

Rikhi R1, Singh T2, Modaresi Esfeh J2. Ann Med Surg (Lond). 2020 Jan 11;50:41-48. doi: 10.1016/j.amsu.2020.01.001. eCollection 2020 Feb.
 
319.NASH (nonalcoholic steatohepatitis), diabetes, and macrovascular disease: multiple chronic conditions and a potential treatment at the metabolic root
 

Colca J1,2. Expert Opin Investig Drugs. 2020 Jan 23:1-6. doi: 10.1080/13543784.2020.1715940. [Epub ahead of print]
 
320.Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date
 

Albhaisi S1, Sanyal AJ2. Pharmaceut Med. 2019 Dec;33(6):451-463. doi: 10.1007/s40290-019-00305-z.
 
321.Macrophage Function in the Pathogenesis of Non-alcoholic Fatty Liver Disease: The Mac Attack
 

Oates JR1,2,3, McKell MC1,3,4, Moreno-Fernandez ME1,2, Damen MSMA1,2, Deepe GS Jr5, Qualls JE1,3,4, Divanovic S1,2,3,6. Front Immunol. 2019 Dec 12;10:2893. doi: 10.3389/fimmu.2019.02893. eCollection 2019.
 
322.Presumed Nonalcoholic Fatty Liver Disease Among Medicare Beneficiaries With HIV, 2006-2016
 

Paik JM1, Henry L2, Golabi P1, Alqahtani SA3, Trimble G4, Younossi ZM1,4. Open Forum Infect Dis. 2020 Jan 7;7(1):ofz509. doi: 10.1093/ofid/ofz509. eCollection 2020 Jan.
 
323.Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials
 

Mantovani A1, Byrne CD2, Scorletti E3, Mantzoros CS4, Targher G5. Diabetes Metab. 2020 Jan 7. pii: S1262-3636(20)30002-1. doi: 10.1016/j.diabet.2019.12.007. [Epub ahead of print]
 
324.The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
 

Romero FA, Jones C, Xu Y, Fenaux M, Halcomb RL. J Med Chem. 2020 Jan 13. doi: 10.1021/acs.jmedchem.9b01701. [Epub ahead of print]
 
325.A Model to Identify Heavy Drinkers at High Risk for Liver Disease Progression
 

Delacôte C1, Bauvin P1, Louvet A2, Dautrecque F3, Ntandja Wandji LC3, Lassailly G2, Voican C4, Perlemuter G4, Naveau S4, Mathurin P2, Deuffic-Burban S5. Clin Gastroenterol Hepatol. 2020 Jan 10. pii: S1542-3565(20)30039-2. doi: 10.1016/j.cgh.2019.12.041. [Epub ahead of print]
 
326.Small but mighty: Platelets in NASH and other chronic liver diseases
 

Hilscher MB1, Shah VH1. Hepatology. 2020 Jan 5. doi: 10.1002/hep.31101. [Epub ahead of print]
 
327.Continued muscle loss increases mortality in cirrhosis- impact of etiology of liver disease
 

Welch N1,2, Dasarathy J3, Runkana A4, Penumatsa R2, Bellar A2, Reen J2, Rotroff D5, McCullough AJ1, Dasarathy S1,2. Liver Int. 2019 Dec 31. doi: 10.1111/liv.14358. [Epub ahead of print]
 
328.Childhood and Adolescent Nonalcoholic Fatty Liver Disease: Is It Different from Adults?
 

Fitzpatrick E1, Dhawan A1. J Clin Exp Hepatol. 2019 Nov-Dec;9(6):716-722. doi: 10.1016/j.jceh.2019.05.005. Epub 2019 May 31.
 
329.Carotenoids and fatty liver disease: Current knowledge and research gaps
 

Clugston RD1. Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Jan 2:158597. doi: 10.1016/j.bbalip.2019.158597. [Epub ahead of print]
 
330.Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression
 

Du K1, Chitneni SK2, Suzuki A1, Wang Y1, Henao R3, Hyun J1, Premont RT1, Naggie S4, Moylan CA1, Bashir MR5, Abdelmalek MF1, Diehl AM6. Cell Mol Gastroenterol Hepatol. 2019 Dec 24. pii: S2352-345X(19)30182-1. doi: 10.1016/j.jcmgh.2019.12.006. [Epub ahead of print]
 
331.A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
 

Harrison SA1, Goodman Z2, Jabbar A3, Vemulapalli R4, Younes ZH5, Freilich B6, Sheikh MY7, Schattenberg JM8, Kayali Z9, Zivony A10, Sheikh A11, Garcia-Samaniego J12, Satapathy SK13, Therapondos G14, Mena E15, Schuppan D16, Robinson J17, Chan JL17, Hagerty DT18, Sanyal AJ19. J Hepatol. 2019 Dec 27. pii: S0168-8278(19)30758-5. doi: 10.1016/j.jhep.2019.11.024. [Epub ahead of print]
 
332.A Pilot Genome-Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH
 

Gawrieh S1, Guo X2, Tan J2, Lauzon M2, Taylor KD2, Loomba R3, Cummings OW4, Pillai S5, Bhatnagar P5, Kowdley KV6, Yates K7, Wilson LA7, Chen YI2, Rotter JI2, Chalasani N1; NASH Clinical Research Network. Hepatol Commun. 2019 Nov 3;3(12):1571-1584. doi: 10.1002/hep4.1439. eCollection 2019 Dec.
 
333.Evaluation of Dietary Approaches for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review
 

Saeed N1, Nadeau B1, Shannon C2, Tincopa M1. Nutrients. 2019 Dec 16;11(12). pii: E3064. doi: 10.3390/nu11123064.
 
334.Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study
 

Baratta F1, Pastori D2, Angelico F3, Balla A4, Paganini AM4, Cocomello N1, Ferro D1, Violi F5, Sanyal AJ6, Del Ben M1. Clin Gastroenterol Hepatol. 2019 Dec 27. pii: S1542-3565(19)31506-X. doi: 10.1016/j.cgh.2019.12.026. [Epub ahead of print]
 
335.When the Liver Gets Stiff, the Tough Get Moving
 

Nguyen TH1, Wardell R1, Chitturi S1, Teoh N1, Farrell G1,2. J Gastroenterol Hepatol. 2019 Dec 22. doi: 10.1111/jgh.14963. [Epub ahead of print]
 
336.Nonalcoholic Fatty Liver Disease: An Emerging Driver of Hypertension
 

Zhao YC1,2, Zhao GJ1,2, Chen Z1,2, She ZG1,2,3,4, Cai J1,5,2, Li H1,2,3. Hypertension. 2020 Feb;75(2):275-284. doi: 10.1161/HYPERTENSIONAHA.119.13419. Epub 2019 Dec 23.
 
337.Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic FattyLiver Disease in Patients With Crohn
 

McHenry S1, Tirath A2, Tsai R3, Sharma Y4, Flores AG1, Davidson NO1, Fowler KJ3,5, Ciorba MA1,4, Deepak P1,6. Inflamm Bowel Dis. 2020 Jan 7. pii: izz324. doi: 10.1093/ibd/izz324. [Epub ahead of print]
 
338.Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity
 

Coccia F1, Testa M1, Guarisco G1, Bonci E2, Di Cristofano C3, Silecchia G4, Leonetti F5, Gastaldelli A6, Capoccia D1. Endocrine. 2019 Dec 19. doi: 10.1007/s12020-019-02155-w. [Epub ahead of print]
 
339.Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension
 

Garcia-Tsao G1, Bosch J2, Kayali Z3, Harrison SA4, Abdelmalek MF5, Lawitz E6, Satapathy SK7, Ghabril M8, Shiffman ML9, Younes ZH10, Thuluvath PJ11, Berzigotti A12, Albillos A13, Robinson JM14, Hagerty DT14, Chan JL14, Sanyal AJ15; IDN-6556-14 Investigators. J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30724-X. doi: 10.1016/j.jhep.2019.12.010. [Epub ahead of print]
 
340.Moderate Alcohol Intake in Non-Alcoholic Fatty Liver Disease: To Drink or Not to Drink?
 

Petroni ML1, Brodosi L1, Marchignoli F1, Musio A1, Marchesini G1. Nutrients. 2019 Dec 13;11(12). pii: E3048. doi: 10.3390/nu11123048.
 
341.Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: a randomised controlled trial
 

Cai H1, Qin YL1, Shi ZY1, Chen JH1, Zeng MJ1, Zhou W1, Chen RQ1, Chen ZY2. BMC Gastroenterol. 2019 Dec 18;19(1):219. doi: 10.1186/s12876-019-1132-8.
 
342.Relationship between non-alcoholic fatty liver disease during pregnancy and abnormal glucose metabolism during and after pregnancy
 

Sattari M1, Bril F2, Egerman R2,3, Kalavalapalli S4, Cusi K4,5,6. J Investig Med. 2019 Dec 17. pii: jim-2019-001186. doi: 10.1136/jim-2019-001186. [Epub ahead of print]
 
343.Bariatric Surgery in Cirrhotic Patients: Is It Safe?
 

Younus H1, Sharma A1, Miquel R1, Quaglia A1, Kanchustambam SR1, Carswell KA1, Patel AG2. Obes Surg. 2019 Dec 18. doi: 10.1007/s11695-019-04214-7. [Epub ahead of print]
 
344.Nonalcoholic Fatty Liver Disease: A Challenge from Mechanisms to Therapy
 

Tarantino G1, Citro V2, Capone D3. J Clin Med. 2019 Dec 19;9(1). pii: E15. doi: 10.3390/jcm9010015.
 
345.Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients
 

Gordon S1, Fraysse J2, Li S3, Ozbay AB2, Wong RJ4. Am J Gastroenterol. 2019 Dec 12. doi: 10.14309/ajg.0000000000000484. [Epub ahead of print]
 
346.Insulin Resistance and Genetic Risk Predict Liver-Related Outcomes and Death in Nonalcoholic Fatty Liver Disease
 

Danford CJ1, Jiang ZG1, Salomaa V2, Färkkilä M3, Jula A2, Männistö S2, Lundqvist A2, Valsta L2, Perola M2, Åberg F4,5. Hepatol Commun. 2019 Oct 10;3(12):1704-1705. doi: 10.1002/hep4.1437. eCollection 2019 Dec.
 
347.Influence of lifestyle factors and staple foods from the Mediterranean diet on non-alcoholic fatty liver disease among older individuals with metabolic syndrome features
 

Bullón-Vela V1, Abete I2, Tur JA3, Pintó X4, Corbella E4, Martínez-González MA5, Toledo E5, Corella D6, Macías M7, Tinahones F7, Fitó M8, Estruch R9, Ros E10, Salas-Salvadó J11, Daimiel L12, Zulet MA13, Martínez JA2; PREDIMED Plus investigators. Nutrition. 2019 Oct 25;71:110620. doi: 10.1016/j.nut.2019.110620. [Epub ahead of print]
 
348.Association between neck circumference and non-alcoholic fatty liver disease in Mexican children and adolescents with obesity
 

Peña-Vélez R1,2, Garibay-Nieto N1,2,3, Cal-Y-Mayor-Villalobos M4, Laresgoiti-Servitje E5, Pedraza-Escudero K1,2, García-Blanco MDC4, Heredia-Nieto OA6, Villanueva-Ortega E1,2. J Pediatr Endocrinol Metab. 2019 Dec 16. pii: /j/jpem.ahead-of-print/jpem-2019-0204/jpem-2019-0204.xml. doi: 10.1515/jpem-2019-0204. [Epub ahead of print]
 
349.A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver DiseaseAnd Non-Alcoholic Steatohepatitis
 

Ganguli S1, DeLeeuw P2, Satapathy SK3. Hepat Med. 2019 Nov 15;11:159-178. doi: 10.2147/HMER.S188991. eCollection 2019.
 
350.Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered
 

Plaz Torres MC1,2,3, Aghemo A3,4, Lleo A3,4, Bodini G1,2,3, Furnari M1, Marabotto E1, Miele L5, Giannini EG1,2,6. Nutrients. 2019 Dec 5;11(12). pii: E2971. doi: 10.3390/nu11122971.
 
351.Higher Sodium Intake Assessed by 24 Hour Urinary Sodium Excretion Is Associated with Non-Alcoholic Fatty Liver Disease: The PREVEND Cohort Study
 

van den Berg EH1,2, Gruppen EG1,3, Blokzijl H2, Bakker SJL3, Dullaart RPF1. J Clin Med. 2019 Dec 6;8(12). pii: E2157. doi: 10.3390/jcm8122157.
 
352.High Protein Diet and Metabolic Plasticity in Non-Alcoholic Fatty Liver Disease: Myths and Truths
 

De Chiara F1, Ureta Checcllo C2, Ramón Azcón J1. Nutrients. 2019 Dec 6;11(12). pii: E2985. doi: 10.3390/nu11122985.
 
353.A retrospective case control study identifies peripheral blood mononuclear cell albumin RNA expression as a biomarker for non-alcoholic fatty liver disease
 

Chu X1, Karasinski K2, Donellan S2, Kaniper S2, Wood GC1, Shi W1, Edwards MA3, Soans R3, Still CD1, Gerhard GS4. Langenbecks Arch Surg. 2019 Dec 11. doi: 10.1007/s00423-019-01848-0. [Epub ahead of print]
 
354.Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis
 

Siddiqui MS1, Van Natta ML2, Connelly MA3, Vuppalanchi R4, Neuschwander-Tetri BA5, Tonascia J2, Guy C6, Loomba R7, Dasarathy S8, Wattacheril J9, Chalasani N4, Sanyal AJ10; NASH CRN. J Hepatol. 2019 Oct 18. pii: S0168-8278(19)30607-5. doi: 10.1016/j.jhep.2019.10.006. [Epub ahead of print]
 
355.Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development
 

Mouries J1, Brescia P1, Silvestri A1, Spadoni I2, Sorribas M3, Wiest R4, Mileti E5, Galbiati M6, Invernizzi P6, Adorini L7, Penna G8, Rescigno M9. J Hepatol. 2019 Dec;71(6):1216-1228. doi: 10.1016/j.jhep.2019.08.005. Epub 2019 Aug 13.
 
356.REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis
 

Ratziu V1, Sanyal AJ2, Loomba R3, Rinella M4, Harrison S5, Anstee QM6, Goodman Z7, Bedossa P8, MacConell L9, Shringarpure R9, Shah A9, Younossi Z7. Contemp Clin Trials. 2019 Sep;84:105803. doi: 10.1016/j.cct.2019.06.017. Epub 2019 Jun 29.
 
357.Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis
 

Loomba R1, Sanyal AJ2, Kowdley KV3, Terrault N4, Chalasani NP5, Abdelmalek MF6, McCullough AJ7, Shringarpure R8, Ferguson B8, Lee L8, Chen J8, Liberman A8, Shapiro D8, Neuschwander-Tetri BA9. Gastroenterology. 2019 Jan;156(1):88-95.e5. doi: 10.1053/j.gastro.2018.09.021. Epub 2018 Sep 15.
 
358.Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
 

Younossi ZM1, Ratziu V2, Loomba R3, Rinella M4, Anstee QM5, Goodman Z1, Bedossa P6, Geier A7, Beckebaum S8, Newsome PN9, Sheridan D10, Sheikh MY11, Trotter J12, Knapple W13, Lawitz E14, Abdelmalek MF15, Kowdley KV16, Montano-Loza AJ17, Boursier J18, Mathurin P19, Bugianesi E20, Mazzella G21, Olveira A22, Cortez-Pinto H23, Graupera I24, Orr D25, Gluud LL26, Dufour JF27, Shapiro D28, Campagna J28, Zaru L28, MacConell L28, Shringarpure R28, Harrison S29, Sanyal AJ30; REGENERATE Study Investigators.

Collaborators (336) Lancet. 2019 Dec 5. pii: S0140-6736(19)33041-7. doi: 10.1016/S0140-6736(19)33041-7. [Epub ahead of print]
 
359.Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes
 

Poynard T1,2, Peta V2,3, Deckmyn O3, Pais R1,2, Ngo Y2,3, Charlotte F4, Ngo A3, Munteanu M2,3, Imbert-Bismut F5, Monneret D5, Housset C2, Thabut D1,2, Valla D6, Boitard C7, Castera L6, Ratziu V1; FLIP consortium, the FibroFrance Group, the EPIC-3 program and the QUID-NASH group.
 
360.The Role of Noninvasive Tests for Differentiating NASH From NAFL and Diagnosing Advanced Fibrosis Among Patients With NAFLD
 

Balakrishnan M1, Loomba R2,3. J Clin Gastroenterol. 2019 Nov 26. doi: 10.1097/MCG.0000000000001284. [Epub ahead of print]
 
361.Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany
 

Labenz C1,2, Huber Y1,2, Michel M1,2, Nagel M1,2, Galle PR1,2, Kostev K3, Schattenberg JM4,5. Dig Dis Sci. 2019 Dec 3. doi: 10.1007/s10620-019-05986-9. [Epub ahead of print]
 
362.New drugs for NAFLD: lessons from basic models to the clinic
 

Reimer KC1, Wree A2, Roderburg C2, Tacke F3. Hepatol Int. 2019 Dec 4. doi: 10.1007/s12072-019-10001-4. [Epub ahead of print]
 
363.Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
 

Smith GI, Shankaran M, Yoshino M, Schweitzer GG, Chondronikola M, Beals JW, Okunade AL, Patterson BW, Nyangau E, Field T, Sirlin CB, Talukdar S, Hellerstein MK, Klein S. J Clin Invest. 2019 Dec 5. pii: 134165. doi: 10.1172/JCI134165. [Epub ahead of print]
 
364.A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
 

Pedrosa M1, Seyedkazemi S2, Francque S3, Sanyal A4, Rinella M5, Charlton M6, Loomba R7, Ratziu V8, Kochuparampil J1, Fischer L2, Vaidyanathan S9, Anstee QM10. Contemp Clin Trials. 2019 Nov 13;88:105889. doi: 10.1016/j.cct.2019.105889. [Epub ahead of print]
 
365.Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease
 

Shili-Masmoudi S1, Wong GL2,3, Hiriart JB1, Liu K4,5, Chermak F1, Shu SS2,3, Foucher J1, Tse YK2,3, Bernard PH1, Yip TC2,3, Merrouche W1, Chan HL2,3, Wong VW2,3, de Lédinghen V1,6. Liver Int. 2019 Nov 20. doi: 10.1111/liv.14301. [Epub ahead of print]
 
366.The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)
 

Thondam SK1, Cuthbertson DJ2, Wilding JPH3. Peptides. 2019 Nov 20:170208. doi: 10.1016/j.peptides.2019.170208. [Epub ahead of print]
 
367.Moderate alcohol use in fatty liver disease; don
 

Gow P1,2, Testro AG1,2, Hey P1,2, Sinclair M1,2. Hepatology. 2019 Nov 29. doi: 10.1002/hep.31049. [Epub ahead of print]
 
368.Diabetes drugs for nonalcoholic fatty liver disease: a systematic review
 

Blazina I1, Selph S2. Syst Rev. 2019 Nov 29;8(1):295. doi: 10.1186/s13643-019-1200-8.
 
369.Systematic review and meta-analysis of Roux-en-Y gastric bypass against laparoscopic sleeve gastrectomy for amelioration of NAFLD using four criteria
 

Baldwin D1, Chennakesavalu M1, Gangemi A2. Surg Obes Relat Dis. 2019 Sep 18. pii: S1550-7289(19)30997-9. doi: 10.1016/j.soard.2019.09.060. [Epub ahead of print]
 
370.Attributable Fractions of NAFLD for Mortality in the United States: Results From NHANES III With 27 Years of Follow-up
 

Alvarez CS1, Graubard BI1, Thistle JE1, Petrick JL1,2, McGlynn KA1. Hepatology. 2019 Nov 16. doi: 10.1002/hep.31040. [Epub ahead of print]
 
371.Alcohol Use is Associated with Hepatic Steatosis Among Persons with Presumed Non-alcoholic Fatty Liver Disease
 

Long MT1, Massaro JM2, Hoffmann U3, Benjamin EJ4, Naimi TS5. Clin Gastroenterol Hepatol. 2019 Nov 14. pii: S1542-3565(19)31309-6. doi: 10.1016/j.cgh.2019.11.022. [Epub ahead of print]
 
372.Hypothetical Treatment of Patients with Nonalcoholic Steatohepatitis: Potential Impact on Important Clinical Outcomes
 

Younossi ZM1,2, Tampi RP1, Nader F3, Younossi IM3, Cable R2, Srishord M2, Racila A1,3. Liver Int. 2019 Nov 9. doi: 10.1111/liv.14292. [Epub ahead of print]
 
373.GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis
 

Best J1, Bechmann LP1, Sowa JP1, Sydor S1, Dechêne A2, Pflanz K3, Bedreli S3, Schotten C3, Geier A4, Berg T5, Fischer J5, Vogel A6, Bantel H6, Weinmann A7, Schattenberg JM7, Huber Y7, Wege H8, von Felden J8, Schulze K8, Bettinger D9, Thimme R10, Sinner F1, Schütte K1, Weiss KH11, Toyoda H12, Yasuda S12, Kumada T13, Berhane S14, Wichert M15, Heider D16, Gerken G3, Johnson P14, Canbay A17. Clin Gastroenterol Hepatol. 2019 Nov 8. pii: S1542-3565(19)31267-4. doi: 10.1016/j.cgh.2019.11.012. [Epub ahead of print]
 
374.Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
 

Harrison SA1, Bashir MR2, Guy CD2, Zhou R3, Moylan CA2, Frias JP4, Alkhouri N5, Bansal MB6, Baum S7, Neuschwander-Tetri BA8, Taub R9, Moussa SE10. Lancet. 2019 Nov 11. pii: S0140-6736(19)32517-6. doi: 10.1016/S0140-6736(19)32517-6. [Epub ahead of print]
 
375.Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives
 

Pennisi G1, Celsa C1, Spatola F1, Dallio M2, Federico A2, Petta S1. Int J Environ Res Public Health. 2019 Nov 7;16(22). pii: E4334. doi: 10.3390/ijerph16224334.
 
376.Niacin for treatment of nonalcoholic fatty liver disease (NAFLD): novel use for an old drug?
 

Kashyap ML1, Ganji S2, Nakra NK2, Kamanna VS3. J Clin Lipidol. 2019 Oct 14. pii: S1933-2874(19)30290-9. doi: 10.1016/j.jacl.2019.10.006. [Epub ahead of print]
 
377.The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives
 

Pennisi G1, Celsa C1, Giammanco A2, Spatola F1, Petta S1. Int J Mol Sci. 2019 Nov 9;20(22). pii: E5613. doi: 10.3390/ijms20225613.
 
378.Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
 

Harrison SA1, Alkhouri N2, Davison BA3, Sanyal A4, Edwards C3, Colca JR5, Lee BH5, Loomba R6, Cusi K7, Kolterman O8, Cotter G3, Dittrich HC5. J Hepatol. 2019 Nov 4. pii: S0168-8278(19)30650-6. doi: 10.1016/j.jhep.2019.10.023. [Epub ahead of print]
 
379.Transarterial Chemoembolization of Hepatocellular Carcinoma: Propensity Score Matching Study Comparing Survival and Complications in Patients with Nonalcoholic Steatohepatitis Versus Other Causes Cirrhosis
 

Young S1, Sanghvi T2, Rubin N3, Hall D3, Roller L3, Charaf Y3, Golzarian J3. Cardiovasc Intervent Radiol. 2019 Nov 4. doi: 10.1007/s00270-019-02363-x. [Epub ahead of print]
 
380.Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Non-alcoholic Fatty Liver Disease
 

Kanwal F1,2,3, Kramer J2,3, Li L4, Dai J4, Natarajan Y1, Yu X2,3, Asch SM5,6, El-Serag HB1,2,3. Hepatology. 2019 Nov 1. doi: 10.1002/hep.31014. [Epub ahead of print]
 
381.A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health
 

Moolla A1,2, Motohashi K1, Marjot T1,3, Shard A3, Ainsworth M3, Gray A4, Holman R2,5, Pavlides M2,3, Ryan JD2,3, Tomlinson JW1,2, Cobbold JF2,3. Frontline Gastroenterol. 2019 Oct;10(4):337-346. doi: 10.1136/flgastro-2018-101155. Epub 2019 Apr 30.
 
382.Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States
 

Paik JM1, Henry L2, De Avila L1, Younossi E1, Racila A1, Younossi ZM1,3. Hepatol Commun. 2019 Aug 14;3(11):1459-1471. doi: 10.1002/hep4.1419. eCollection 2019 Nov.
 
383.Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low-Density Lipoprotein Cholesterol
 

Labenz C1, Prochaska JH2,3,4, Huber Y1, Nagel M1, Straub BK5, Wild P2,3,4, Galle PR1, Schattenberg JM1,6. Hepatol Commun. 2019 Sep 30;3(11):1472-1481. doi: 10.1002/hep4.1428. eCollection 2019 Nov.
 
384.Hepatocellular carcinoma and non-alcoholic fatty liver disease
 

Golabi P1,2, Rhea L1, Henry L2, Younossi ZM3,4. Hepatol Int. 2019 Nov 7. doi: 10.1007/s12072-019-09995-8. [Epub ahead of print]
 
385.Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial
 

Navarro VJ1, Belle SH2, D'Amato M3, Adfhal N4, Brunt EM5, Fried MW6, Reddy KR7, Wahed AS2, Harrison S8; Silymarin in NASH and C Hepatitis (SyNCH) Study Group. PLoS One. 2019 Sep 19;14(9):e0221683. doi: 10.1371/journal.pone.0221683. eCollection 2019.
 
386.Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients
 

Sebastiani G1,2, Saeed S3, Lebouche B1, de Pokomandy A1, Szabo J1, Haraoui LP1, Routy JP1,4, Wong P2, Deschenes M2, Ghali P2, Klein M1; LIVEHIV Study Group. AIDS. 2019 Oct 16. doi: 10.1097/QAD.0000000000002412. [Epub ahead of print]
 
387.Nonalcoholic Fatty Liver Disease Among Individuals with HIV Mono-infection: A Growing Concern?
 

Morrison M1, Hughes HY2,3, Naggie S4,5, Syn WK6,7,8. Dig Dis Sci. 2019 Oct 23. doi: 10.1007/s10620-019-05861-7. [Epub ahead of print]
 
388.Severe obesity is associated with liver disease severity in pediatric non-alcoholic fatty liver disease
 

Seth A1, Orkin S2, Yodoshi T2, Liu C3, Fei L3, Hardy J2, Trout AT4, Arce Clachar AC2, Bramlage K2, Xanthakos S2, Mouzaki M2. Pediatr Obes. 2019 Oct 27. doi: 10.1111/ijpo.12581. [Epub ahead of print]
 
389.Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the United States
 

Younossi ZM1,2, Tampi RP3, Racila A3,2, Qiu Y4, Burns L4, Younossi I5, Nader F5. Diabetes Care. 2019 Oct 28. pii: dc191113. doi: 10.2337/dc19-1113. [Epub ahead of print]
 
390.Polycystic Ovary Syndrome (PCOS) Is Associated With NASH Severity and Advanced Fibrosis
 

Sarkar M1, Terrault N2, Chan W1, Cedars M3, Huddleston H3, Duwaerts CC1, Balitzer D4, Gill RM4. Liver Int. 2019 Oct 18. doi: 10.1111/liv.14279. [Epub ahead of print]
 
391.Decreased Physical Working Capacity in Adolescents With Non-Alcoholic Fatty Liver DiseaseAssociates With Reduced Iron Availability: PWC in NAFLD Relates to Iron Bioavailability
 

Mitchell T1, McKinnon E2, Ayonrinde O3, Adams LA4, Trinder D5, Chua ACG5, Newton RU6, Straker L7, Olynyk JK8. Clin Gastroenterol Hepatol. 2019 Oct 16. pii: S1542-3565(19)31116-4. doi: 10.1016/j.cgh.2019.10.017. [Epub ahead of print]
 
392.Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction in Patients With Nonalcoholic Fatty Liver Disease
 

Packer M1. Am J Med. 2019 Oct 14. pii: S0002-9343(19)30843-5. doi: 10.1016/j.amjmed.2019.09.002. [Epub ahead of print]
 
393.Effect of alcohol consumption on nonalcoholic fatty liver disease
 

Weng G1, Dunn W1. Transl Gastroenterol Hepatol. 2019 Sep 17;4:70. doi: 10.21037/tgh.2019.09.02. eCollection 2019.
 
394.Non-alcoholic fatty liver disease in adults: Current concepts in etiology, outcomes and management
 

Marjot T1,2, Moolla A2, Cobbold JF1, Hodson L2, Tomlinson JW2. Endocr Rev. 2019 Oct 20. pii: bnz009. doi: 10.1210/endrev/bnz009. [Epub ahead of print]
 
395.Editorial: The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis due to NASH
 

Loomba R1,2, Adams LA3,4. Hepatology. 2019 Sep 13. doi: 10.1002/hep.30946. [Epub ahead of print]
 
396.MRI presentation of hepatocellular carcinoma in non-alcoholic steatohepatitis (NASH)
 

Al-Sharhan F1, Dohan A2, Barat M3, Feddal A4, Terris B5, Pol S6, Mallet V7, Soyer P8. Eur J Radiol. 2019 Oct;119:108648. doi: 10.1016/j.ejrad.2019.108648. Epub 2019 Sep 7.
 
397.Dietary cholesterol does not break your heart but kills your liver
 

Püschel GP1, Henkel J1. Porto Biomed J. 2019 Jun 29;3(1):e12. doi: 10.1016/j.pbj.0000000000000012. eCollection 2018 Aug.
 
398.Overview of studies of the vitamin D/vitamin D receptor system in the development of non-alcoholic fatty liver disease
 

Cimini FA1, Barchetta I1, Carotti S2, Morini S3, Cavallo MG1. World J Gastrointest Pathophysiol. 2019 Sep 10;10(2):11-16. doi: 10.4291/wjgp.v10.i2.11.
 
399.Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
 

Stanley TL1, Fourman LT1, Feldpausch MN1, Purdy J2, Zheng I1, Pan CS1, Aepfelbacher J2, Buckless C3, Tsao A3, Kellogg A4, Branch K5, Lee H6, Liu CY7, Corey KE8, Chung RT8, Torriani M3, Kleiner DE9, Hadigan CM2, Grinspoon SK10. Lancet HIV. 2019 Oct 11. pii: S2352-3018(19)30338-8. doi: 10.1016/S2352-3018(19)30338-8. [Epub ahead of print]
 
400.Low Awareness of Nonalcoholic Fatty Liver Disease in a Population-Based Cohort Sample: the CARDIA Study
 

Cleveland ER1, Ning H2, Vos MB3, Lewis CE4, Rinella ME1, Carr JJ5, Lloyd-Jones DM2,6, VanWagner LB7,8. J Gen Intern Med. 2019 Oct 8. doi: 10.1007/s11606-019-05340-9. [Epub ahead of print]
 
401.Is There a Link between Basal Metabolic Rate, Spleen Volume and Hepatic Growth Factor Levels in Patients with Obesity-Related NAFLD?
 

Tarantino G1, Citro V2, Conforti P3, Balsano C4, Capone D5. J Clin Med. 2019 Sep 20;8(10). pii: E1510. doi: 10.3390/jcm8101510.
 
402.Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults
 

Alexander M1, Loomis AK2, van der Lei J3, Duarte-Salles T4, Prieto-Alhambra D5, Ansell D6,7, Pasqua A8, Lapi F8, Rijnbeek P3, Mosseveld M3, Avillach P3,9, Egger P1, Dhalwani NN10, Kendrick S11, Celis-Morales C12, Waterworth DM13, Alazawi W14, Sattar N12. BMJ. 2019 Oct 8;367:l5367. doi: 10.1136/bmj.l5367.
 
403.Chronic hepatitis B and NASH: Is "fat" all bad?
 

Li J1, Cheung RC2,3, Nguyen MH3. Hepatology. 2019 Oct 8. doi: 10.1002/hep.30983. [Epub ahead of print]
 
404.A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe
 

Lazarus JV1, Ekstedt M2, Marchesini G3, Mullen J4, Novak K5, Pericàs JM6, Roel E7, Romero-Gómez M8, Ratziu V9, Tacke F10, Cortez-Pinto H11, Anstee QM12; EASL International Liver Foundation NAFLD Policy Review Collaborators. J Hepatol. 2019 Sep 10. pii: S0168-8278(19)30521-5. doi: 10.1016/j.jhep.2019.08.027. [Epub ahead of print]
 
405.Associations of chronic diarrhoea with non-alcoholic fatty liver disease and obesity-related disorders among US adults
 

Shin A1, Xu H2, Imperiale TF1,3. BMJ Open Gastroenterol. 2019 Aug 12;6(1):e000322. doi: 10.1136/bmjgast-2019-000322. eCollection 2019.
 
406.Genetic Causes of Liver Disease: When to Suspect a Genetic Etiology, Initial Lab Testing, and the Basics of Management
 

Schonfeld EA1, Brown RS Jr2. Med Clin North Am. 2019 Nov;103(6):991-1003. doi: 10.1016/j.mcna.2019.07.003.
 
407.Impact of a preoperative low-calorie diet on liver histology in patients with fatty liver diseaseundergoing bariatric surgery
 

Wolf RM1, Oshima K2, Canner JK3, Steele KE4. Surg Obes Relat Dis. 2019 Aug 22. pii: S1550-7289(19)30380-6. doi: 10.1016/j.soard.2019.08.013. [Epub ahead of print]
 
408.Metabolic profiling of adolescent non-alcoholic fatty liver disease
 

Hartley A1,2,3, Santos Ferreira DL2,3, Anderson EL2,3, Lawlor DA2,3. Version 2. Wellcome Open Res. 2019 Sep 19 [revised 2019 Sep 19];3:166. doi: 10.12688/wellcomeopenres.14974.2. eCollection 2018.
 
409.Reversal of NASH fibrosis with pharmacotherapy
 

Alukal JJ1, Thuluvath PJ2,3. Hepatol Int. 2019 Sep;13(5):534-545. doi: 10.1007/s12072-019-09970-3. Epub 2019 Jul 30.
 
410.Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life
 

Younossi ZM1,2, Stepanova M3, Lawitz EJ4, Reddy KR5, Wai-Sun Wong V6, Mangia A7, Muir AJ8, Jacobson I9, Djedjos CS10, Gaggar A10, Myers RP10, Younossi I3, Nader F3, Racila A3. Am J Gastroenterol. 2019 Oct;114(10):1636-1641. doi: 10.14309/ajg.0000000000000375.
 
411.What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
 

Doumas M1, Imprialos K1,2, Stavropoulos K1,2, Athyros VG1,2. Curr Vasc Pharmacol. 2019;17(5):425-428. doi: 10.2174/157016111705190703102816.
 
412.Statin Use is Protective Against Hepatocellular Carcinoma in Patients With Nonalcoholic FattyLiver Disease: A Case-control Study
 

German MN1,2, Lutz MK1,2, Pickhardt PJ2,3, Bruce RJ2,3, Said A1,2. J Clin Gastroenterol. 2019 Sep 17. doi: 10.1097/MCG.0000000000001260. [Epub ahead of print]
 
413.Prevalence, trends, outcomes, and disparities in hospitalizations for nonalcoholic fatty liverdisease in the United States
 

Adejumo AC1,2,3,4, Samuel GO5, Adegbala OM6, Adejumo KL4, Ojelabi O3, Akanbi O7, Ogundipe OA8, Pani L1,2. Ann Gastroenterol. 2019 Sep-Oct;32(5):504-513. doi: 10.20524/aog.2019.0402. Epub 2019 Jul 17.
 
414.Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic FattyLiver Disease Who Have Normal Aminotransferase Levels
 

Gawrieh S1, Wilson LA2, Cummings OW3, Clark JM2, Loomba R4, Hameed B5, Abdelmalek MF6, Dasarathy S7, Neuschwander-Tetri BA8, Kowdley K9, Kleiner D10, Doo E11, Tonascia J2, Sanyal A12, Chalasani N1; and the NASH Clinical Research Network. Am J Gastroenterol. 2019 Oct;114(10):1626-1635. doi: 10.14309/ajg.0000000000000388.
 
415.Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study
 

Gawrieh S1, Dakhoul L1, Miller E2, Scanga A3, deLemos A4, Kettler C1, Burney H1, Liu H1, Abu-Sbeih H2, Chalasani N1, Wattacheril J5. Aliment Pharmacol Ther. 2019 Oct;50(7):809-821. doi: 10.1111/apt.15464. Epub 2019 Sep 1.
 
416.Increased Prevalence of Colorectal Adenomas in Patients with Nonalcoholic Fatty LiverDisease: A Cross-Sectional Study
 

Blackett JW1, Verna EC2, Lebwohl B2,3. Dig Dis. 2019 Aug 30:1-9. doi: 10.1159/000502684. [Epub ahead of print]
 
417.Multi-drug approaches to NASH: what's in the development pipeline?
 

Johnston MP1, Patel J1, Byrne CD2,3. Expert Opin Investig Drugs. 2019 Sep 23:1-8. doi: 10.1080/13543784.2020.1668926. [Epub ahead of print]
 
418.ANNALS EXPRESS: A review of the clinical utility of the Enhanced Liver Fibrosis test in multiple aetiologies of Chronic Liver Disease
 

Patel P1, Connoley D1, Jones F1, Srivastava A1, Rosenberg W1. Ann Clin Biochem. 2019 Sep 17:4563219879962. doi: 10.1177/0004563219879962. [Epub ahead of print]
 
419.Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges
 

Thiagarajan P1, Aithal GP1. J Clin Exp Hepatol. 2019 Jul-Aug;9(4):515-521. doi: 10.1016/j.jceh.2019.03.002. Epub 2019 Mar 13.
 
420.Screening of Cardiovascular Disease in Nonalcoholic Fatty Liver Disease: Whom and How?
 

Choudhary NS1, Duseja A2. J Clin Exp Hepatol. 2019 Jul-Aug;9(4):506-514. doi: 10.1016/j.jceh.2019.02.005. Epub 2019 Feb 15.
 
421.Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective
 

Samji NS1, Verma R1,2, Satapathy SK3. J Clin Exp Hepatol. 2019 Jul-Aug;9(4):497-505. doi: 10.1016/j.jceh.2019.05.001. Epub 2019 May 16.
 
422.HDL Flux is Higher in Patients with Nonalcoholic Fatty Liver Disease
 

McCullough A1, Previs SF2, Dasarathy J3, Lee K4, Osme A4, Kim C4, Ilchenko S4, Lorkowski SW5, Smith JD5, Dasarathy S1, Kasumov T6. Am J Physiol Endocrinol Metab. 2019 Sep 10. doi: 10.1152/ajpendo.00193.2019. [Epub ahead of print]
 
423.Magnitude of Nonalcoholic Fatty Liver Disease: Eastern Perspective
 

Ching-Yeung Yu B1, Kwok D1, Wong VW1. J Clin Exp Hepatol. 2019 Jul-Aug;9(4):491-496. doi: 10.1016/j.jceh.2019.01.007. Epub 2019 Feb 7.
 
424.Editorial: The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis due to NASH
 

Loomba R1,2, Adams LA3,4. Hepatology. 2019 Sep 13. doi: 10.1002/hep.30946. [Epub ahead of print]
 
425.Nicotinamide and NAFLD: Is There Nothing New Under the Sun?
 

Guarino M1,2, Dufour JF3,4. Metabolites. 2019 Sep 10;9(9). pii: E180. doi: 10.3390/metabo9090180.
 
426.Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness
 

Liebig S1, Stoeckmann N1, Geier A2, Rau M2, Schattenberg JM3, Bahr MJ4, Manns MP1, Jaeckel E1, Schulze-Osthoff K5, Bantel H1. Clin Transl Gastroenterol. 2019 Aug;10(8):e00066. doi: 10.14309/ctg.0000000000000066.
 
427.HDL Flux is Higher in Patients with Nonalcoholic Fatty Liver Disease
 

McCullough A1, Previs SF2, Dasarathy J3, Lee K4, Osme A4, Kim C4, Ilchenko S4, Lorkowski SW5, Smith JD5, Dasarathy S1, Kasumov T6. Am J Physiol Endocrinol Metab. 2019 Sep 10. doi: 10.1152/ajpendo.00193.2019. [Epub ahead of print]
 
428.Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
 

Drescher HK1, Weiskirchen S2, Weiskirchen R3. Cells. 2019 Aug 7;8(8). pii: E845. doi: 10.3390/cells8080845.
 
429.Non-Alcoholic Fatty Liver Disease is Associated with Higher Metabolic Expenditure in Overweight and Obese Subjects: A Case-Control Study
 

Reddavide R1, Cisternino AM1, Inguaggiato R1, Rotolo O1, Zinzi I1, Veronese N1, Guerra V2, Fucilli F3, Di Giovanni G3, Leandro G4, Giannico S1, Caruso MG5. Nutrients. 2019 Aug 7;11(8). pii: E1830. doi: 10.3390/nu11081830.
 
430.The decreasing predictive power of MELD in an era of changing etiology of liverdisease
 

Godfrey EL1, Malik TH1, Lai JC2, Mindikoglu AL1,3, Galván NTN1, Cotton RT1, O'Mahony CA1, Goss JA1, Rana A1. Am J Transplant. 2019 Aug 8. doi: 10.1111/ajt.15559. [Epub ahead of print]
 
431.Body Composition and Genetic Lipodystrophy Risk Score Associate With Nonalcoholic Fatty Liver Disease and Liver Fibrosis
 

Chen VL1,2, Wright AP1,3, Halligan B1, Chen Y1, Du X1, Handelman SK1,2, Long MT4, Kiel DP5,6, Speliotes EK1,2. Hepatol Commun. 2019 Jun 18;3(8):1073-1084. doi: 10.1002/hep4.1391. eCollection 2019 Aug.
 
432.Nonalcoholic Fatty Liver Identification and Characterization Using Big Data
 

Goldshtein I1, Chodick G2, Kochba I3, Gal N3, Webb M4, Shibolet O5. Clin Gastroenterol Hepatol. 2019 Aug 9. pii: S1542-3565(19)30863-8. doi: 10.1016/j.cgh.2019.08.007. [Epub ahead of print]
 
433.Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life
 

Younossi ZM1,2, Stepanova M3, Lawitz EJ4, Reddy KR5, Wai-Sun Wong V6, Mangia A7, Muir AJ8, Jacobson I9, Djedjos CS10, Gaggar A10, Myers RP10, Younossi I3, Nader F3, Racila A3. Am J Gastroenterol. 2019 Aug 20. doi: 10.14309/ajg.0000000000000375. [Epub ahead of print]
 
434.Non-Alcoholic Fatty Liver Disease is Associated with Higher Metabolic Expenditure in Overweight and Obese Subjects: A Case-Control Study
 

Reddavide R1, Cisternino AM1, Inguaggiato R1, Rotolo O1, Zinzi I1, Veronese N1, Guerra V2, Fucilli F3, Di Giovanni G3, Leandro G4, Giannico S1, Caruso MG5. Nutrients. 2019 Aug 7;11(8). pii: E1830. doi: 10.3390/nu11081830.
 
435.Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation
 

Chen F1, Esmaili S1,2, Rogers G3, Bugianesi E4, Petta S5, Marchesini G6, Bayoumi A1, Metwally M1, Azardaryany MK1, Coulter S1, Choo JM3, Younes R4, Rosso C4, Liddle C1, Adams LA7, Craxì A5, George J1, Eslam M1. Hepatology. 2019 Aug 23. doi: 10.1002/hep.30908. [Epub ahead of print]
 
436.The Risk of Incident Extrahepatic Cancers is higher in Nonalcoholic Fatty Liver Disease than Obesity - a Longitudinal Cohort Study
 

Allen AM1, Hicks SB2, Mara KC3, Larson JJ3, Therneau TM3. J Hepatol. 2019 Aug 27. pii: S0168-8278(19)30485-4. doi: 10.1016/j.jhep.2019.08.018. [Epub ahead of print]
 
437.Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
 

Drescher HK1, Weiskirchen S2, Weiskirchen R3. Cells. 2019 Aug 7;8(8). pii: E845. doi: 10.3390/cells8080845.
 
438.Implications of Nonalcoholic Fatty Liver Disease on Pregnancy and Maternal and Child Outcomes
 

Hershman M1, Mei R1, Kushner T1. Gastroenterol Hepatol (N Y). 2019 Apr;15(4):221-228.
 
439.Incidence and Risks for Non Alcoholic Fatty Liver Disease and Steatohepatitis Post LiverTransplant: Systematic Review and Meta-analysis
 

Saeed N1, Glass L1, Sharma P1, Shannon C2, Sonnenday CJ3, Tincopa MA1. Transplantation. 2019 Aug 12. doi: 10.1097/TP.0000000000002916. [Epub ahead of print]
 
440.What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-AlcoholicSteatohepatitis?
 

Doumas M1, Imprialos K1,2, Stavropoulos K1,2, Athyros VG1,2. Curr Vasc Pharmacol. 2019;17(5):425-428. doi: 10.2174/157016111705190703102816.
 
441.Diet and Non-Alcoholic Fatty Liver Disease: The Mediterranean Way
 

Abenavoli L1, Boccuto L2, Federico A3, Dallio M3, Loguercio C3, Di Renzo L4, De Lorenzo A4. Int J Environ Res Public Health. 2019 Aug 21;16(17). pii: E3011. doi: 10.3390/ijerph16173011.
 
442.CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
 

Pockros PJ1, Fuchs M2, Freilich B3, Schiff E4, Kohli A5, Lawitz EJ6, Hellstern PA7, Owens-Grillo J8, Van Biene C8, Shringarpure R8, MacConell L8, Shapiro D8, Cohen DE9. Liver Int. 2019 Aug 11. doi: 10.1111/liv.14209. [Epub ahead of print]
 
443.Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Clinic
 

Pandyarajan V1, Gish RG1, Alkhouri N1, Noureddin M1. Gastroenterol Hepatol (N Y). 2019 Jul;15(7):357-365.
 
444.Noninvasive Tests of Liver Fibrosis and Their Combination in NAFLD: From Selected Patients to Real-Life Populations
 

Boursier J1,2, Francque S3,4. Hepatology. 2019 Aug 5. doi: 10.1002/hep.30886. [Epub ahead of print]
 
445.Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease
 

Golabi P1, Fukui N2, Paik J1, Sayiner M2, Mishra A2, Younossi ZM1,2. Hepatol Commun. 2019 Jun 6;3(8):1050-1060. doi: 10.1002/hep4.1387. eCollection 2019 Aug.
 
446.Importance of fatigue and its measurement in chronic liver disease
 

Gerber LH1, Weinstein AA2, Mehta R3, Younossi ZM4. World J Gastroenterol. 2019 Jul 28;25(28):3669-3683. doi: 10.3748/wjg.v25.i28.3669.
 
447.Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program
 

Huber Y1, Pfirrmann D2, Gebhardt I1, Labenz C1, Gehrke N1, Straub BK3, Ruckes C4, Bantel H5, Belda E6, Clément K7, Leeming DJ8, Karsdal MA8, Galle PR1, Simon P2, Schattenberg JM1. Aliment Pharmacol Ther. 2019 Jul 25. doi: 10.1111/apt.15427. [Epub ahead of print]
 
448.Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
 

Bril F1, Biernacki DM1, Kalavalapalli S1, Lomonaco R1, Subbarayan SK1, Lai J2, Tio F3, Suman A4, Orsak BK5, Hecht J6, Cusi K7,8. Diabetes Care. 2019 Aug;42(8):1481-1488. doi: 10.2337/dc19-0167. Epub 2019 May 21.
 
449.eNOS Deletion Impairs Mitochondrial Quality Control and Exacerbates Western Diet Induced NASH
 

Sheldon RD1, Meers GM1, Morris EM2, Linden MA1, Cunningham RP1, Ibdah JA3, Thyfault JP4, Laughlin MH5, Rector RS6. Am J Physiol Endocrinol Metab. 2019 Jul 30. doi: 10.1152/ajpendo.00096.2019. [Epub ahead of print]
 
450.Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness
 

Liebig S1, Stoeckmann N1, Geier A2, Rau M2, Schattenberg JM3, Bahr MJ4, Manns MP1, Jaeckel E1, Schulze-Osthoff K5, Bantel H1. Clin Transl Gastroenterol. 2019 Aug 8. doi: 10.14309/ctg.0000000000000066. [Epub ahead of print]
 
451.Serum Vitamin E Levels of Adults with Nonalcoholic Fatty Liver Disease: An Inverse Relationship with All-Cause Mortality in Non-Diabetic but Not in Pre-Diabetic or Diabetic Subjects
 

Tsou P1, Wu CJ2. J Clin Med. 2019 Jul 19;8(7). pii: E1057. doi: 10.3390/jcm8071057.
 
452.Novel Strategies to Treat Hepatic Steatosis and Steatohepatitis
 

Perry RJ1. Obesity (Silver Spring). 2019 Jul 25. doi: 10.1002/oby.22559. [Epub ahead of print]
 
453.Pocket-Sized Versus Conventional Ultrasound for Detecting Fatty Infiltration of the Liver
 

Miles DA1, Levi CS2, Uhanova J1, Cuvelier S1, Hawkins K1, Minuk GY3,4. Dig Dis Sci. 2019 Aug 2. doi: 10.1007/s10620-019-05752-x. [Epub ahead of print]
 
454.Hyperferritinemia in Nonalcoholic Fatty Liver Disease: Iron Accumulation or Inflammation?
 

Moris W1,2,3, Verhaegh P#2,3, Jonkers D2,3, Deursen CV1,2, Koek G2,3,4. Semin Liver Dis. 2019 Jul 22. doi: 10.1055/s-0039-1693114. [Epub ahead of print]
 
455.Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: Diagnostic accuracy and cost analysis
 

Crossan C1, Majumdar A2, Srivastava A2, Thorburn D2, Rosenberg W2, Pinzani M2, Longworth L1,3, Tsochatzis EA2. Liver Int. 2019 Jul 22. doi: 10.1111/liv.14198. [Epub ahead of print]
 
456.Pathogenesis of NASH: The Impact of Multiple Pathways
 

Noureddin M1, Sanyal AJ2. Curr Hepatol Rep. 2018 Dec;17(4):350-360. doi: 10.1007/s11901-018-0425-7. Epub 2018 Oct 31.
 
457.How Would You Manage This Patient With Nonalcoholic Fatty Liver Disease?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center
 

Libman H1, Jiang ZG1, Tapper EB2, Reynolds EE1. Ann Intern Med. 2019 Aug 6;171(3):199-207. doi: 10.7326/M19-1125.
 
458.Insulin Resistance Exacerbates Genetic Predisposition to Nonalcoholic Fatty Liver Disease in Individuals Without Diabetes
 

Barata L1, Feitosa MF1, Bielak LF2, Halligan B3, Baldridge AS4, Guo X5, Yerges-Armstrong LM6, Smith AV7, Yao J5, Palmer ND8, VanWagner LB4,9, Carr JJ10, Chen YI5, Allison M11, Budoff MJ12, Handelman SK3, Kardia SLR2, Mosley TH Jr13, Ryan K6, Harris TB14, Launer LJ14, Gudnason V15,16, Rotter JI5, Fornage M17, Rasmussen-Torvik LJ4, Borecki IB1, O'Connell JR6, Peyser PA2, Speliotes EK3, Province MA1. Hepatol Commun. 2019 Apr 18;3(7):894-907. doi: 10.1002/hep4.1353. eCollection 2019 Jul.
 
459.Metabolic control of gene transcription in non-alcoholic fatty liver disease: the role of the epigenome
 

Sinton MC1, Hay DC2, Drake AJ3. Clin Epigenetics. 2019 Jul 18;11(1):104. doi: 10.1186/s13148-019-0702-5.
 
460.Relationship between abdominal fat stores and liver fat, pancreatic fat, and metabolic comorbidities in a pediatric population with non-alcoholic fatty liver disease
 

Trout AT1,2,3, Hunte DE4, Mouzaki M5,6, Xanthakos SA5,6, Su W7, Zhang B5,8, Dillman JR4,9. Abdom Radiol (NY). 2019 Jul 16. doi: 10.1007/s00261-019-02123-y. [Epub ahead of print]
 
461.Clinically Significant Fibrosis is Associated With Longitudinal Increases in Fibrosis-4 and NAFLD Fibrosis Scores
 

Patel PJ1, Cheng JC2, Banh X2, Gracen L2, Radford-Smith D3, Hossain F4, Horsfall LU1, Lee Hayward K2, Williams S4, Johnson T4, Brown NN5, Saad N6, Stuart KA7, Russell AW8, Valery PC9, Clouston AD2, Irvine KM10, Bernard A11, Powell EE12. Clin Gastroenterol Hepatol. 2019 Jul 25. pii: S1542-3565(19)30780-3. doi: 10.1016/j.cgh.2019.07.036. [Epub ahead of print]
 
462.Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease
 

Koopman N1, Molinaro A2, Nieuwdorp M3, Holleboom AG3. Aliment Pharmacol Ther. 2019 Aug 2. doi: 10.1111/apt.15416. [Epub ahead of print]
 
463.Reversal of NASH fibrosis with pharmacotherapy
 

Alukal JJ1, Thuluvath PJ2,3. Hepatol Int. 2019 Jul 30. doi: 10.1007/s12072-019-09970-3. [Epub ahead of print]
 
464.Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis
 

Wong RJ1, Tran T2, Kaufman H3, Niles J3, Gish R4. PLoS One. 2019 Aug 1;14(8):e0220612. doi: 10.1371/journal.pone.0220612. eCollection 2019.
 
465.Diabetes is Associated with Increased Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease
 

Yang JD1,2,3,4, Ahmed F1, Mara KC5, Addissie BD6, Allen AM1, Gores GJ1, Roberts LR1. Hepatology. 2019 Jul 15. doi: 10.1002/hep.30858. [Epub ahead of print]
 
466.Triglyceride Glucose Index Is Superior to the Homeostasis Model Assessment of Insulin Resistance for Predicting Nonalcoholic Fatty Liver Disease in Korean Adults
 

Lee SB#1,2, Kim MK#3, Kang S1,2, Park K1,2, Kim JH1,2, Baik SJ4, Nam JS1,2, Ahn CW1,2, Park JS1,5. Endocrinol Metab (Seoul). 2019 Jun;34(2):179-186. doi: 10.3803/EnM.2019.34.2.179.
 
467.Oral Diseases Associated with Nonalcoholic Fatty Liver Disease in the United States
 

Weintraub JA1, Lopez Mitnik G2, Dye BA2. J Dent Res. 2019 Aug 1:22034519866442. doi: 10.1177/0022034519866442. [Epub ahead of print]
 
468.Non-invasive assessment of hepatic lipid subspecies matched with non-alcoholic fatty liver disease phenotype
 

Erickson ML1, Haus JM2, Malin SK3, Flask CA4, McCullough AJ5, Kirwan JP6. Nutr Metab Cardiovasc Dis. 2019 Jun 21. pii: S0939-4753(19)30240-6. doi: 10.1016/j.numecd.2019.06.012. [Epub ahead of print]
 
469.Epidemiology of chronic liver diseases in the USA in the past three decades
 

Younossi ZM1,2, Stepanova M3, Younossi Y3, Golabi P4,2, Mishra A4,2, Rafiq N4,2, Henry L3. Gut. 2019 Jul 31. pii: gutjnl-2019-318813. doi: 10.1136/gutjnl-2019-318813. [Epub ahead of print]
 
470.Effect of dietary intervention, with or without co-interventions, on inflammatory markers in patients with nonalcoholic fatty liver disease: a systematic literature review
 

Reddy AJ1, George ES1,2,3, Roberts SK4, Tierney AC1,3,5. Nutr Rev. 2019 Jul 30. pii: nuz029. doi: 10.1093/nutrit/nuz029. [Epub ahead of print]
 
471.Non-Alcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B
 

Choi HSJ1,2, Brouwer WP3, Zanjir WMR1, de Man RA3, Feld JJ1, Hansen BE1,3,4, Janssen HLA1, Patel K1. Hepatology. 2019 Jul 15. doi: 10.1002/hep.30857. [Epub ahead of print]
 
472.ASKing no more: the emerging role of DUSP12 in the regulation of hepatic lipid metabolism
 

Bubici C1, Lepore A2, Papa S2. Hepatology. 2019 Jul 12. doi: 10.1002/hep.30851. [Epub ahead of print]
 
473.Overview of Pediatric Nonalcoholic Fatty Liver Disease: A Guide for General Practitioners
 

Shakir AK1, Suneja U1, Short KR2, Palle S1. J Okla State Med Assoc. 2018 Oct;111(8):806-811.
 
474.NAFLD in children: new genes, new diagnostic modalities and new drugs
 

Nobili V1,2, Alisi A3, Valenti L4,5, Miele L6,7, Feldstein AE8, Alkhouri N9. Nat Rev Gastroenterol Hepatol. 2019 Jul 5. doi: 10.1038/s41575-019-0169-z. [Epub ahead of print]
 
475.Depression is associated with non-alcoholic fatty liver disease among adults in the United States
 

Kim D1, Yoo ER2, Li AA3, Tighe SP1, Cholankeril G1, Harrison SA4, Ahmed A1. Aliment Pharmacol Ther. 2019 Jul 22. doi: 10.1111/apt.15395. [Epub ahead of print]
 
476.Potential Mechanisms Influencing the Inverse Relationship Between Cannabis and Nonalcoholic Fatty Liver Disease: A Commentary
 

Dibba P1, Li AA2, Cholankeril G3, Ali Khan M4, Kim D3, Ahmed A3. Nutr Metab Insights. 2019 May 13;12:1178638819847480. doi: 10.1177/1178638819847480. eCollection 2019.
 
477.Risks of light and moderate alcohol use in fatty liver disease - follow-up of population cohorts
 

Åberg F1,2, Puukka P3, Salomaa V3, Männistö S3, Lundqvist A3, Valsta L3, Perola M3, Färkkilä M4, Jula A3. Hepatology. 2019 Jul 19. doi: 10.1002/hep.30864. [Epub ahead of print]
 
478.Readiness for the epidemic: The adult nonalcoholic fatty liver disease toolkit for primary care nurse practitioners
 

Casler K1,2, Trees K1, Bosak K1. J Am Assoc Nurse Pract. 2019 Jun 27. doi: 10.1097/JXX.0000000000000223. [Epub ahead of print]
 
479.Relationship between Grip Strength and Nonalcoholic Fatty Liver Disease in Men Living with HIV Referred to a Metabolic Clinic
 

Debroy P1, Lake JE, Malagoli A, Guaraldi G. J Frailty Aging. 2019;8(3):150-153. doi: 10.14283/jfa.2018.37.
 
480.The Effect of Low Glycemic Index and Glycemic Load Diets on Hepatic Fat Mass, Insulin Resistance, and Blood Lipid Panels in Individuals with Nonalcoholic Fatty Liver Disease
 

Parker A1, Kim Y1. Metab Syndr Relat Disord. 2019 Jul 15. doi: 10.1089/met.2019.0038. [Epub ahead of print]
 
481.Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD
 

Rinella ME1, Tacke F2, Sanyal AJ3, Anstee QM4; participants of the AASLD/EASL Workshop. J Hepatol. 2019 Jul 9. pii: S0168-8278(19)30283-1. doi: 10.1016/j.jhep.2019.04.019. [Epub ahead of print]
 
482.Liver sympathetic denervation reverses obesity-induced hepatic steatosis
 

Hurr C1,2, Simonyan H1, Morgan DA3, Rahmouni K3, Young CN1. J Physiol. 2019 Jul 6. doi: 10.1113/JP277994. [Epub ahead of print]
 
483.Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven nonalcoholic fatty liver disease
 

Nobili V1, Mantovani A2, Cianfarani S3, Alisi A4, Mosca A5, Rita Sartorelli M6, Maffeis C7, Loomba R8, Byrne CD9, Targher G10. J Hepatol. 2019 Jul 4. pii: S0168-8278(19)30395-2. doi: 10.1016/j.jhep.2019.06.023. [Epub ahead of print]
 
484.Fructose Promotion of Intestinal and Liver Injury: A Sugar by Any Other Name That Isn
 

Kennedy L1, Francis H1,2, Alpini G1,2. Hepatology. 2019 Jul 5. doi: 10.1002/hep.30843. [Epub ahead of print]
 
485.Obesity and Liver Disease: The New Era of Liver Transplantation
 

Marrero JA1. Hepatology. 2019 Jul 13. doi: 10.1002/hep.30854. [Epub ahead of print]
 
486.The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis
 

Younossi ZM1, Golabi P2, de Avila L2, Minhui Paik J2, Srishord M2, Fukui N3, Qiu Y4, Burns L4, Afendy A5, Nader F5. J Hepatol. 2019 Jul 4. pii: S0168-8278(19)30393-9. doi: 10.1016/j.jhep.2019.06.021. [Epub ahead of print]
 
487.Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD
 

Rinella ME1, Tacke F2, Sanyal AJ3, Anstee QM4; participants of the AASLD/EASL Workshop. Hepatology. 2019 Jul 9. doi: 10.1002/hep.30782. [Epub ahead of print]
 
488.Non-alcoholic fatty liver disease in non-obese individuals: Prevalence, pathogenesis and treatment
 

Molina-Molina E1, Krawczyk M2, Stachowska E3, Lammert F4, Portincasa P5. Clin Res Hepatol Gastroenterol. 2019 Jun 10. pii: S2210-7401(19)30095-6. doi: 10.1016/j.clinre.2019.04.005. [Epub ahead of print]
 
489.Microbiome Signatures Associated with Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease
 

Schwimmer JB1, Johnson JS2, Angeles JE3, Behling C4, Belt PH5, Borecki I6, Bross C7, Durelle J8, Goyal NP9, Hamilton G10, Holtz ML11, Lavine JE12, Mitreva M13, Newton KP14, Pan A15, Simpson PM16, Sirlin CB17, Sodergren E18, Tyagi R19, Yates KP20, Weinstock G21, Salzman NH22. Gastroenterology. 2019 Jun 27. pii: S0016-5085(19)41037-8. doi: 10.1053/j.gastro.2019.06.028. [Epub ahead of print]
 
490.A structured literature review of interventions used in the management of nonalcoholic steatohepatitis (NASH)
 

Povsic M1, Oliver L1, Jiandani NR1, Perry R1, Bottomley J2. Pharmacol Res Perspect. 2019 May 27;7(3):e00485. doi: 10.1002/prp2.485. eCollection 2019 Jun.
 
491.Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
 

Newsome P1,2, Francque S3, Harrison S4, Ratziu V5, Van Gaal L6, Calanna S7, Hansen M7, Linder M7, Sanyal A8. Aliment Pharmacol Ther. 2019 Jul;50(2):193-203. doi: 10.1111/apt.15316. Epub 2019 Jun 10.
 
492.Fatty Liver and the Forensic Pathologist
 

Milroy CM. Acad Forensic Pathol. 2018 Jun;8(2):296-310. doi: 10.1177/1925362118782061. Epub 2018 Jun 6.
 
493.Trends in Mortality From Extrahepatic Complications in Patients With Chronic Liver Disease, From 2007 Through 2017
 

Kim D1, Adejumo AC2, Yoo ER3, Iqbal U4, Li AA5, Pham EA6, Cholankeril G6, Glenn JS6, Ahmed A6. Gastroenterology. 2019 Jun 25. pii: S0016-5085(19)41033-0. doi: 10.1053/j.gastro.2019.06.026. [Epub ahead of print]
 
494.Selective Trafficking of Fatty Acids in the Liver: Add Them2 to the List of Influencers
 

Ginsberg HN1. Hepatology. 2019 Jun 2. doi: 10.1002/hep.30800. [Epub ahead of print]
 
495.Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis
 

Said A1, Akhter A2. Ann Hepatol. 2017 Jul - Aug;16(4):538-547. doi: 10.5604/01.3001.0010.0284.
 
496.Efficacy of Probiotics and Synbiotics in Patients with Nonalcoholic Fatty Liver Disease: A Meta-Analysis
 

Liu L1,2, Li P3,4, Liu Y1, Zhang Y1. Dig Dis Sci. 2019 Jun 15. doi: 10.1007/s10620-019-05699-z. [Epub ahead of print]
 
497.Psychotropic Medications are Associated with Increased Liver Disease Severity in Pediatric NAFLD
 

Mouzaki M1, Yodoshi T1, Arce-Clachar AC1, Bramlage K1, Fei L2, Hunsaker SL3, Xanthakos SA1. J Pediatr Gastroenterol Nutr. 2019 May 18. doi: 10.1097/MPG.0000000000002401. [Epub ahead of print]
 
498.Considering the links between NAFLD and insulin resistance: revisiting the role of protein kinase c
 

Samuel VT1, Petersen MC2, Gassaway BM3, Vatner DF4, Rinehart J2, Shulman GI5. Hepatology. 2019 Jun 20. doi: 10.1002/hep.30829. [Epub ahead of print]
 
499.Brain involvement in non-alcoholic fatty liver disease (NAFLD): A systematic review
 

Lombardi R1, Fargion S1, Fracanzani AL2. Dig Liver Dis. 2019 Jun 5. pii: S1590-8658(19)30594-8. doi: 10.1016/j.dld.2019.05.015. [Epub ahead of print]
 
500.Macrophage Nourishment in NASH: A Novel Role for Ketone Bodies
 

Torok NJ1. Hepatology. 2019 May 20. doi: 10.1002/hep.30777. [Epub ahead of print]
 
501.Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations from the Liver Forum
 

Cheung A1, Neuschwander-Tetri BA2, Kleiner DE3, Schabel E4, Rinella M5, Harrison S6, Ratziu V7, Sanyal AJ8, Loomba R9, Jeannin Megnien S10, Torstenson R11, Miller V12; Liver Forum Case Definitions Working Group. Hepatology. 2019 Apr 29. doi: 10.1002/hep.30672. [Epub ahead of print]
 
502.Non-nutritive sweeteners and their association with the metabolic syndrome and non-alcoholic fatty liver disease: a review of the literature
 

Green CH1, Syn WK2,3,4. Eur J Nutr. 2019 May 22. doi: 10.1007/s00394-019-01996-5. [Epub ahead of print]
 
503.Review article: emerging role of the gut microbiome in the progression of nonalcoholic fattyliver disease and potential therapeutic implications
 

Jayakumar S1, Loomba R1,2. Aliment Pharmacol Ther. 2019 May 31. doi: 10.1111/apt.15314. [Epub ahead of print]
 
504.Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification
 

Ioannou GN1, Green P2, Kerr KF3, Berry K2. J Hepatol. 2019 May 27. pii: S0168-8278(19)30291-0. doi: 10.1016/j.jhep.2019.05.008. [Epub ahead of print]
 
505.Is Trimming the Fat Enough? Fibroblast Growth Factor 21 as An Emerging Treatment for NAFLD
 

Dushay J1. Hepatology. 2019 May 28. doi: 10.1002/hep.30789. [Epub ahead of print]
 
506.Increasing Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease Among Hospitalized Adults in the United States
 

Hirode G1, Vittinghoff E2, Wong RJ1. J Clin Gastroenterol. 2019 May 22. doi: 10.1097/MCG.0000000000001229. [Epub ahead of print]
 
507.A critical appraisal of the use of ultrasound in hepatic steatosis
 

Ballestri S1, Nascimbeni F2, Lugari S3, Lonardo A2, Francica G4. Expert Rev Gastroenterol Hepatol. 2019 May 29:1-15. doi: 10.1080/17474124.2019.1621164. [Epub ahead of print]
 
508.The Patient Perspectives on Future Therapeutic Options in NASH and Patient Needs
 

Cook N1, Geier A2, Schmid A3, Hirschfield G4, Kautz A5, Schattenberg JM6, Balp MM1. Front Med (Lausanne). 2019 Apr 3;6:61. doi: 10.3389/fmed.2019.00061. eCollection 2019.
 
509.Non-Alcoholic Fatty Liver Disease, Liver Fibrosis Score and Cognitive Function in Middle-Aged Adults: The Framingham Study
 

Weinstein G1, Davis-Plourde K2,3, Himali JJ2,3,4, Zelber-Sagi S1,5, Beiser AS2,3,4, Seshadri S3,4,6. Liver Int. 2019 Jun 2. doi: 10.1111/liv.14161. [Epub ahead of print]
 
510.The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content
 

Gepner Y1, Shelef I2, Komy O3, Cohen N3, Schwarzfuchs D4, Bril N3, Rein M3, Serfaty D3, Kenigsbuch S3, Zelicha H3, Yaskolka Meir A3, Tene L3, Bilitzky A3, Tsaban G3, Chassidim Y2, Sarusy B5, Ceglarek U6, Thiery J6, Stumvoll M6, Blüher M6, Stampfer MJ7, Rudich A3, Shai I8. J Hepatol. 2019 May 8. pii: S0168-8278(19)30274-0. doi: 10.1016/j.jhep.2019.04.013. [Epub ahead of print]
 
511.Fatty liver disease in persons with HIV infection
 

Seth A1, Sherman KE1. Top Antivir Med. 2019 May;27(2):75-82.
 
512.Dietary Carotenoids and Non-Alcoholic Fatty Liver Disease among US Adults, NHANES 2003?2014
 

Christensen K1, Lawler T2, Mares J3. Nutrients. 2019 May 17;11(5). pii: E1101. doi: 10.3390/nu11051101.
 
513.Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liverdisease: a qualitative study
 

Hallsworth K1,2, Dombrowski SU3, McPherson S2, Anstee QM1,2, Avery L4. Transl Behav Med. 2019 May 23. pii: ibz080. doi: 10.1093/tbm/ibz080. [Epub ahead of print]
 
514.A Structured Literature Review of the Epidemiology and Disease